{"title": "PDF", "author": "PDF", "url": "https://www.insp.mx/images/stories/Centros/cisp/Docs/lim/LIM_Prev_CtrlCancer.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \n1  \nCENTRO DE INVESTIGACI\u00d3N EN SALUD POBLACIONAL \n \nLIM EN ACCI\u00d3N: \n \nPREVENCI\u00d3N Y CONTROL DE C\u00c1NCER \n \nMayo del 2010 \n \n \n \nEl Fruto de la Investigaci\u00f3n \n \nPara la UNESCO, la finalidad esencial de un art\u00edculo cient\u00edfico es \u201ccomunicar los resultados de \ninvestigaciones, ideas y debates de una manera clara, concisa y fidedigna, para lo cual, los autores y \nlos jefes de redacci\u00f3n deben poner su m\u00e1ximo esfuerzo para lograr dicho objetivo\u201d.  \nEl \u00e9xito obtenido con la publicaci\u00f3n cient\u00edfica una vez  que ha pasado la revisi\u00f3n por pares y dem\u00e1s \ncriterios de selecci\u00f3n seg\u00fan la revista que se haya elegido como medio de difusi\u00f3n de los hallazgos \ny resultados, se compartir\u00e1 con los dem\u00e1s,  lo cual generar\u00e1 cr\u00edticas tanto negativas como positivas, \ncontroversias, confirmar\u00e1 previos estudios o sentar\u00e1n las bases para investigaciones futuras. Sin \nembargo, el impacto final de toda investigaci\u00f3n no termina ah\u00ed, sino que debe medirse  mediante el \nuso de t\u00e9cnicas cienciom\u00e9tricas y bibliom\u00e9tricas para el  an\u00e1lisis de las citas de  estas aportaciones \noriginales. \nEn el CISP del INSP hemos comenzado a trabajar esta parte mediante el estudio de las citaciones  a \nlos art\u00edculos publicados con autor\u00eda o coautor\u00eda de la fuerza de investigaci\u00f3n de este centro \nmediante la recuperaci\u00f3n de una muestra importante de citas a estos art\u00edculos y tomando como \nbase las diferentes l\u00edneas de investigaci\u00f3n del INSP en la cuales participan, con el objetivo de \nrecabar indicadores primordiales como lo son el inter\u00e9s tem\u00e1tico de los investigadores externos \ntanto nacionales como internacionales, conocer el nombre de las revistas en las cuales  son \nfrecuentemente citados, presentar los t\u00edtulos de los trabajos m\u00e1s citados y asimismo conocer el \nnombre de las revistas que los  investigadores eligen para difundir sus hallazgos. \nComo tercer estudio  de  la serie \u201cLIM en Acci\u00f3n\u201d  corresponde  publicar    el an\u00e1lisis citograf\u00edco  de \nla producci\u00f3n cient\u00edfica  de los investigadores del CISP sobre la  L\u00ednea de Investigaci\u00f3n por Misi\u00f3n   \nPrevenci\u00f3n y  Control del C\u00e1ncer.  \n \n \n \n \n \n \n2  \n \n \n \n \n \nINDICE \n \n \n \nEL FRUTO DE LA INVESTIGACI\u00d3N \u2026\u2026\u2026\u2026\u2026  \n P\u00e1g.  1 \nINVESTIGADORES LIM - C\u00c1NCER \u2026\u2026\u2026\u2026\u2026..  \n P\u00e1g.  3 \nDATOS GLOBALES SOBRE EL C\u00c1NCER \u2026\u2026....  \n P\u00e1g.  4-5 \nAN\u00c1LISIS CITOGR\u00c1FICO  \n  \n\uf0d8 TRABAJOS M\u00c1S CITADOS \u2026\u2026\u2026\u2026\u2026..  \n P\u00e1g.  6-8 \n\uf0d8 SOBRE LAS REVISTAS CIENT\u00cdFICAS  P\u00e1g.  9-13 \n \n\uf0d8 TEM\u00c1TICA CON SULTADA  \n  \nP\u00e1g.  14 \nGEORGE N. PAPANICOLAOU : \n\u201cEL LEGADO DE LA ESPERANZA\u201d \u2026\u2026\u2026\u2026...  \n  \nP\u00e1g.  15-16 \nCITOGRAF\u00cdA \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...  \n P\u00e1g.  17-115 \nMUJER  Y C\u00c1NCER:  \nMAR\u00cdA EVA DUARTE DE PER\u00d3N \u2026\u2026\u2026\u2026\u2026\u2026  \n  \nP\u00e1g.  116 \nCR\u00c9DITOS \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026  P\u00e1g.  117 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \n3  \n \n \nINVESTIGADORES CITADOS DEL CISP: \n(Orden alfab\u00e9tico) \n \n \n \n \n DRA. AHIDEE GUADALUPE LEYVA FLORES \n DRA. ANG\u00c9LICA ROCIO ANGELES LLERENAS \n DR. AURELIO CRUZ VALD\u00c9Z \n DRA. BETANIA ALLEN LEIGH \n DR. CARLOS A. HERN\u00c1NDEZ GIR\u00d3N \n DRA. EDNA JUDITH ARILLO SANTILL\u00c1N \n DR. EDUARDO C\u00c9SAR LAZCANO PONCE \n DR. EDUARDO SALAZAR MART\u00cdNEZ \n MTRA. ELSA MAR\u00cdA YUNES D\u00cdAZ \n DRA. GABRIELA TORRES MEJ\u00cdA \n LIC. IDANELLI BARRIOS JACOBO \n DRA. ISABELLE ROMIEU DE HERN\u00c1NDEZ \n MTRA. LEONOR RIVERA RIVERA \n DRA. LIZBETH TERESITA L\u00d3PEZ CARRILLO \n MTRO. FRANCISCO JAVIER L\u00d3PEZ ESPINO Y DE ANTU\u00d1ANO \n DRA. MA. DE LOURDES GUADA FLORES LUNA \n DRA. LUISA ELVIRA TORRES S\u00c1NCHEZ \n DRA. LUISA MAR\u00cdA S\u00c1NCHEZ ZAMORANO \n DRA. LUZ MYRIAM REYNALES SHIGEMATSU \n DRA. MARCIA VER\u00d3NICA GALVAN PORTILLO \n DR. MART\u00cdN LAJOUS LOAEZA \n MTRA. MA. DEL PILAR HERN\u00c1NDEZ NEVAR\u00c9Z \n DR. RAYDEL VALD\u00c9S SALGADO \n \n \n \n \n \n \n \n  \n4 DATOS GLOBALES SOBRE EL C\u00c1NCER. \n \nEn M\u00e9xico el alto \u00edndice de casos relacionados al c\u00e1ncer es considerado un problema  grave de Salud P\u00fablica por \nsu alta letalidad y por los diversos factores de riesgo tanto individuales como ambientales, lo que  constituye  \njunto con las Enfermedades Cardiovasculares y  las complicaciones de la Diabetes  Mellitus una de las  \nprincipales causas de muerte en nuestro pa\u00eds. A continuaci\u00f3n se presentan algunas cifras y datos relevantes a este \ntema. \n \n\uf0d8 Conforme al \u00faltimo reporte mundial de c\u00e1ncer 2008 publicado por la OMS fueron 12 millones de casos \nnuevos de c\u00e1ncer diagnosticados durante ese a\u00f1o, la mortalidad fue de 7 millones por la misma causa y 25 \nmillones de personas viven con esa enfermedad. [1] \n \n\uf0d8 Para la regi\u00f3n de las Am\u00e9ricas, durante el 2008 el estimado de nuevos casos de c\u00e1ncer fue de 2 617 000;  de \nellos 1 338 000 correspondieron a hombres y 1 279 000 a mujeres. La mortalidad estimada fue de 1 258 000 \nmuertes, en hombres se calcul\u00f3 en 651 000 defunciones y 607 000 en mujeres. [1] \n \n\uf0d8 Para la regi\u00f3n espec\u00edfica de Centro, Sudam\u00e9rica y el Caribe el numero total de casos nuevos fue de 1 011 \n000; con un total 589 000 muertes por esta causa; 302 000 fueron hombres y 287 000 mujeres. El c\u00e1ncer mas \nincidente en esta misma regi\u00f3n fue el de pr\u00f3stata para los hombres y el de mama entre las mujeres; siendo \nel de pulm\u00f3n el mas letal para ambos sexos. [1] \n \nWorld Cancer Report 2008. pag 19 \n \n\uf0d8 El mayor carcin\u00f3geno asociado a las muertes por c\u00e1ncer es el tabaco.  [1] \n \n\uf0d8 Desde el 2006 en M\u00e9xico, entre las neoplasias, el c\u00e1ncer de mama se ha convertido en la principal causa de \nmuerte para las mujeres adultas de entre 30 y 54 a\u00f1os de edad, en ese a\u00f1o se registraron 4 451 defunciones. \n[2] \n \n\uf0d8 En 2006 las mujeres en M\u00e9xico con edades entre 30 y 65 a\u00f1os presentaron un riesgo mayor de morir por \nc\u00e1ncer mamario que por c\u00e1ncer de cuello uterino, mientras que en 1980 el riesgo de morir por este \u00faltimo \nera 2 veces mayor. [2] \n \n\uf0d8 La tendencia de Ca de mama en M\u00e9xico ha sido ascendente con una tasa de 5.6 muertes por cada 100 000 \nmujeres en 1979  a 10.1 en 2006; las tasas mas altas de mortalidad se encuentran en la capital y en el norte \ndel pa\u00eds. [3] \n \n \n5  \n \n\uf0d8 En el 2007 se se\u00f1ala al c\u00e1ncer como la tercera causa de muerte entre las mujeres mexicanas con 35 303 \ndefunciones mientras que en los hombres fue la cuarta causa de muerte con un total de 33 509 defunciones; \neste mismo reporte indica que los 3 principales tipo de c\u00e1ncer que causaron mas muertes en las mujeres \nfueron el de mama, cuello uterino e h\u00edgado.  [4] \n \n\uf0d8 La primera causa neopl\u00e1sica de muerte en M\u00e9xico en 2007 entre los hombres fue el de pr\u00f3stata, seguido por \nel de pulm\u00f3n y estomago. [4] \n \n\uf0d8 El c\u00e1ncer  c\u00e9rvico-uterino es el segundo tipo de c\u00e1ncer que afecta a las mujeres entre 15 y 44 a\u00f1os de edad a \nnivel mundial con 493 243 nuevos casos y 273 505 defunciones anuales. En Am\u00e9rica 86 532 nuevos casos son \ndiagnosticados anualmente por esta enfermedad. [5] \n \n\uf0d8 En M\u00e9xico el c\u00e1ncer c\u00e9rvico-uterino ocupa el segundo lugar de muertes en mujeres despu\u00e9s del c\u00e1ncer de \nmama, durante los \u00faltimos 25 a\u00f1os ha causado mas de 100 000 defunciones. [6] \n \n\uf0d8 La asociaci\u00f3n del virus del papiloma humano con el c\u00e1ncer de cuello uterino es establecida s\u00f3lidamente a \ntrav\u00e9s de muchos estudios en los cuales se ha encontrado el ADN de este virus en el 99.7% de muestras \ntumorales en distintas zonas de todo el mundo. [7] \n \n\uf0d8 Hay mas de 100 subtipos del VPH pero los que se encuentran mas frecuentemente asociados (90%)  con el  \nc\u00e1ncer cervical son:   16, 18, 45, 31, 33, 52, 58 y 35, de los anteriores, los  tipos m\u00e1s comunes son el 16 y el 18  \ncausantes del 70 % de los carcinomas de c\u00e9lulas escamosas y 89% de los carcinomas adenoescamosos; los \nsubtipos de bajo riesgo mas frecuentemente encontrados son el 6 y el 11. [5,7,8]  \n \n\uf0d8 Actualmente existen dos vacunas preventivas disponibles principalmente contra los tipos: VPH 16 y 18 \n(bivalente); VPH 6, 11, 16 y 18 (cuadrivalente).  [6,7,8]  \n \n\uf0d8 Anualmente se producen en las Am\u00e9ricas cerca de 39  000 muertes debido al c\u00e1ncer de cuello uterino  de las \ncuales 33  000 defunciones se presentan  en Am\u00e9rica Latina y el Caribe, lo cual indica que la tasa de \nmortalidad es 7 veces superior a la de Am\u00e9rica del Norte (Estados Unidos y Canad\u00e1); un estudio de 15 a\u00f1os \nde investigaci\u00f3n presentado recientemente reporta qu e la prevalencia encontrada de VPH es de 20 a 30 % \nen mujeres de 15 a 24  a\u00f1os de edad, 11% en mujeres de entre 45 y 54 a\u00f1os y de 20% en mujeres de mas de \n65 a\u00f1os de edad. [8] \n4 \n\uf0d8 La bacteria Heli cobacter  pylori y las infecciones de hepatitis v\u00edrica se cons ideran los agentes causales de 2 \nde los 4 tipos de c\u00e1ncer m\u00e1s mortales para los hombres que son el de est\u00f3mago e h\u00edgado respectivamente . \n[9] \n \n\uf0d8 El c\u00e1ncer es la segunda causa de muerte infantil en M\u00e9xico, anualmente 7 000 ni\u00f1os adquieren la \nenfermedad de los cuales se estima que 1500 mueren por esta causa. La leucemia es el tipo de c\u00e1ncer  m\u00e1s \ncom\u00fan en esta poblaci\u00f3n.  [10] \n \n \nBIBLIOGRAF\u00cdA \n \n1. World Health Organization. World Cancer Report 2008 .  International Agency for Research on Cancer. Lyon \nFrance  2008. Dispon ible en:< http://www.iarc.fr/en/publications/pdfs-online/wcr/index.php > \n2. Knaul FM,  Lozano R, Arreola H. G\u00f3mez-Dant\u00e9s H.  M\u00e9xico: numeralia de c\u00e1ncer de mama . Competitividad, \nSalud y Observatorio de la Salud;  FUNSALUD. Marzo 2008.  \n3. Palacio-Mej\u00eda LS, Lazcano-Ponce EC, Allen-Leigh B, Hern\u00e1ndez-Avila M. Diferencias regionales en la mortalidad \npor c\u00e1ncer de mama y cervix en M\u00e9xico entre 1979 y 2006 . Salud Publica Mex 2009;51(Supl 2):S 208-S219. \n4. INEGI. Estad\u00edsticas a prop\u00f3sito del d\u00eda mundial contra el c\u00e1ncer: datos nacionales . M\u00e9xico Febrero del  2009. \n5. WHO/ICO Information Centre on HPV and Cervical Cancer. HPV and Cervical Cancer in the World: 2007 \nReport.  Vaccine 2007 1Nov;25(Suppl 3): C1-230. \n6. Lazcano Ponce EC. Salmer\u00f3n Castro J, Garc\u00eda Carranc\u00e1 A, et al . Recomendaciones para la definici\u00f3n de la \npol\u00edtica de vacunaci\u00f3n contra el virus del papiloma en M\u00e9xico.  Salud Publica Mex 2009 Jul-Ago;51(4):336- 41. \n7. Abarca K. Valenzuela MT. Vergara R. et al. Declaraci\u00f3n del comit\u00e9 consultivo de inmunizaciones de la Sociedad \nChilena de Infectolog\u00eda respecto a la vacuna anti-virus papiloma humano . Septiembre 2008. Rev Chil Infectol \n2008;25(6):428-34. \n8. OPS/OMS/SV I/CDC. Hacia la prevenci\u00f3n y control integra les del c\u00e1ncer cervicouterino. Regi\u00f3n de las \nAm\u00e9ricas.   Reuni\u00f3n sobre el Virus del Papiloma Humano Ciudad de M\u00e9xico 12 -13 de mayo del 2008.  Sabin \nVaccine Institute.  \n9. UICC. Protecci\u00f3n contra las infecciones que provocan c\u00e1ncer . Uni\u00f3n Internacional Contra el C\u00e1ncer 2010. \n10. Asociaci\u00f3n Mexicana de Lucha Contra el C\u00e1ncer. C\u00e1ncer Infantil. Consultado el 07 de abril del 2010. Disponible \nen: <http://www.amlcc.org/elcancer06.html>  \n \n  \n6 AN\u00c1LISIS CITOGR\u00c1FICO  \nSe realiz\u00f3 una revisi\u00f3n para obtener el mayor n\u00famero de citas de los investigadores del CISP correspondientes \na los a\u00f1os 2008-2009 dando como resultado la obtenci\u00f3n de: \n\uf0fc 112  trabajos seleccionados de la producci\u00f3n cient\u00edfica del CISP relacionadas a la LIM en estudio \n\uf0fc 1116 citas a esos trabajos. \n\uf0fc  866 art\u00edculos que citan esta producci\u00f3n (ver citograf\u00eda ) \nTRABAJOS M\u00c1S CITADOS \nEn relaci\u00f3n a lo s 112 art\u00edculos, 41 son  los que tienen el mayor n\u00famero de citas (6 o m\u00e1s): \nTabla 1: Art\u00edculos  m\u00e1s citados \n \n                                                                       ART\u00cdC ULOS  CITADOS   \nCITAS  \nVilla LL, et al. (The Future II Study Group, Lazcano -Ponce E .) Quadrivalent vaccine against human \npapillomavirus to prevent high -grade cervical lesions. NEJM 2007 10Ma y;356(19):1915 -27.  \n 287 \nFranceschi S. Herrero R. Clifford GM. Snij ders PJF. Arslan A. Anh PTH. Bosch FX. Ferreccio C. Hieu \nNT. Lazcano -Ponce E.  Variations in the age -specific curves of human papillomavirus prevalence in \nwomen worldwide:  et al. Int J Canc er 2006 1Dec;119(11):2677 -2684.  \n 56 \nReisinger KS. Block SL. Lazcan o-Ponce E.  Samakoses R. Esser MT. Erick J. Puchalski D.  Giacoletti \nKED. Sings HL. Lukac S. Alvarez FB. Barr E . Safety and persistent immunogenicity of a quadrivalent \nhuman papillomavirus types 6, 11, 16, 18 L1 virus -like particle vaccine in preadolescents  and \nadolescents - A randomized controlled trial.. Pediatr Infect Dis J 2007 Mar;26(3):201 -9.  \n 51 \nZimet GD. Liddon N. Rosenthal SL. Lazcano -Ponce E. Allen B.  Psychosocial aspects of vaccine \nacceptability. Vaccine 2006 31A ug;24(Suppl 3);201 -9. \n 43 \nLazcan o-Ponce EC.  Miquel JF. Mun\u00f3z N. Herrero R. Ferrecio C. Wistuba II. de Ruiz PA. Urista GA. \nNervi F. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer Journal for \nClinicians 2001 No v-Dec;51(6):349 -64.  \n 37 \nLazcano -Ponce E . Herrero R. Mun oz N. Cruz A.  Shah KV. Alonso P. Hern\u00e1ndez P . Salmeron J. \nHernandez M. Epidemiology of HPV infection among Mexican women with normal cervical cytology.  \nInt J Cancer 2001 1Feb;91(3):412 -20.  \n 28 \nBerumen J. Ordonez RM. Lazcano E.  Salmeron J. Galvan SC. Est rada RA. Yunes E.  Garcia -Carranca A. \nMadrigal -de la Campa A. Asian -American variants of human papillomavirus 16 and risk for cervical \ncancer: a case -control study.  J Natl Cancer Inst 2001 1Sep;93 (17):1325 -30. \n 25 \nVaccarella S. Franceschi S. Herrero R. Mu nioz N. Snijders PJF. Clifford GM. Smith JS . Lazcano -Ponce \nE. Sukvirach S. Shin HR. de Sanjose S. Molano M. Matos E. Ferreccio C. Anh PTH. Thomas JO. Meijer \nCJLM.  Sexual behavior, condom use, and human papillomavirus: Pooled analysis of the IARC human \npapi llomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev  2006 Feb;15(2):326 -33.  \n 25 \nVaccarella S. Herrero R. Dai M. Snijders PJF. Meijer CJLM. Thomas JO. Anh PTH. Ferreccio C. Matos E. \nPosso H. de Sanjose S. Shin HR. Sukvirach S. Lazcano -Ponce E.  Ronco G.Rajkumar R. Qiao YL. Munoz \nN. Franceschi S.Reproductive factors, oral contraceptive use, and human papillomavirus infection: \nPooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 2006 \nNov;15(11):2148 -2153.  20 \nLajous  M. Mueller N. Cruz -Valdez A.  Aguilar LV. Franceschi S. Hernandez -Avila M. Lazcano -Ponce \nE. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy \nMexican military men. Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):17 10-6.  \n 19  \n7 Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. \nLacasa\u00f1a -Navarro M. Ling D.  L\u00f3pez -Carrillo L.  et al. Meta - and pooled analyses of the \nmethylenetetrahydrofolate reductase C677T and A1298C polymorphism s and gastric cancer risk: a \nhuge -GSEC review. Am J Epidemiol . 2008;(5):505 -516. \n 19 \nSoto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. \nAssessment of lymphocyte subpopulations and cytokine secretion in childr en exposed to arsenic. \nFASEB J 20(6):779 \u2013781. \n 18 \nVaccarella S. Lazcano -Ponce E.  Castro -Garduno JA. Cruz -Valdez A.  Diaz V. Schiavon R. Hern\u00e1ndez P . \nKornegay JR. Hernandez -Avila M. Franceschi S. Prevalence and determinants of human \npapillomavirus infection  in men attending vasectomy clinics in Mexico.. Int J Cancer 2006 \n15Oct;119(8):1934 -9. \n 17 \nLazcano -Ponce E. Rivera L. Arillo -Santillan E . Salmeron J. Hernandez -Avila M. Munoz N. \nAcceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in \nCuernavaca, Mexico. Arch Med Res 2001 May -Jun;32(3):243 -7.              16 \nL\u00f3pez -Cervantes M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez -Carrillo L . 2004. \nDichlorodiphenyldichloroethane burden and breast cancer risk: A meta -analysis of the epidemiol ogic \nevidence. Environ. Health Perspect. 112:207 \u2013214. 15 \nInsinga RP. Dasbach EJ. Elbasha EH. Puig A. Reynales -Shigematsu LM . Cost -effectiveness of \nquadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model \nbased evaluation . Vaccine 2007, 26:128 -139. 15 \nSalazar -Martinez E. Lazcano -Ponce E. Sanchez -Zamorano LM.  Gonz\u00e1lez -Lira G. Escudero -De Los \nRios P. Hern\u00e1ndez -Avila M. Dietary factors and endometrial cancer risk. Results of a case -control \nstudy in Mexico. Int J Gynecol Canc er 2005 Sep -Oct;15(5):938 -45.  15 \nLajous M. Lazcano -Ponce E.  Hern\u00e1ndez -Avila M. Willett W. Romieu I.  Folate, vitamin B -6, and \nvitamin B -12 intake and the risk of breast cancer among Mexican women. Cancer Epidemiol \nBiomarkers Prev 200 6 Mar;15(3):443 -8.   15 \nVaccarella S. Herrero R. Snijders PJF. Dai M. Thomas JO. Hieu NT. Ferreccio C. Matos E. Posso H. de \nSanjose S. Shin HR. Sukvirach S. Lazcano -Ponce E.  Mun\u00f3z N. Meijer CJLM. Franceschi S. Smoking and \nhuman papillomavirus infection: pooled analysis of the International Agency for Research on Cancer \nHPV Prevalence Surveys. Int J Epidemiol 200 8 Jun;37(3):536 -46.  14 \nSicinschi LA. L\u00f3pez -Carrillo L.  Constanza -Camargo M. et al. 2006. Gastric cancer risk in a Mexican \npopulation: role of Helicobacter pylori CagA positive infection and polymorphisms in interleukin -1 \nand -10 genes. Int. J. Cancer. 118:649 \u2013657. 13 \nRomieu I.  Hernandez -Avila M. Lazcano -Ponce E.  Weber JP. Dewailly E. Breast cancer, lactation \nhistory, and serum organochlorines . Am J Epidemiol 2000 15Aug ;152(4):363 -70.  13 \nDzuba IG. Yunes -D\u00edaz E. Allen B.  Leonard YF. Lazcano -Ponce EC.  et al. The Acceptability of Self -\ncollected Samples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. \nJournal of Women\u2019s Health & Gender -Based M edicine, 2002;11(3):265 -275. 11 \nL\u00f3pez -Carrillo L . Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in \nMexico: a case -control study. Am J Epidemiol 1994;139:263 -71. 11 \nLajous M. Romieu I.  Sabia S. Boutron -Ruault MC. Clavel -Chapelon  F. Folate, vitamin B12 and \npostmenopausal breast cancer in a prospective study of French women. Cancer Causes Control 17, 1209 \u2013\n1213, 2006.  11 \nRomieu I. Lazcano -Ponce E. S\u00e1nchez -Zamorano LM.  Willett W. Hern\u00e1ndez -Avila M. Carbohydrates \nand the risk of brea st cancer among Mexican women. Cancer Epidemiol Biomarkers Prev 2004 \nAug;13(8):1283 -9 \n 11  \n8 P\u00e9rez G. Lazcano -Ponce E.  Hern\u00e1ndez -Avila M. Garcia PJ. Mun\u00f3z N. Villa LL. Bryan J. Taddeo FJ. Lu \nS. Esser MT. Vuoco S. Sattler C. Barr E. Safety, immunogenicity, an d efficacy of quadrivalent human \npapillomavirus (types 6, 11, 16, 18) L1 virus -like-particle vaccine in Latin American women. Int J \nCanc er 2008 15Mar;122(6):1311 -8.  10 \nMurillo R. Almonte M Pereira A. Ferrer E. Gamboa OA. Jeronimo J. Lazcano -Ponce E.  Cerv ical Cancer \nScreening Programs in Latin America and the Caribbean. Vaccine 2008 19Aug;2 6(Suppl 11):L37 -L48. \n 10 \nWard MH. L\u00f3pez -Carrillo L.  Dietary Factors and the Risk of Gastric Cancer in Mexico City.  Am J \nEpidemiol 1999;149(10):925 - 32. \n 9 \nSalazar -Mar tinez E. Lazcano -Ponce EC.  Lira-Lira GG. Escudero -De los Rios P. Salmeron -Castro J. \nLarrea F. Hernandez -Avila M.Case -control study of diabetes, obesity, physical activity and risk of \nendometrial cancer among Mexican women. Cancer Causes Control 2000  Sep;11 (8):707 -11.  9 \nSalmeron J. Lazcano -Ponce E . Lorincz A. Hernandez M. Hernandez P . Leyva A . Uribe M. Manzanares \nH. Antunez A. Carmona E. Ronnett BM. Sherman ME. Bishai D. Ferris D. Flores Y. Yunes E. Shah KV. \nComparison of HPV -based assays with Papanicolaou  smears for cervical cancer screening in Morelos \nState, Mexico. Cancer Causes Control 20 03 Aug;14(6):505 -12.  9 \nHern\u00e1ndez -Gir\u00f3n C.  Smith JS. Lorincz A . Lazcano E.  Hern\u00e1ndez -Avila M. Salmeron J. High -risk \nhuman papillomavirus detection and related risk fac tors among pregnant and nonpregnant women in \nMexico. Sex Transm Dis 2005  Oct;32(10):613 -8.  9 \nPalacio -Mejia LS. Rangel -G\u00f3mez G. Hern\u00e1ndez -Avila M.  Lazcano -Ponce E . Cervical cancer, a disease \nof poverty: Mortality differences between urban and rural areas in Mexico. Salud Publica Mex \n2003;45 (Suppl 3):S315 -S325.  9 \nLajous M.  Willett W. Lazcano -Ponce E.  S\u00e1nchez -Zamorano LM,  Hernandez -Avila M , Romieu I.  \nGlycemic load, glycemic index, and the risk of breast cancer among Mexican women. Cancer Causes \nControl 200 5 Dec;16(10):1165 -9.  8 \nLazcano Ponce EC . Najera Aguilar P. Buiatti E. Alonso De Ruiz P. Kuri P. Cantoral L. Hern\u00e1ndez Avila \nM. The cervical cancer screening program in Mexico: problems with access and coverage.  Cancer \nCauses Control 19 97 Sep;8(5):698 -704. 8 \nLajous M.  Boutron -Ruault MC. Fabre A. Clavel -Chapelon F. Romieu I. Carbohydrate intake, glycemic \nindex, glycemic load, and risk of postmenopausal breast cancer in a prospective study of French \nwomen. Am J Clin Nutr. 2008;87(5):1384 \u20131391.  7 \nOrtega -Altamirano D. L\u00f3pez -Carrillo L.  L\u00f3pez -Cervantes M.  Estrategias para la ense\u00f1anza del \nautoexamen del seno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 \u201325. 7 \nL\u00f3pez -Carrillo L.  Blair A. L\u00f3pez -Cervantes M. Cebrian M. Rueda C.  Reyes R et al (1997) \ndichlorodiphenyltrichloroethane serum levels and breast cancer risk: a case -control study from Mexico. \nCancer Res 57:3728 \u20133732  \n6 \nGiuliano AR. Lazcano -Ponce E . Villa L. Nolan T. Marchant C. Radley D. Golm G.  McCarroll K. Yu J. \nEsser MT. Vuocolo  SC. Barr EImpact of baseline covariates on the immunogenicity of a quadrivalent \n(types 6, 11, 16, and 18) human papillomavirus virus -like-particle vaccine.. J Infect Dis 20 07 \n15Oct;196(8):1153 -62. \n 6 \nSalazar -Mart\u00ednez E.  Lazcano -Ponce EC.  Lira-Lira GG. Es cudero -De los Rios P. Hern\u00e0ndez -Avila M. \nNutritional determinants of epithelial ovarian cancer risk: A case -control study in Mexico. Oncology \n2002;63(2):151 -7. \n 6 \nSalazar -Martinez E . Lazcano -Ponce EC.  Lira-Lira GG. Escudero -De los Rios P. Salmeron -Castro J. \nHern\u00e1ndez -Avila M. Reproductive factors of ovarian and endometrial cancer risk in a high fertility \npopulation in Mexico. Cancer Res 1999 1Aug;59(15):3658 -62. No de Citas 6  \n 6 \nFranco EL. Tsu V. Herrero R. Lazcano -Ponce E.  Hildesheim A. Mun\u00f3z N. Murillo R. S\u00e1nchez GI. \nAndrus JK. Integration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin \nAmerica and the Caribbean. Vaccine 2008 19 Aug;26(Suppl 11):L88 -L95  6  \n9  \nSOBRE LAS REVISTAS CIENT\u00cdFICAS \nI. REVISTAS EN LAS CUALES LOS INVESTIGADORES DE LA LIM EN ESTUDIO \nFUERON CITADOS. \nEn cuanto a las revistas que fueron mas citadas (Tabla 2 ) derivadas de las 1116 citas a la producci\u00f3n del \nCISP tenemos como l\u00edder al \u201cNew England Journal of Medicine\u201d  (Estados Unidos)  de la \u201cMassachusetts \nMedical Soc iey\u201d con \u00e9nfasis en Medicina Interna. Su alto Factor de Impacto  50.017  la ubica dentro del \nnivel V y como una de las m\u00e1s importantes publicaciones cient\u00edficas dentro del vasto campo de la \nMedicina. Otras publicaciones relevantes son: \u201cThe International Journal of Cancer\u201d  (Estados Unidos)  \nrevista oficial de la International Union Against Cancer (UICC) con un FI de 4.734   con nivel IV ; \u201cC\u00e1ncer \nEpidemiology, Biomarkers & Research\u201d  (Estados Unidos) su FI es de 4.770  - nivel  IV; \u201c Vaccine\u201d \n(Holanda) FI de 3.298  - nivel IV  y  \u201cSalud Publica de M\u00e9xico\u201d  publicaci\u00f3n oficial del Instituto Nacional \nde Salud P\u00fablica (M\u00e9xico)  con un FI de  0.937  y clasificada dentro del nivel III.  Con nivel V  \nmencionaremos  a: \u201cCA: A Cancer Journal for Clinicians\u201d (Estados Unidos),  \u201cJour nal of the National \nCancer Institute\u201d (Estados Unidos),   \u201cEnvironmental Health Perspectives\u201d  (Estados Unidos)  y \u201cFaseb \nJournal\u201d  (Estados Unidos) y por parte de Sudam\u00e9rica a la \u201cRevista de Saude Publica \u201d (Brasil) con nivel \nIII \n \n              Tabla 2  Revist as que aparecen con m\u00e1s citas  a los trabajos publicados del CISP (  5 citas o m\u00e1s).  \nREVISTAS CITADAS  Citas  *Nivel   \nNEW ENGLAND JOURNAL OF MEDICINE  287 V \nINTERNATIONAL JOURNAL OF CANCER  134 IV \nCANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION  109 IV \nVACCINE  82 IV \nSALUD PUBLICA DE M\u00c9XICO  59 III \nAMERICAN JOURNAL OF EPIDEMIOLOGY  56 IV \nPEDIATRIC INFECTIOUS DISEASE JOURNAL   51 IV \nCANCER, CAUSES AND CONTROL  47 IV \nCA: A CANCER JOURNAL FOR CLINICIANS  37 V \nARCHIVES OF MEDICAL RESEARCH  32 III \nJOURNAL OF THE NA TIONAL CANCER INSTITUTE  25 V \nENVIRONMENTAL HEALTH PERSPECTIVES  20 V \nFASEB JOURNAL  18 V \nINTERNATIONAL JOURNAL OF EPIDEMIOLOGY  18 IV \nJOURNAL OF WOMEN\u00b4S  HEALTH  16 III \nINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER  15 III \nSEXUALLY TRANSMITTED DISEASES  13 III \nCANCER RESEARCH  12 V \nNUTRITION AND CANCER  9 III \nREVISTA SAUDE PUBLICA  9 III \nAMERICAN JOURNAL OF CLINICAL NUTRITION  7 V \nINTERNATIONAL JOURNAL OF GYNECOLOGY AND OBSTETRICS   7 III \nJOURNAL OF INFECTIOUS DISEASES  6 IV \nONCOLOGY  6 III \nEUROPEAN JOURNAL OF CANCER  5 IV \n** Nivel de la revista seg\u00fan el Factor de impacto por a\u00f1o del JCR 2008 y conforme al criterio de \u201cClasificaci\u00f3n Cualitativa d e \nRevistas Cient\u00edficas Peri\u00f3dicas\u201d.  \n \n  \n10  \n \n \n \n Tabla 3. Distibuci\u00f3n de los 112  art\u00edculos seleccionados de la producci\u00f3n cient\u00edfica de la LIM de acuerdo al \nnivel de la revista en la que fueron publicados. \n \n \nRevistas de Nivel III \n  \nRevistas de Nivel IV  \n  \nRevistas de Nivel V \n \n57 art\u00edculos  \n  \n45 art\u00edculos  \n  \n10 art\u00edculos  \n \n \n \nGr\u00e1fico 1.  Misma  distribuci\u00f3n mas el n\u00famero correspondiente de citas para cada nivel,  lo que nos da un \ntotal de 1116 citaciones .  \n \n \n \n \nII. REVISTAS DONDE SE PUBLICARON LOS ART\u00cdCULOS QUE CITARON LA \nPRODUCCI\u00d3N CIENT\u00cdFICA DEL CISP. \nEsta secci\u00f3n corresponde al an\u00e1lisis de revistas donde se publicaron los 866 art\u00edculos  que citan los \ntrabajos del CISP, aparece en primer lugar \u201cVaccine\u201d  (Holanda), especializada en la prevenci\u00f3n de \nenfermedades y basada primordialmente en el estudio de las vacunas, cuenta con un factor de \nimpacto por a\u00f1o de 3.298  y de acuerdo a la clasificaci\u00f3n cualitativa de revistas cient\u00edficas peri\u00f3dicas \nse ubica en el nivel IV . Otras con aporte generoso son \u201cThe International Journal of Cancer\u201d  \n(Estados Unidos);  \u201cSalud Publica de M\u00e9xico\u201d ; \u201cC\u00e1ncer Epidemiology, Biomarkers & Research\u201d  ya \ncomentadas en el an\u00e1lisis de las revistas citadas. Clasificadas con nivel V  podemos mencionar al \n\u201cAmerican Journal of Clinical Nutrition\u201d (Estados Unidos),  \u201cEnvironmental Health Perspectives\u201d  \n(Estados Unidos),   \u201cCancer\u201d (Estados Unidos),   y \u201cBMJ\u201d (Inglaterra)  y por \u00faltimo, entre las \nsudamericanas  la \u201cRevista M\u00e9dica de Chile\u201d de nivel III . (Tabla 4) \n \n \n \n0100200300400500600\narticulos 57 45 10\ncitas 195 514 407NIVEL III NIVEL IV NIVEL V \n11  \n             Tabla 4 .  Revistas donde se publicaron los art\u00edculos que citaron la producci\u00f3n del CISP (5 o m\u00e1s art\u00edculos) \nREVISTA   *Art\u00edculos  **Nivel  \nVACCINE  55 IV \nINTERNATIONAL JOURNAL OF CANCER  32 IV \nSALUD P\u00daBLICA DE M\u00c9XICO  22 III \nCANCER  EPIDEMIOLOGY, BIOMARKERS & PREVENTION  17 IV \nJOURNAL OF INFECTIOUS DISEASES  16 IV \nGYNECOLOGIC ONCOLOGY  14 III \nBRITISH JOURNAL OF CANCER  13 IV \nINTERNATIONAL JOURNAL OF  GYNECOLOGICAL CANCER  12 III \nEUROPEAN JOURNAL OF CANCER  11 IV \nJOURNAL OF ADOLESCENT HEALTH  10 III \nSEXUALLY TRANSMITTED DISEASES  10 III \nCANCER, CAUSES & CONTROL  10 IV \nAMERICAN JOURNAL OF CLINICAL NUTRITION  9 V \nJOURNAL OF WOMEN\u00b4S  HEALTH  8 III \nACTA OB STETRICA ET GYNECOLOGICA SCANDINAVICA  7 III \nOBSTETRICS & GYNECOLOGY  7 IV \nENVIRONMENTAL HEALTH PERSPECTIVES  7 V \nANNALS OF EPIDEMIOLOGY  6 III \nINDIAN JOURNAL OF MEDICAL RESEARCH  6 III \nJOURNAL OF MEDICAL VIROLOGY  6 III \nPREVENTIVE MEDICINE  6 III \nREVISTA M\u00c9DICA DE CHILE  6 III \nSEXUALLY TRANSMITTED INFECTIONS  6 III \nAMERICAN JOURNAL OF EPIDEMIOLOGY  6 IV \nANNALS OF ONCOLOGY  6 IV \nBRITISH MEDICAL JOURNAL  6 V \nCANCER  6 V \nAMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY  5 III \nEUROPEAN JOURNAL OF CANCER PREVENTIO N 5 III \nEUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY  5 III \nEUROPEAN JOURNAL OF OBSTET GYNECOL REPRO BIOL  5 III \nEXPERT REVIEW OF VACCINES  5 III \nPUBLIC HEALTH GENOMICS  5 III \nJOURNAL OF THE NATIONAL CANCER INSTITUTE  5 V \nNEW ENGLAND JOURNAL OF MEDICINE  5 V \n \n** Nivel de la revista seg\u00fan el Factor de impacto por a\u00f1o del JCR 2008 y conforme al criterio de \u201cClasificaci\u00f3n Cualitativa d e \nRevistas Cient\u00edficas Peri\u00f3dicas\u201d.  \n \n  \n12  \n \n   Gr\u00e1fico 2 .  Distribuci\u00f3n por nivel de la revista de los  art\u00edculos que citan la prod ucci\u00f3n cient\u00edfica del CISP  (LIM C\u00e1ncer)  \n \n \n \n  Gr\u00e1fico 3. Distribuci\u00f3n por  reg\u00ed\u00f3n de procedencia de la revista.  \n \n \n \nCon respecto a los pa\u00edses con mayor contribuci\u00f3n de art\u00edculos fueron: Estados Unidos  por parte de \nAm\u00e9rica e Inglaterra y Holanda  (en ese orden) por parte de Europa. Las revistas latinoamericanas \ncontribuyeron con 70 art\u00edculos (incluido M\u00e9xico). \n \n \n \n \n \n8127946442\nNivel VNivel IVNivel IIINivel I-IINIVEL DE LA REVISTAART\u00cdCULOS= 866\nCONTINENTES\n-ASIA -AFRICA\nOCEAN\u00cdA\n55\n6%\nAMERICA\n442\n51%EUROPA\n369\n43% \n13  \n \nRevistas que aparecen en ambas tablas (2 y 4) \n \nREVISTA  NIVEL  \nAMERICAN JOURNAL OF CLINICAL NUTRITION  V \nAMERICAN JOURNAL OF EPIDEMIOLOGY  IV \nCAN CER EPIDEMIOLOGY, BIOMARKERS & PREVENTION  IV \nCANCER, CAUSES AND CONTROL  IV \nENVIRONMENTAL HEALTH PERSPECTIVES  V \nEUROPEAN JOURNAL OF CANCER  IV \nINTERNATIONAL JOURNAL OF CANCER  IV \nINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER  III \nJOURNAL OF INFECTIOUS DISEASES  IV \nJOURNAL OF THE NATIONAL CANCER INSTITUTE  V \nJOURNAL OF WOMEN\u00b4S  HEALTH  III \nNEW ENGLAND JOURNAL OF MEDICINE  V \nSALUD PUBLICA DE M\u00c9XICO  III \nSEXUALLY TRANSMITTED DISEASES  III \nVACCINE  IV \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \n14  \n \nTEM\u00c1TICA CONSULTADA POR LOS AUTORES QUE CITARON LOS TRABAJOS DEL CISP. \n \nwww.eleconomista.com.mx \n \n \nAl ser el virus del papiloma humano la etiolog\u00eda principal  de c\u00e1ncer cervicouterino, es razonable \nque las investigaciones  en c\u00e1ncer  se enfoquen en la prevenci\u00f3n de la transmisi\u00f3n de este agent e \ncausal,  despu\u00e9s de analizar los trabajos m\u00e1s citados podemos concluir que  el mayor interes entre \nlos investigadores externos quienes citan esta producci\u00f3n son: \n \n1.- El estudio de las vacunas contra el VPH: a) seguridad; b) eficacia e inmunogenicidad - sobre \ntodo de la vacuna cuadrivalente \u2013 c) aceptabilidad y d) los  estudios de costo-efectividad. \n2.- C\u00e1ncer cervico-uterino: a) estudios epidemiol\u00f3gicos; b) mortalidad b) prevalencia del HPV en \nmujeres; d) prevalencia HPV en hombres. \n3.- Factores de riesgo: a) Las variantes asiatico-americanas del HPV-16 y el riesgo de contraer c\u00e1ncer \ncervical; b)  detecci\u00f3n de HPV tanto en mujeres embarazadas como en la no-embarazadas; c) \nrelaci\u00f3n del tabaquismo con la adquisici\u00f3n de la infecci\u00f3n por HPV ;  d) comparaci\u00f3n de la \nmortalidad por c\u00e1ncer cervical asociada a la pobreza en \u00e1reas rurales y urbanas;  e) infecciones del \nHPV relacionadas  a conductas sexuales, uso del cond\u00f3n, anticonceptivos orales y factores \nreproductivos. \n4.- Programas de detecci\u00f3n oportuna de c\u00e1ncer: a ) accesibilidad; b) cobertura ;  c) aceptabilidad; d) \nconocimiento; e) las barreras para su implementaci\u00f3n;  f) la integraci\u00f3n de las vacunas a los \nprogramas nacionales y g) la situaci\u00f3n actual en Latinoam\u00e9rica. \n5.- C\u00e1ncer de mama: a) prevalencia; b) la relaci\u00f3n con la exposici\u00f3n al DDT; d)  la relaci\u00f3n de este \ntipo de c\u00e1ncer con la ingesta de carbohidratos, vitamina B6, B12, carga glic\u00e9mica y ag\u00f9nos otros \nfactores diet\u00e9ticos y reproductivos. \n6.- C\u00e1ncer g\u00e1strico: a) Helicobacter pylori; b) h\u00e1bitos alimenticios o nutricionales y b) el rol del \nfolato en la carcinog\u00e9nesis g\u00e1strica y  la actividad  de la enzima MTHFR en este proceso.  \n7.-  La epidemiolog\u00eda y patolog\u00eda molecular del c\u00e1ncer de ri\u00f1\u00f3n tambi\u00e9n se encuentra presente entre \nlos temas m\u00e1s citados.  \n8.- Los factores de riesgo nutricionales as\u00ed como la relaci\u00f3n de la la obesidad y la diabetes con el \ndesarrollo de c\u00e1ncer de ovario y endometrio tambi\u00e9n estuvieron presentes.  \n \n \n \n \n \n \n15 \u201cEL LEGADO DE LA ESPERANZA \u201c    \n \n16  \n \n17 CITOGRAF\u00cdA \n \n1) A Brief History of Vitamin D and Cancer Prevention . Mohr SB. Ann Epidemiol 2009 Feb;19(2):79- 83. \n                Trabajo (s) citado (s): \n Salazar -Martinez E .Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Gonz\u00e1lez-Lira G . Escudero-De Los Rios P . \nHern\u00e1ndez-Avila M . Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico . Int J \nGynecol Cancer 2005 Sep -Oct;15(5 ):938 -45.  \n \n2) A cost \u2013utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening \nprogramme. Dee A. Howell F. Eur J Public Health. OnLine October 2009. \n                Trabajo (s) citado (s): \n Insinga RP. Dasbach EJ. Elbasha EH. Puig A. Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human \npapillomavirus (HPV) vaccination in Mexico: a transmission dynamic model based evaluation. Vaccine 2007, \n26:128-139. \n \n3) A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females . Anonychuk AM. et al. \nBMC Public Health 2009;9.401 \n                Trabajo (s) citado (s): \n Insinga RP. Dasbach EJ. Elbasha EH. Puig A. Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human \npapillomavirus (HPV) vaccination in Mexico: a transmission dynamic model based evaluation. Vaccine 2007, \n26:128-139. \n \n4) A Different Approach to Breast Self-Examination Education Daughters Educating Mothers Creates Positive \nResults in Turkey. Gursoy AA. et al. Cancer Nurs 2009;32(2):127- 34 \n                Trabajo (s) citado (s): \n Ortega-Altamirano D. L\u00f3pez-Carrillo L.  L\u00f3pez-Cervantes M.  Estrategias para la ense\u00f1anza del autoexamen del \nseno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 \u201325. \n \n5) A Genome -Scale Metabolic Reconstruc tion of Mycoplasma genitalium, i PS189. Suthers PF. et al.  PLoS Comp \nBiol 2009;Feb 2009;5(2):14p.  \n                Trabajo (s) citado (s): \n Oliva G. Romero I. Ayala G. Barrios-Jacobo I . Celis H (2000) Characterization of the inorganic pyrophosphatase \nfrom the pathogenic bacterium Helicobacter pylori. Arch Microbiol 174: 104 \u2013110. \n \n6) A Multi-Individual Pharmacokinetic Model Framework for Interpreting Time Trends of Persistent Chemicals \nin Human Populations: Application to a Postban Situation. Ritter R. et al. Environ Health Perspect 1009 \nAug;117(8):1280-6 \n                Trabajo (s) citado (s): \n Verner MA. Charbonneau M. L\u00f3pez-Carrillo L.  Haddad S. Physiologically based pharmacokinetic modeling of \npersistent organic pollutants for lifetime exposure assessment: a new tool in breast cancer epidemiologic studies. \nEnviron Health Perspect. 2008;116(7):886 \u2013892. \n \n7) A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Huber VC, Thomas \nPG, McCullers JA. Vaccine 2009 18Feb;27(8):1192- 200. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n8) A new look at vitamin B12 deficiency. Nettina SM. Nurse Practitioner 2009 Nov;34(11):18- 24 \n                Trabajo (s) citado (s): \n Lajous M. Romieu I.  Sabia S. Boutron-Ruault MC. Clavel-Chapelon F. Folate, vitamin B12 and postmenopausal \nbreast cancer in a prospective study of French women. Cancer Causes Control 17, 1209 \u20131213, 2006. \n \n9) A non -radioactive PCR -SSCP analysis allows to distinguish between HPV 16 European and Asian -American \nvariants in squamous cell carcinomas of the uterin e cervix in Colombia. Moreno -Acosta P, Molano M, Huertas \nA, et al. Virus Genes 2008 Aug;37(1):22 -30. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n10) A package of primary health care services for comprehensive family-centred HIV/AIDS care and treatment \nprograms in low-income settings. Tolle MA. Trop Med Int Health 2009 Jun;14(6):663- 72. \n                Trabajo (s) citado (s): \n \n18 \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n11) A Perspective on Nutritional Genomics. Escott-Stump S. Topics Clin Nutr 2009:24(2):92- 113 \n                Trabajo (s) citado (s): \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carrillo L.  et al. Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T \nand A1298C polymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n \n12) A pilot study on the distribut ion of human papillomavirus genotypes and HPV -16 variants in cervical \nneoplastic lesions from Ecuadorian women. Tornesello ML, Buonaguro L, Izzo S, et al. J Med Virol 2008 \nNov;80(11):1959 -65. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n13) A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types \n6/11/16/18) Vaccine against High -grade Cervical and External Genital Lesions . Kjaer SK, Sigurdsson K, Iversen \nOE, et al. Cancer Prev  Res 2009 Oct;2(10):868 -78. \n                Trabajo (s) citado (s): \n Giulia no AR . Lazcano-Ponce E.  Villa L . Nolan T . Marchant C . Radley D . Golm G .  McCarroll K . Yu J . Esser MT . \nVuocolo SC . Barr E Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) \nhuman papillomavirus virus-like-particle vaccine .. J Infect Dis 2007 15Oct;196(8):1153- 62. \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n14) A primary healthcare-based intervention to improve a Danish cervical cancer screening programme: a cluster \nrandomised controlled trial . Jensen H, Svanholm H, Stovring H, et al. J Epidemiol Commun Health 2009 \nJul;63(7):5105. \n                Trabajo (s) citado (s): \n Torres -Mejia G . Salmeron-Castro J . Tellez-Rojo MM . Lazcano-Ponce EC . Juarez-Marquez SA . Torres-Torija I . Gil-\nAbadie L . Buiatti E. Call and recall for cervical cancer screening in a developing country: A randomised field trial . \nInt J Cancer 2000 15Sep;87(6):869- 73. \n \n15) A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative \nbreast disease. Rohan TE. et al.  Breast Cancer Res Treat 2009 jul;116( 2):339 -50 \n                Trabajo (s) citado (s): \n Galv\u00e1n-Portillo M. Torres-S\u00e1nchez L. L\u00f3pez-Carrillo L.  Dietary and reproductive factors associated with benign \nbreast disease in Mexican women. Nutr Cancer 2002;43(2):133- 40 \n \n16) A randomised trial of-human-papillomavirus (HPV) testing in primary cervical screening.  Kitchener HC, \nAlmonte M, Gilham C, et al. Health Technol Assess 2009 Nov;13(51):1-+ \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n17) A Review of Prophylactic Human Papillomavirus Vaccines: Recommendations and Monitoring in the US.  \nDunne EF, Datta SD, Markowitz LE. Cancer 2008 15Nov;113(10):2995-3003 Suppl. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n18) A review of the evidence comparing the human papillomavirus vaccine versus condoms in the prevention of \nhuman papillomavirus infections. Miksis S. JOGNN \u2013 Journal of Obstetric Gynecologic and Neonatal Nursing \n2008 May-Jun;37(3):329- 37. \n                Trabajo (s) citado (s):  \n19 \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n19) A perspective from Mexico . Rodriguez-Lopez MH. J Public Health Policy 2008 Apr;29(1):26-31.  \n                Trabajo (s) citado (s): \n Lazcano- Ponce E. Alonso P . Ruiz-Moreno JA . Hern\u00e1ndez-Avila M . Recommendations for cervical cancer \nscreening programs in developing countries. The need for equity and technological development . Salud Publica \nMex 2003;45(Suppl 3):S449-S462.  \n \n20) A Systematic Review of Meta -Analyses on Gene Polymorphisms and Gastric Cancer Risk. Gianfagna F.  De \nFeo E. et al. Curr Genom 2008; 9(6): 361 -374. \n                Trabajo (s) citado (s): \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carrillo L.  et al. Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T \nand A1298C polymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008;167(5):505 -516. \n \n21) A Systematic Review of the Association between Breastfeeding and Breast Cancer . Yang L, Jacobsen KH. J \nWomens Health 2008 Dec;17(10):1635-45. \n                Trabajo (s) citado (s): \n Olaya -Contreras P . Pierre B . Lazcano- Ponce EC.  Villamil-Rodriguez J . Posso-Valencia HJ . Reproductive risk \nfactors associated with breast cancer in Columbian women . Rev Saude Publica 1999 Jun;33(3):237- 45. \n \n22) A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early \ntermination in pediatric clinical trials. Fernandes RM. van der Lee JH.  et al. BMC Pediatrics 2009; 9: 16. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n23) A Woman with an Abnormal Papanicolaou Smear CIN 3 (severe dysplasia or carcinoma in situ) of the uterine \ncervix. Endocervical adenocarcinoma in situ. Goldstein MA, Goodman A, del Carm en MG, et al. NEJM 2009 \n26Mar;360(13):1337 -44. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n24) Acceptability of th e Human Papillomavirus Vaccine among Latina Mothers . Bair RM, Mays RA, Sturm LA, et \nal. J Pediatr Adolesc Gynecol 2008 Dec;21(6):329 -34. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Rivera L. Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n25) Acceptability of human papillomavirus vaccination among Chinese women: concerns and implications . Kwan \nTTC, Chan KKL, Yip AMW, et al. BJOG An International Journal of Obstetrics and Gynaecology 2009 \nMar;116(4):501-10. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC. Castro R . Allen B . Najera P . De Ruiz PA. Hern\u00e1ndez-Avila M . Barriers to early detection of \ncervical-uterine cancer in Mexico . J Womens Health 1999 Apr;8(3):399- 408. \n \n26) Acceptability   to Latino parents of sexually transmitted infection vaccination. Bair RM, Mays RM, Sturm LA, et \nal. Ambul Pediatr 2008 Mar -Apr;8(2):98 -103. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Rivera L. Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n27) Acceptance of human papillomavirus vaccination among first year female university students in Hong Kong. \nWong WCW, Fong B, Chan PKS. Sex health 2009;6(4):264- 71. \n                Trabajo (s) citado (s):  \n20 \n Lazcano- Ponce E.  Rivera L. Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n \n28) Acceptance of Human Papillomavirus Vaccine by Gynecologists in an Urban Setting. Jaspan DM, Dunton CJ, \nCook TL.  J Low Genit Tract Dis 2008 Apr;12(2):118- 21. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n29) Acne and oral contraceptives: Update on women's health screening guidelines. Frangos JE, Alavian CN, \nKimball AB. J Am Acad Dermatol 2008 May;58(3):781- 6. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915- 27.  \n \n30) Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer \nvaccines. Einstein MH. Cancer Immunol Immunother 2008 Apr;57(4):443- 51. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n31) Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV cohort study . \nGoodman MT, Shvetsov YB, McDuffie K, et al. J infect Dis 2008 1Apr;197(7):957- 66. \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n32) ACS releases guidelines for HPV vaccination. Cox JT, Mahoney MC, Saslow D, et al. Am Fam Physician 2008 \n15Mar;77(6):852. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n33) Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Textor S, \nDurst M, Jansen L, et al. Int J Cancer 2008 15Nov;123(10):2343- 53. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n34) Adeno -associated virus and human papillomavirus types in cervical samples of pregnant and non -pregnant \nwomen . Freitas LB, Pereira CC, Checon R, e t al. Eur J Obstet Gynecol Reprod Biol 2009 Jul;145(1):41 -4. \n                Trabajo (s) citado (s): \n Hern\u00e1ndez -Gir\u00f3n C . Smith JS . Lorincz A . Lazcano E.. Hern\u00e1ndez-Avila M . Salmeron J . High-risk human \npapillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico . Sex \nTransm Dis 2005 Oct;32(10):613-8.  \n \n35) Adlea (ALGRX-4975), an injectable capsaicin (TRPV1 receptor agonist) formulation for long-lasting pain relief. \nRemadevi R. et al. Drugs 2008 Feb;11(2):120- 32 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L.  Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case-\ncontrol study. Am J Epidemiol 1994;139:263- 71. \n \n36) Advantages and Disadvantages of Current Prophylactic Vaccines Against HPV. Madrid -Marina V, Torres -\nPoveda K, Lopez -Toledo G, et al. Arch Med Res 2009 Aug;40(6):471 -7. Sp. Iss. SI  \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n \n21 37) Adverse pregnancy outcomes after treatment for cervical intraepithelial neoplasia . Jakobsson M, Bruinsma F. \nBMJ 2008 4Oct;337(7673):a1350  \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Snijders PJF. Dai M . Thomas JO . Hieu NT . Ferreccio C . Matos E . Posso H . de Sanjose S . \nShin HR . Sukvirach S . Lazcano-Ponce E. Mun\u00f3z N . Meijer CJLM . Franceschi S . Smoking and human \npapillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence \nSurveys. Int J Epidemiol 2008 Jun;37(3):536- 46.  \n \n38) Aetiology of Cancer in Asia. Park S, Bae J, Nam BH, et al. Asian Pac J Cancer Prev 2008;9(3):371-80. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n39) African, Asian or Indian enigma, the East Asian Helicobacter pylori : facts or medical myths. Graham DY. et al. J \nDig Dis 2009;10:77- 84 \n                Trabajo (s) citado (s): \n Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Gastric cancer risk in a Mexican population: \nrole of Helicobacter pylori CagA po sitive infection and polymorphisms in interleukin -1 and -10 genes. Int. J. \nCancer. 118:649 \u2013657. \n \n40) Age and Severity of Mucosal Lesions Influence the Performance of Serologic Markers in Helicobacter pylori \u2013\nAssociated Gastroduodenal Pathologies. Carmolinga -Ponce M. et al. Cancer Epidemiol Biomarkers Prev \n2008;17(9):2498 -504 \n                Trabajo (s) citado (s): \n Tovar -Guzm\u00e1n V. Hern\u00e1ndez -Gir\u00f3n C . Barquera S. Rodr\u00edguez -Salgado N. L\u00f3pez -Carrillo L.. Epidemiologic \npanorama of stomach cancer mortality in Mexico. Arc h Med Res 2001;32:312 \u2013 7. \n \n41) Age at menarche is not an independent risk factor for high-risk human papillomavirus infections and cervical \nintraepithelial neoplasia . Syrjanen K, Shabalova I, Petrovichev N, et al. Int J STD AIDS 2008 Jan;19(1):16- 25. \n                Trabajo (s) citado (s): \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n Hern\u00e1ndez -Gir\u00f3n C . Smith JS . Lorincz A . Lazcano E. . Hern\u00e1ndez-Avila M . Salmeron J . High -risk human \npapillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico . Sex \nTransm Dis 2005 Oct;32(10):613-8.  \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n42) Age at menopause and factors associated with attainment of menopause in an urban community in Ibadan, \nNigeria . OlaOlorun F, Lawoyin T. Climacteric 2009;12(4):352- 63. \n                Trabajo (s) citado (s): \n Garrido -Latorre F . Lazcano-Ponce EC . L\u00f3pez-Carrillo L . Hern\u00e1ndez-Avila M . Age of natural menopause among \nwomen in Mexico City . Int J Gynecol Obstet 1996 May;53(2):159-66.  \n \n43) Age at sexual initiation and number of sexual partners in the female Spanish population Results from the \nAFRODITA survey . de Sanjose S, Cortes X, Mendez C, et al. Eur J Obstet Gynecol Reprod Biol 2008 \nOct;140(2):234-40. \n                Trabajo (s) citado (s): \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n44) Age considerations when vaccinating against HPV. Wright TC, Huh WK, Monk BJ, et al. Gynecol Oncol 2008 \nMay;109(2):S40-S47. Suppl 1. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n45) Age for HPV vaccination. Harper DM, Paavonen J. Vaccine 2008 14Mar;26(Suppl 1):A7-A11. \n \n22                 Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n46) Age-appropriate use of human papillomavirus vaccines in the US. Castle PE, Fetterman B, Akhtar I, et al. \nGynecol Oncol 2009 Aug;114(2):365- 9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n47) Age-Based Programs for Vaccination against HPV. Elbasha EH, Dasbach EJ, Insinga RP, et al. Value in Health \n2009 Jul-Aug;12(5):697- 707. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n48) Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic \nvaccination and screening. Coupe VMH, Berkhof J, Bulkmans NWJ, et al. Br J Cancer 2008 12Feb;98(3):646- 51. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n49) Age-specific prevalence of high-risk human papillomavirus infection in a Hungarian female population with \npositive cytology. Sapy T, Poka R, Szarka K, et al. Eur J Obstet Gynecol Reprod Biol 2008 Jun;138(2):194- 8. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n50) Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US \nmen. Giuliano AR, Lu BB, Nielson CM, et al. J Infect Dis 2008 15Sep;198 (6):827 -35. \n                Trabajo (s) citado (s): \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n51) Age-Specific Prevalence of Infection with Human Papillomavirus in Females: A Global Review. Smith JS, \nMelendy A, Rana RK, et al. J Adolesc Health 2008 Oct;43(4):S5-S25. Suppl.     \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Salmeron J . Lazcano-Ponce E.  Lorincz A . Hernandez M . Hern\u00e1ndez P . Leyva A . Uribe M . Manzanares H . Antunez \nA. Carmona E . Ronnett BM . Sherman ME . Bishai D . Ferris D . Flores Y . Yunes E . Shah KV . Comparison of HPV-\nbased assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico . Cancer Causes \nControl 2003 Aug;14(6):505-12.  \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n Hern\u00e1ndez -Gir\u00f3n C . Smith JS . Lorincz A . Lazcano E. . Hern\u00e1ndez-Avila M . Salmeron J . High-risk human \npapillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico . Sex \nTransm Dis 2005 Oct;32(10):613-8.  \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n Hern\u00e1ndez Avila M . Lazcano-Ponce EC . Berumen Campos J . Cruz Vald\u00e9z A . De Ruiz PPA . Gonzalez Lira \nG.Human papilloma virus 16-18 infection and cervical cancer in Mexico: A case-control study . Arch Med Res 1997 \nSummer;28(2):265- 71. \n \n52) AgNOR polymorphism association with squamous intraepithelial lesions and inva sive carcinoma with HPV \ninfection. Alarcon -Romero LD, Illades -Aguiar B, Flores -Alfaro E, et al. Salud Publica Mex 2009 Mar -\nApr;51(2):134 -40. \n                Trabajo (s) citado (s):  \n23 \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n Hern\u00e1ndez Avila M . Lazcano-Ponce EC . Berumen Campos J . Cruz Vald\u00e9z A . De Ruiz PPA . Gonzalez Lira \nG.Human papilloma virus 16-18 infection and cervical cancer in Mexico: A case-control study . Arch Med Res 1997 \nSummer;28(2):265- 71. \n Lazcano-Ponce EC . Rasc\u00f3n-Pacheco RA . Lozano-Ascencio R . Velasco-Mondrag\u00f3n HE . Mortality from cervical \ncarcinoma in Mexico - Impact of screening, 1980- 1990. Acta Cytol 1996 May-Jun;40(3):506- 12. \n \n53) Alaska native parental attitudes on cervical cancer, HPV,and the HPV vaccine. Toffolon-Weiss M, Hagan K, \nLeston J, et al. Int J Circump Health 2008 Sep;67(4):363- 73. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Rivera L. Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n \n54) Allium vegetables intake and endometrial cancer risk . Galeone C, Pelucchi C, Dal Maso L, et al. Public Health \nNutr 2009 Sep;12(9):1576- 9. \n                Trabajo (s) citado(s):  \n Salazar -Martinez E . Lazcano-Ponce E . Lira-Lira GG . Escudero-De los Rios P . Salmeron-Castro J . Larrea F . \nHernandez-Avila M .Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer \namong Mexican women . Cancer Causes Control 2000 Sep;11(8):707- 11. \n \n55) An approach to formative research in HPV vaccine  introduction planning in low-resources settings. Bingham \nA. et al. The Open Vaccine Journal 2009;2:1- 16 \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n56) An epidemiological study to identify the risk factors with two different types of controls in high-grade cervical \nlesions including invasive cancer . Sardana S, Sharma S, Sodhani P, et al. Eur J Cancer Care 2009 Nov;18(6):620-\n4. \n                Trabajo (s) citado (s): \n Tovar -Guzman V . Hern\u00e1ndez-Gir\u00f3n C . Lazcano -Ponce E.  Romieu I . Avila MH . Breast cancer in Mexican women: \nan epidemiological study with cervical cancer control . Rev Saude Publica 2000 Apr;34(2):113-9.  \n \n57) An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Schiller JT, \nCastellsague X, Villa LL, et al. Vaccine 2008 19Aug;26(Suppl 10):K53-K61. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n Giuliano AR . Lazcano-Ponce E.  Villa L . Nolan T . Marchant C . Radley D . Golm G .  McCarroll K . Yu J . Esser MT . \nVuocolo SC . Barr E Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) \nhuman papillomavirus virus-like-particle vaccine .. J Infect Dis 2007 15Oct;196(8):1153- 62. \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n58) An update on mortality in systemic lupus erythematosus.  Ippolito A, Petri M. Clin Exp Rheumatol 2008 Sep-\nOct;26(5):S72-S79. Suppl 51. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n59) Anal human papillomavirus genotype diversity and co-infection in a community-based sample of homosexual \nmen. Vajdic CM, van Leeuwen MT, Jin F, et al. Sex Transm Infect sep;85(5))330- 5. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n60) Analysis of content about sexuality and human reproduction in school textbooks in Spain . de Irala J, Urdiain \nIG, del Burgo CL. Public Health 2008 Oct;122(10):1093-1103. \n                Trabajo (s) citado (s):  \n24 \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n61) Animal models for human papillomavirus-associated cervical pathogenesis. Wang XD, Zhuang J, Xie ZY, et al. \nRev Med Microbiol 2009 Apr;20(2):33- 40. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n62) Anti-HPV vaccination: A review of recent economic data for Italy. Mennini FS, Costa S, Favato G, et al. Vaccine \n2009 29May;27(Suppl 1):A54-A61. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions. NEJM 2007 10May;356(19):1915-27.  \n \n63) An\u00e1lisis coste -efectividad de vareniclina (Champix) frente a los parches de nicotina en el tratamiento del \ntabaquismo en M\u00e9xico. Mould- Quevedo JF. Contreras -Hern\u00e1ndez I. PharmaEconomics Spanis h Res Artic \n2009;6(1):22 -32  \n                Trabajo (s) citado (s): \n Reynales-Shigematsu L . Ju\u00e1rez-M\u00e1rquez S. Valdez-Salgado R . Costo de atenci\u00f3n m\u00e9dica atribuible al tabaquismo \nen el IMSS, Morelos. Salud P\u00fablica Mex 2005; 47: 451- 7. \n Reynales-Shigematsu L . Rodr\u00edguez-Bola\u00f1os RA. Jim\u00e9nez JA. Ju\u00e1rez-M\u00e1rquez S. Castro-R\u00edos A. Hern\u00e1ndes-\u00c1vila \nM. Costo de atenci\u00f3n m\u00e9dica atribuible al tabaquismo en el Instituto Mexicano del Seguro Social. Salud P\u00fablica \nMex 2006; 48(supl 1):S48-S64 \n Salmer\u00f3n-Casto J. Franco-Marina F. Salazar-Mart\u00ednez E . et al. Panorama epidemiol\u00f3gico de la mortalidad por \nc\u00e1ncer en el Instituto Mexicano del Seguro Social: 1991-1995. Salud Publica Mex 1997;39(4):266- 73 \n \n64) Analysis of T -cell proliferation and cytokine secretion in the individuals exposed to arsenic. Biswas R. et al. \nHum Exp Toxicol 2008;27:381 -6 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessment \nof lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n65) Analysis of whole genomic expression profiles of Helicobacter pylori related chronic atrophic gastritis with IL-\n1B-31CC/-511TT genotypes. Wang SY. et al.  J Dig Dis 2009;10(2):99- 106 \n                Trabajo (s) citado(s):  \n Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Gastric cancer risk in a Mexican population: \nrole of Helicobacter pylori CagA positive infection and polymorphisms in interleukin -1 and -10 genes. Int. J. \nCancer. 118:649 \u2013657. \n \n66) Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland. Syrjanen KJ. Scand \nJ Infect Dis 2009;41(Suppl 107):3- 32. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n67) Annual disease burden due to human papillomavirus 16 and 18 infections in Finland. Syrjanen KJ. Scand J \nInfect Dis 2009;41(Suppl 108):2- 32. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC. Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n68) Antioxidant vitamins and the risk of endometrial cancer: a dose-response meta-analysis . Bandera EV, Gifkins \nDM, Moore DF, et al. Cancer Causes Control 2009 Jul;20(5):699- 711. \n                Trabajo (s) citado (s): \n Salazar -Martinez E .Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Gonz\u00e1lez-Lira G . Escudero-De Los Rios P . \nHern\u00e1ndez-Avila M . Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico . Int J \nGynecol Cancer 2005 Sep -Oct;15(5 ):938 -45.  \n \n69) Appropriate use of cervical cancer vaccine. Zimet GD, Shew ML, Kahn JA. Annu Rev Med 2008;59:223- 36. \n                Trabajo (s) citado (s):  \n25 \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n70) Are we ready for mandatory fortification with vitamin B- 12?  Refsum H, Smith AD.  Am J Clin Nutr 2008 \n1Aug;88(2):253- 4. \n                Trabajo (s) citado (s): \n Lajous M . Lazcano- Ponce E . Hern\u00e1ndez-Avila M . Willett W . Romieu I . Folate, vitamin B-6, and vitamin B- 12 \nintake and the risk of breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2006 \nMar;15(3):443-8.   \n71)  \nArsenic in drinking water and adult mortality: a population -based cohort study in rural Bangladesh. Sohel N. \net al. Epidemiology 2009 Nov;20(6):824 -30 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessment \nof lymphocyte subpop ulations and cytokine secretion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n72) Arsenic -induced mitochondrial instability leading to programmed cell death in the exposed individuals. \nBanerjee N. et al. Toxicology 2008 18Apr;246(2 -3):101 -11 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessment \nof lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n73) Arsenic i nduces telomerase expression and maintains telomere length in human cord blood cells. Ferrario D. et \nal. Toxicology 2009 Jun;260(1 -3):132 -41 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebr ian ME. et al. 2006. Assessment \nof lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n74) ARTISTIC: a randomised trial of-human-papillomavirus (HPV) testing in primary cervical screening. \nKitchener HC, Almonte M, Gilham C, et al. Health Technol Assess 2009 Nov;13(51):1+ \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n75) Asia Pacific: Cervical Cancer Screening and Human Papillomavirus Vaccination Policy and Delivery. Shah KV. \nVaccine 26 19Aug;26(Suppl 12):III-IV. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n76) Assessing Cervical Cancer Screening Guidelines in Patient Education Materials. Roland KB. Benard VB. J \nWomens Health 2009; 18(1): 5- 12. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n77) Assessing participation of women in a cervical cancer screening program in Peru . Robles SC, Ferreccio C, Tsu \nV, et al. Rev Panam Salud Publica 2009 Mar;25(3):189 -95. \n                Trabajo (s) citado (s): \n Torres -Mejia G . Salmeron-Castro J . Tellez-Rojo MM . Lazcano-Ponce E.  Juarez-Marquez SA . Torres-Torija I . Gil-\nAbadie L . Characteristics of respondents to a cervical cancer screening program in a developing country . Arch \nMed Res 2002 May-Jun;33(3):295-300.  \n Aguilar -Perez JA . Leyva-L\u00f3pez AG . Angulo-Najera D . Salinas A . Lazcano-Ponce EC . Cervical cancer screening: \nknowledge of Pap smear benefits and utilization in Mexico .. Rev Saude Publica 2003 Feb;37(1):100-6.  \n Lazcano- Ponce EC. Castro R . Allen B . Najera P . De Ruiz PA. Hern\u00e1ndez-Avila M . Barriers to early detection of \ncervical-uterine cancer in Mexico . J Womens Health 1999 Apr;8(3):399- 408. \n \n78) Assessment of average exposure to organochlorine pesticides in southern Togo from water, maize (Zea mays) \nand cowpea (Vigna unguiculata) . Mawussi G, Sanda K, Merlina G, et al. Food Addit Contam Part A Chem Anal \nControl Exp Risk Assess 2009;26(3):348- 54. \n                Trabajo (s) citado (s): \n Romieu I . Hernandez-Avila M . Lazcano- Ponce E. . Weber JP . Dewailly E . Breast cancer, lactation history, and \nserum organochlorines . Am J Epidemiol 2000 15Aug;152(4):363- 70. \n  \n26 79) Association between a pro -inflammatory genetic profile and the risk of chronic atrophic gastritis among older \nadults from Germany. Gao L. et al. Eur J Cancer 2009 Feb;45(3):428 -34 \n                Trabajo (s) citado (s): \n Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Gastric cancer risk in a Mexican population: \nrole of Helicobacter pylori CagA positive infection and polymorphisms in interleukin -1 and -10 genes. Int. J. \nCancer. 118:649 \u2013657. \n \n80) Association between human papillomavirus DNA load and development of cervical intraepithelial neoplasia \nand cervical cancer . Huang Y, Huang MN, Li N, et al. Int J Gynecol Cancer 2008 Jul-Aug;18(4):755-60.  \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n81) Association between the methylenetetrahydrofolate reductase C677T polymorphism and hepatocellular \ncarcinoma risk: a meta-analysis. Jin F. et al. Diagnost Pathol 2009;4:39 \n                Trabajo (s) citado (s): \n  S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro M. \nLing D . L\u00f3pez -Carrillo L. et al. Meta - and pooled analyses of the met hylenetetrahydrofolate reductase C677T and \nA1298C polymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n \n82) Association Between Toll -like Receptor 4 Gene Polymorphism and Biopsy -proven Giant Cell Arteritis  . \nPalomino -Morales R, Torres O, Vazquez -Rodriguez TR. et al.  J Rheumatol 2009 Jul;36(7):1501 -6.  \n                Trabajo (s) citado (s): \n Trejo -de la OA . Torres J . P\u00e9rez-Rodr\u00edguez M . Camorlinga-Ponce M . Flores- Luna L . Abdo-Francis JM . Lazcano E.  \nMaldonado-Bernal C . TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine patterns in \nMexican patients with Helicobacter pylori-associated gastroduodenal diseases . Clin Immunol 2008 Nov;129(2) \n:333-340.  \n \n83) Association of CYP1A1 Msp1 polymorphism with tobacco-related risk of gallbladder cancer in a north Indian \npopulation. Pandey SN, Choudhuri G, Mittal B. Eur J Cancer Prev 2008 Apr;17(2):77- 81. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n84) Association of Helicobacter pylori infection and diet on the risk of gastric cancer: a case \u2013control study in \nHawaii. Epplein M. et al. Cancer Causes Control 2008;19:869- 77 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L.  L\u00f3pez-Cervantes M. Robles-D\u00edaz G. Ram\u00edrez-Espitia A. Mohar-Betancourt A. Meneses-Garc\u00eda A. \nL\u00f3pez-Vidal Y. Blair A. Capsaicin consumption, helicobacter pylori positivity and gastric cancer in Mexico. Int J \nCancer 2003;106(2):277- 82 \n Ward MH. L\u00f3pez-Carrillo L.  Dietary Factors and the Risk of Gastric Cancer in Mexico City.  Am J Epidemiol \n1999;149(10):925- 32. \n \n85) Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US \npopulation. Zuna RE, Moore WE, Shanesmith RP, et al. Int J Cancer 2009 1Dec;125(11):2609- 13. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n86) Associations between Male Anogenital Human Papillomavirus Infection and Circumcision by Anatomic Site \nSampled and Lifetime Number of Female Sex Partners. Nielson CM, Schiaffino MK, Dunne EF, et al. . J Infect \nDis 2009 1Jan;199(1):7- 13. \n                Trabajo (s) citado (s): \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n \n27 87) Atmospheric DDTs over the North Pacific Ocean and the adjacent Arctic region: Spatial distribution, congener \npatterns and source implication. Ding X. et al. Atmosph Environ 2009 Sep;43(28):4319- 26 \n                Trabajo (s) citado (s): \n L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez -Carrillo L . 2004. Dichlorodiphenyldi chloroethane burden \nand breast cancer risk: A meta -analysis of the epidemiologic evidence. Environ. Health Perspect. 112:207 \u2013214. \n \n88) Attitudes towards HPV immunization of Italian mothers of adolescent girls and potential role of health \nprofessionals in the i mmunization program. Tozzi AE. Rava L. et al. Vaccine 2009; 27(19): 2625 -2629.  \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n89) Attitudes toward HPV vaccination among parents of adolescent girls in Mysore, India. Madhivanan P, Krupp \nK, Yashodha MN, et al. Vaccine 2009 20Aug;27(38):5203 -8. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Rivera L. Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n Winkler JL . Wittet S . Bartolini RM . Creed-Kanashiro HM . Lazcano-Ponce E. Lewis-Bell K . Lewis MJ . Penny ME . \nDeterminants of Human Papillomavirus Vaccine Acceptability in Latin America and the Caribbean . Vaccine 2008 \n19Aug;26(Suppl 11):L73-L79.  \n \n90) Augmented serum level of major histocompatibility complex class I -related chain A (MICA) protein and \nreduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions . \nArreygue -Garcia NA, Daneri -Navarro A, del Toro -Arreola A, et al. BMC Cancer 2008 21Jan;8:Artic 16.  \n                Trabajo (s) citado (s): \n Lazcano-Ponce EC.  Moss S . de Ruiz PA . Castro JS . Avila MH .Cervical cancer screening in developing countries: \nWhy is it ineffective? The case of  Mexico . Arch Med Res 1999 May-Jun;30(3):240-50.  \n \n91) Automation of the linear array HPV genotyping test and its application for routine typing of human \npapillomaviruses in cervical specimens of women without cytological abnormalities in Switzerland. Dobec M, \nBannwart F, Kaeppeli F, et al. J Clin Virol 2009 May;45(1):23- 7. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n92) Available resources for the treatment of breast cancer in Mexico . Moh ar A, Bargallo E, Ramirez MT, et al. Salud \nPublica Mex 2009;51(Suppl 2):S263 -S269.  \n                Trabajo (s) citado (s): \n Romieu I . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Willett W . Hern\u00e1ndez-Avila M . Carbohydrates and the risk \nof breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2004 Aug;13(8):1283-9.  \n \n93) Awareness, knowledge, and beliefs about human papillomavirus in a racially diverse sample of young adults. \nGerend MA. Magloire ZF. J Adolesc Health 2008; 42(3): 237- 242. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n94) Background Review Paper on Total Fat, Fatty Acid Intake and Cancers. Gerber M. Ann Nutr Metab 2009;55:140-\n61. \n                Trabajo (s) citado (s): \n Lajous M.  Boutron-Ruault MC. Fabre A. Clavel-Chapelon F. Romieu I . Carbohydrate intake, glycemic index, \nglycemic load, and risk of postmenopausal breast cancer in a prospective study of French women. Am J Clin Nutr. \n2008;87(5):1384 \u20131391.  \n \n95) Barreras de acceso al diagn\u00f3stico temprano del c\u00e1ncer de mama en el Distrito Federal y en Oaxaca. Nigenda G. \net al. Salud Publica Mex 2009;51(supl 2):S254-S262. \n                Trabajo (s) citado (s): \n Poblano-Verastegui O. Figueroa-Perea JG. L\u00f3pez -Carrillo L.  Institutional factors contributing to the utilization of \nbreast clini cal examination. Salud P\u00fablica de M\u00e9xico, 2004;46(4):294 \u2013305. \n \n96) Barriers to acceptance of the human papillomavirus prophylactic vaccine. Blumenthal J. Heyman KP. et al. J \nPediat Infect Dis 2008;3(3): 159-165. \n                Trabajo (s) citado (s): \n \n28 \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n97) Barriers to Acceptance of Self-sampling for Human Papillomavirus across Ethnolinguistic Groups of Women. \nHoward M.  Lytwyn A. et al. Canadian Journal of Public Health-Revue Canadienne De Sante Publique \n2009; 100(5): 365- 369. \n                Trabajo (s) citado (s): \n Dzuba IG. Yunes -D\u00edaz E. Allen B.  Leonard YF. Lazcano- Ponce EC.  et al. The Acceptability of Self -collected \nSamples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women\u2019s \nHealth & Gender -Based Medicine, 2002;11(3):265 -275. \n \n98) Baseline assessment of prevalence and geographical distribution of HPV types in Chile using self-collecte d \nvaginal samples. Ferreccio C, Corvalan A, Margozzini P, et al. BMC Public Health 2008 28Feb;8:78. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Dzuba IG. Yunes -D\u00edaz E. Allen B.  Leonard YF. Lazcano- Ponce EC.  et al. The Acceptabili ty of Self -collected \nSamples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women\u2019s \nHealth & Gender -Based Medicine, 2002;11(3):265 -275. \n \n99) Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III \nclinical trials of a quadrivalent HPV (6/11/16/18) vaccine. Barthell E, Woelber L, Hellner K, et al. Arch Gynecol \nObstet 2009 Jun;279(6):803- 7. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n100) Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) \nvaccine clinical trials. Paavonen J. Curr Med Res Opin 2008 Jun;24(6):1623- 34. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n101) Bayesian mixture modeling of gene-environment and gene-gene interactions. Wakefield J. et al. Genetic \nEpidemiol 2009 \n                Trabajo (s) citado (s): \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carrillo L.  et al. Meta - and pooled analys es of the methylenetetrahydrofolate reductase C677T \nand A1298C polymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n \n102) Beneficial influence of capsaicin on lipid peroxidation, membrane -bound enzymes and glycoprotein  profile \nduring experimental lung carcinogenesis. Anandakumar P. et al. J Pharm Pharmacol 2008;60(6):803 -8 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L.  Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case-\ncontrol study. Am J Epidemiol 1994;139:263- 71. \n \n103) Biomarkers of oxidative stress and damage in human populations exposed to arsenic. De Vizcaya -Ru\u00edz A. et al. \nMutat Res 2009 Mar;674(1,2):85 -92 \n                Trabajo (s) citado (s): \n M\u00e9ndez -G\u00f3mez J. Garc\u00eda -Vargas GG. L\u00f3pez -Carrillo L.  Calder\u00f3n- Aranda ES. G\u00f3mez A. Vera E. Valverde M. \nCebri\u00e1n ME. Rojas E. Genotoxic Effects of environmental exposure to arsenic and lead on children in region \nLagunera, Mexico, NY Acad. Sci 2008;1140:358 -67. \n \n104) Breast Cancer Care in Developing Countries . Agarwal G, Ramakant P, Forgach ERS, et al. World J Surg 2009 \nOct;33(10):2069-76. \n                Trabajo (s) citado (s): \n Lajous M . Lazcano-Ponce E.  Hern\u00e1ndez-Avila M . Willett W . Romieu I . Folate, vitamin B-6, and vitamin B- 12 \nintake and the risk of breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2006 \nMar;15(3):443-8.   \n Romieu I . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Willett W . Hern\u00e1ndez-Avila M . Carbohydrates and the risk \nof breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2004 Aug;13(8):1283-9.  \n Romieu I . Hernandez-Avila M . Lazcano- Ponce E. . Weber JP . Dewailly E . Breast cancer, lactation history, and \nserum organochlorines . Am J Epidemiol 2000 15Aug;152(4):363- 70. \n  \n29 105) Breast cancer in Mexico: a pressing priority . Knaul FM, Nigenda G, Lozano R, et al. Reprod Health Matt 2008 \nNov;16(32):113- 123. \n                Trabajo (s) citado (s): \n Romieu I . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Willett W . Hern\u00e1ndez-Avila M . Carbohydrates and the risk \nof breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2004 Aug;13(8):1283-9.  \n L\u00f3pez-Carrillo L . Torres-S\u00e1nchez L . L\u00f3pez-Cervantes M. et al. Identificaci\u00f3n de lesiones mamarias en M\u00e9xico. \nSalud P\u00fablica de M\u00e9xico 2001;43(3):199 \u2013202. \n Ortega-Altamirano D. L\u00f3pez-Carrillo L.  L\u00f3pez-Cervantes M.  Estrategias para la ense\u00f1anza del autoexamen del \nseno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 \u201325. \n Poblano-Verastegui O. Figueroa-Perea JG. L\u00f3pez -Carrillo L.  Institutional factors contributing to the utilization of \nbreast clinical examination. Salud P\u00fablica de M\u00e9xico, 2004;46(4):294 \u2013305. \n \n106) Breast cancer  trends in Latin America and the Caribbean . Lozano -Ascencio R, Gomez -Dantes H, Lewis S, et al. \nSalud Publica Mex 2009;51(Suppl 2):S147 -S156.  \n                Trabajo (s) citado (s): \n L\u00f3pez -Rios O . Lazcano-Ponce EC . Tovar Guzman V . Hernandez Avila M . Breast cancer epidemiology in Mexico. \nDemographic transition consequence . Salud Publica Mex 2997 Jul -Aug;39(4):259 -65.  \n107)  \nBreast cancer : why link early detection to reproductive health interventions in developing countries? . Knaul \nFM. Et al. Salud Publica Mex 2009;50(suppl 2):S220-S227 \n                Trabajo (s) citado (s): \n Bernstein J. L\u00f3pez-Carrillo L.  Wang L. Epidemiology of Her-2/neu and P53 in breast cancer. Salud Publica Mex \n1999; 41: suppl 2:114-123. \n L\u00f3pez-Carrillo L.  Bravo-Alvarado J. Poblano-Verastegui O. Ortega Altamirano D., Reproductive determinants of \nbreast cancer in Mexican women. Ann N Y Acad Sci 1997; 837:537-50. \n \n108) Breast- feeding as a source of prevention in healthcare . Antunes LD, Antunes LAA, Corvino MPF, et al. Ciencia \nSaude Colectiva 2008 Jan -Feb;13(1):103 -9. \n                Trabajo (s) citado (s): \n Olaya -Contreras P . Pierre B . Lazcano- Ponce EC.  Villamil-Rodriguez J . Posso-Valencia HJ . Reproductive risk \nfactors associated with breast cancer in Columbian women . Rev Saude Publica 1999 Jun;33(3):237- 45. \n \n109) Breastfeeding and breast cancer risk in India: A multicenter case-control study . Gajalakshmi V, Mathew A, \nBrennan P, et al. Int J Cancer 2009 1Aug;125(3):662- 5. \n                Trabajo (s) citado (s): \n Romieu I . Hern\u00e1ndez-Avila M . Lazcano E.  L\u00f3pez L . Romero-Jaime R . Breast cancer and lactation history in \nMexican women . Am J Epidemiol 1996 15Mar;143(6):543-52.  \n \n110) Breast risk cancer and environmental endocrine disruptors. Fenichel P. et al. Gynecol Obstetr Fertil 2008 \nOct;36(10): 969-977. \n                Trabajo (s) citado (s): \n L\u00f3pez -Carrillo L . Blair A. L\u00f3pez -Cervantes M. Ce brian M. Rueda C.  Reyes R et al (1997) \ndichlorodiphenyltrichloroethane serum levels and breast cancer risk: a case -control study from Mexico. Cancer \nRes 57:3728 \u20133732  \n Romieu I . Hernandez-Avila M . Lazcano- Ponce E. . Weber JP . Dewailly E . Breast cancer, lactation history, and \nserum organochlorines . Am J Epidemiol 2000 15Aug;152(4):363- 70. \n \n111) British HIV Association guidelines for HIV-associated malignancies 2008. Bower M, Collins S, Cottrill C, et al. \nHIV Med 2008 Jul;9(6):336- 88. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n112) Burden and Trends of Type -Specific Human Papillomavirus Infections and Related Diseases in the Latin \nAmerica and Caribbean Region .  Parkin DM,  et al.  Vaccine 2008 19Aug;26(Suppl 11):L1 -L15.  \n                Trabajo (s) citado (s): \n Murillo R . Almonte M  Pereira A . Ferrer E . Gamboa OA . Jeronimo J . Lazcano-Ponce E. Cervical Cancer Screening \nPrograms in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48.  \n P\u00e9rez G . Lazcano- Ponce E . Hern\u00e1ndez-Avila M . Garcia PJ . Mun\u00f3z N . Villa LL. Bryan J . Taddeo FJ . Lu S . Esser MT . \nVuoco S. Sattler C . Barr E . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, \n11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8.  \n Flores -Luna L . Salazar-Martinez E . Escudero-De los Rios P . Gonzalez-Lira G . Zamora-Mu\u00f1\u00f3z S . Lazcano -Ponce \nEC. Prognostic factors related to cervical cancer survival in Mexican women . Int J Gynecol Obstet 2001 \nOct;75(1):33-42.  \n  \n30 113) Burden of Invasive Squamous Cell Carcinoma of the Penis in the United States, 1998-2003. Hernandez BY, \nBarnholtz-Sloan J, German RR, et al. Cancer 2009 15Nov;113(10):2883- 91. \n                Trabajo (s) citado (s): \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n \n114) C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine -based therapy  \npersonalisation. De Mattia E. Toffoli G. Eur J Cancer 2009;45:1333 -51 \n                Trabajo (s) citado (s): \n  S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro M. \nLing D . L\u00f3pez -Carrillo L. et al. Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T and \nA1298C polymorphisms and  gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n \n115) Can cervical cancer be eradicated by prophylactic HPV vaccination? Challenges to vaccine implementation.  \nGarland SM. Ind J Med Res 2009 Sep;130(3):311- 21. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n116) Can human papillomavirus DNA testing of self -collected vaginal samples compare with phy sician -collected \ncervical samples and cytology for cervical cancer screening in developing countries?  Bhatla N, Dar L, Patro AR, \net al. Cancer Epidemiol 2009 Dec;33(6):446 -50. \n                Trabajo (s) citado (s): \n Salmeron J . Lazcano-Ponce E.  Lorincz A . Hernandez M . Hern\u00e1ndez P . Leyva A . Uribe M . Manzanares H . Antunez \nA. Carmona E . Ronnett BM . Sherman ME . Bishai D . Ferris D . Flores Y . Yunes E . Shah KV . Comparison of HPV-\nbased assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico . Cancer Causes \nControl 2003 Aug;14(6):505-12.  \n \n117) Cancer and globalization. Sasco AJ. Biomed Pharmacother 2008 Feb;62(2):110- 21. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n118) Cancer cervico-uterino asociado al embarazo. Reporte de un caso. Urdaneta J. Zambrano NB. \nContreras-Benitez A. Rev Chil Obstet Ginecol 2009;74(%):315- 21. \n                Trabajo (s) citado (s): \n Hern\u00e1ndez -Gir\u00f3n C . Smith JS . Lorincz A . Lazcano E. . Hern\u00e1ndez-Avila M . Salmeron J . High-risk human \npapillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico . Sex \nTransm Dis 2005 Oct;32(10):613-8.  \n \n119) C\u00e1ncer de mama en M\u00e9xico: una prioridad apremiante. Knaul FM. Et al. Salud Publica Mex 2009;51 (supl \n2):S335-S344  \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L . Torres-S\u00e1nchez L . L\u00f3pez-Cervantes M. et al. Identificaci\u00f3n de lesiones mamarias en M\u00e9xico. \nSalud P\u00fablica de M\u00e9xico 2001;43(3):199 \u2013202. \n Romieu I . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Willett W . Hern\u00e1ndez-Avila M . Carbohydrates and the risk \nof breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2004 Aug;13(8):1283-9.  \n Ortega-Altamirano D. L\u00f3pez-Carrillo L.  L\u00f3pez-Cervantes M.  Estrategias para la ense\u00f1anza del autoexamen del \nseno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 \u201325. \n Poblano-Verastegui O. Figueroa-Perea JG. L\u00f3pez -Carrillo L.  Institutional factors contributing to the utilization of \nbreast clinical examination. Salud P\u00fablica de M\u00e9xico,  2004;46(4):294 \u2013305. \n \n120) Cancer disparities in indigenous polynesian populations: Maori, Native Hawaiians, and Pacific people. Dachs \nGU, Currie MJ, McKenzie F, et al. Lancet Oncol 2008 May;9(5):473- 84. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n121) Cancer prevention research - then and now.  Bode AM, Dong ZG. Nat Rev Cancer 2009 Jul;9(7):508- 16. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n122) Cancer prevention research: Back to the Future. Lippman SM. Cancer Prev Res 2009 Jun;2(6):503- 13.  \n31                 Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n123) Cancer Prevention: From 1727 to Milestones of the Past 100 Years.  Lippman SM, Hawk ET. Cancer Res 2009 \n1Jul;69(13):5269- 84. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n124) Candidate Vaccine Sequences to Represent Intra- and Inter-Clade HIV-1 Variation. Yang OO. PLoS One 2009 \n8Oct;4(10): Article: e7388. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents. Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n125) Capsaicin-induced apoptosis in human breast cancer MCF-7 cells through caspase-independent pathway. Chou \nCC. et al. Oncol Rep 2009;21(3):665- 71 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L.  Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case-\ncontrol study. Am J Epidemiol 1994;139:263- 71. \n \n126) Carbohydrate intake, glycemic index, glycemic load, and risk of postmenopausal breast cancer in a prospective \nstudy of French women .  Lajous M, Boutron-Ruault MC, Fabre A, et al. Am J Clin Nutr 2008 May;87(5):1384- 91. \n                Trabajo (s) citado (s): \n Romieu I . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Willett W . Hern\u00e1ndez-Avila M . Carbohydrates and the risk \nof breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2004 Aug;13(8):1283-9.  \n \n127) Case -control study of coffee consumption and the risk of endometrial endometrioid adenocarcinoma . Koizumi \nT, Nakaya N, Okamura C, et al. Eur J Cancer Prev 2008 Aug;17(4):358 -63. \n                Trabajo (s) citado (s): \n Salazar -Martinez E .Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Gonz\u00e1lez-Lira G . Escudero-De Los Rios P . \nHern\u00e1ndez-Avila M . Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico . Int J \nGynecol Cancer 2005 Sep -Oct;15(5 ):938 -45.  \n \n128) Cervical cancer: the sub-Saharan African perspective . Anorlu RI. Reprod Health Matt 2008 Nov;16(32):41- 9. \n                Trabajo (s) citado (s): \n Palacio -Mejia LS . Rangel-G\u00f3mez G . Hern\u00e1ndez-Avila M. Lazcano-Ponce E.  Cervical cancer, a disease of poverty: \nMortality differences between urban and rural areas in Mexico . Salud Publica Mex 2003;45(Suppl 3):S315 -S325.  \n \n129) Cervical cancer and HIV in Africa: a review. Ouattara S. Some DA. Bambara M. Da B.  J Afr Cancer   2009;1:110 -4 \n                Trabajo (s) citado (s): \n Herrero R . Ferreccio C . Salmeron J . Almonte M . S\u00e1nchez GI . Lazcano-Ponce E. Jeronimo J . New Approaches to \nCervical Cancer Screening in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L49-L58.  \n \n130) Cervical cancer and the human immunodeficiency virus: a review. Firnhaber CS. Michelow P. South Afr J HIV \nMed 2009 Jul;34:23- 7.  \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Palacio-Mejia LS . Allen-Leigh B . Yunes-Diaz E . Alonso P . Schiavon R . Hern\u00e1ndez-Avila M . \nDecreasing cervical cancer mortality in Mexico: Effect of Papanicolaou coverage, birthrate and the importance of \ndiagnostic validity of cytology . Cancer Epidemiol Biomarkers Prev 2008 Oct;17(10):2808- 17. \n   \n131) Cervical cancer prevention &  the role of human papillomavirus vaccines in India. Bhatla N, Joseph E. Ind J \nMed Res 2009 Sep;130(3):334- 340. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n132) Cervical cancer prevention by vaccination: nurses' knowledge, attitudes and intentions. Duval B. Gilca V. et al. \nJ Adv Nurs 2009; 65(3): 499 -508. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n \n32 133) Cervical Cancer Prevention in the Human Papilloma Virus Vaccine Era. Ghazal-Aswad S. An  NY Acad Sci \n2008;1138:253- 6. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n134) Cervical cancer prevention: who should receive vaccination?  Meijer CJ, Berkhof J, Heideman DA, et al. Nat \nClin Pract Oncol 2008 Jan;5(1):12 -13. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n135) Cervical Cancer Screening Among Women Who Gave Birth in the US-Mexico Border Region, 2005: The \nBrownsville- Matamoros Sister City Project for Women\u2019s Health. Castrucci BC. Echegollen -Guzm\u00e1n A. et al. \nPreventing Chronic Disease 2008 Oct;5(4):1- 15. \n                Trabajo (s) citado (s): \n Palacio -Mejia LS . Rangel-G\u00f3mez G . Hern\u00e1ndez-Avila M . Lazcano-Ponce E.  Cervical cancer, a disease of poverty: \nMortality differences between urban and rural areas in Mexico . Salud Publica Mex 2003;45(Supl 3):S315-S325. \n \n136) Cervical Cancer Screening in the Early Postvaccine Era. Waxman AG. Obstet Gynecol Clin North Am 2008 \nDec;35(4):537. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n137) Cervical cancer screening program integrating Pap smear and HPV DNA testing: A population-based study . \nChao A, Hsu KH, Lai CH, et al. Int J Cancer 2008 15Jun;122(12):2835- 41. \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A . Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n138) Cervical cancer: Screening and therapeutic perspectives. Sankaranaraya nan R, Thara S, Esmy PO, et al. Med \nPrincip Pract 2008;17(5):351 -64. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n139) Cervical cancer  vaccination indications, efficacy, and side effects. Bayas JM, Costas L, Munoz A. Gynecol \nOncol 2008 Sep;110(3):S11_S14. Suppl. 2. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n140) Cervical Cancers After Human Papillomavirus Vaccination. Beller U, Abu -Rustum NR. Obstet Gynecol 2009 \nFeb;113(2):550 -2. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n141) Cervical Carcinoma and Sexual Behavior: Collaborative Reanalysis of Individual Data on 15,461 Women with \nCervical Carcinoma and 29,164 Women without Cervical Carcino ma from 21 Epidemiological Studies .  \nAppleby P, Beral V, de Gonzalez AB, et al. Cancer Epidemiol Biomarkers Prev 2009 Apr;18(4):1060 -9. \n                Trabajo (s) citado (s): \n Vaccarella S . Franceschi S . Herrero R. Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n Lazcano- Ponce EC.  Hern\u00e1ndez -Avila M. L\u00f3pez -Carrillo L.  De Ru\u00edz PA. Torres -Lobat\u00f3n A. Gonz\u00e1lez -Lira A. \nRomieu I.  Reproductive factors and sex life -history and cervical -cancer in Mexico City. Rev Invest Clin 1995 Sep -\nOct;47(5):377 -85. \n \n33  \n142) Cervical carcinoma in Southern Mexic o: Human papillomavirus and cofactors . Illades -Aguiar B, Cortes -\nMalagon EM, Antonio -Vejar V, et al. Cancer Detect Prev 2009;32(4):300 -7.  \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Hern\u00e1ndez -Avila M. L\u00f3pez -Carrillo L.  De Ru\u00edz PA. Torres -Lobat \u00f3n A. Gonz\u00e1lez -Lira A. \nRomieu I.  Reproductive factors and sex life -history and cervical -cancer in Mexico City. Rev Invest Clin 1995 Sep -\nOct;47(5):377 -85. \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n Palacio -Mejia LS . Rangel-G\u00f3mez G . Hern\u00e1ndez-Avila M . Lazcano-Ponce E.  Cervical cancer, a disease of poverty: \nMortality differences between urban and rural areas in Mexico . Salud Publica Mex 2003;45(Suppl 3):S315 -S325.  \n Lazcano-Ponce EC . Najera Aguilar P . Buiatti E. Alonso De Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The \ncervical cancer screening program in Mexico: problems with access and coverage .  Cancer Causes Control 1997 \nSep;8(5):698 -704. \n \n143) Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women. Marais \nDJ, Constant D, Allan B, et al. J Clin Microbiol 2008 Feb;46(2):732- 9. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A . Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n144) Cervical screening according to age and HPV status. Ronco G, Arbyn M, Segnan N. BMJ 2009 28Jul;339. \nArticle:b3005  \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A . Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n145) CCR5 Delta 32 polymorphism: Associated with gallbladder cancer susceptibility. Srivastava A, Pandey SN, \nChoudhuri G, et al. Scand J Immunol 2008 May;67(5):516- 22. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n146) Challenges in treating malignancies in HIV in Nigeria. Akinwande O, Ogundiran T, Akarolo-Anthony S, et al. \nCurr Opin Oncol 2009 Sep;21(5):455- 61. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n147) Characterization of sequence variations within HPV16 isolates among Indian women: Prediction of causal role \nof rare non-synonymous variations within intact isolates in cervical cancer pathogenesis. Bhattacharjee B, \nMandal NR, Roy S, et al. Virology 2008 20Jul;337(1):143- 50. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA . Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n148) Children playing with poison: Arsenic exposure from CCA-treated wood. Baptist PL. et al. Leslie NS. J Nurs \nPract 2008 Jan;4(1):48- 53 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessment \nof lymphocyte subpopulations and cytokine secre tion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n149) Cholecystokinin receptor A gene polymorphism in gallstone disease and gallbladder cancer. Srivastava A, \nPandey SN, Dixit M, et al. J Gastroenterol Hepatol 2008 Jun;32(6):970 -5. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n  \n34 150) Cholesterol gallstones and cancer of gallbladder (CAGB): molecular links. Venniyoor A. Med Hypoth \n2008;70(3):646-53. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C. Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n151) Cigarette smoking, alcohol drinking and the risk of gallbladder cancer death: A prospective cohort study in \nJapan. Yagyu K, Kikuchi S, Obata Y, et al. Int J Cancer 2008 15Feb;122(4):924- 9. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n152) Chronic Arsenic Exposure Impairs Macrophage Functions in the Exposed Individuals. Banerjee N. et al. J Clin \nImmunol 2009 Sep;29(5):582 -94 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessment \nof lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n153) Chronic Exposure to Arsenic in the Drinking Water Alters the Expression of Immune Response Genes in \nMouse Lung. KOzul CD. et al. Environ Health Perspect 2009 Jul;117(7):1108 -15 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessment \nof lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n154) Circumcision and human papillomavirus infection in men: A site-specific comparison. Hernandez BY, Wilkens \nLR, Zhu X, et al. . J Infect Dis 2008 15Mar;197(6):787- 94. \n                Trabajo (s) citado (s): \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n155) Citrus fruit intake and stomach cancer risk: a quantitative systematic review. Bae JM. Et al. Gastric Cancer \n2008;11;23- 32. \n                Trabajo (s) citado (s): \n Ward MH. L\u00f3pez-Carrillo L.  Dietary Factors and the Risk of Gastric Cancer in Mexico City.  Am J Epidemiol \n1999;149(10):925- 32. \n \n156) Classification of Cancer Recurrence with Alpha-Beta BAM . Acevedo ME, Acevedo MA, Felipe F. Math Probl \nEngineer 2009 Article Number: 680212. \n                Trabajo (s) citado (s): \n L\u00f3pez -Rios O . Lazcano-Ponce EC . Tovar Guzman V . Hernandez Avila M . Breast cancer epidemiology in Mexico. \nDemographic transition consequence . Salud Publica Mex 2997 Jul -Aug;39(4):259 -65.  \n \n157) Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific \nregion. Tay EH, Garland S, Tang G, et al. Int J Gynecol Obstet 2008 Oct;102(3):275- 83. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n158) Clinician's guide to human papillomavirus immunology: knowns and unknowns. Einstein MH, Schiller JT, \nViscidi RP, et al. Lancet Infect Dis 2009 Jun;9(6):347- 56. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n159) Clinicopathologic Characteristics of Endometrial Adenocarcinomas in Young Women . Choi G, Kim JW, Khang \nSK, et al. Kor J Pathol 2009 Oct;43(5):441- 7. \n \n35                 Trabajo (s) citado (s): \n Salazar -Martinez E . Lazcano-Ponce E . Lira-Lira GG . Escudero-De los Rios P . Salmeron-Castro J . Larrea F . \nHernandez-Avila M .Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer \namong Mexican women . Cancer Causes Control 2000 Sep;11(8):707- 11. \n \n160) Coffee drinking and endometrial cancer risk: a metaanalysis of observational studies . Bravi F, Scotti L, Bosetti \nC, et al. Am J Obstet Gynecol 2009 Feb;200(2):130- 5. \n                Trabajo (s) citado (s): \n Salazar -Martinez E . Lazcano-Ponce E . Lira-Lira GG . Escudero-De los Rios P . Salmeron-Castro J . Larrea F . \nHernandez-Avila M .Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer \namong Mexican women . Cancer Causes Control 2000 Sep;11(8):707- 11. \n Salazar -Martinez E .Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Gonz\u00e1lez-Lira G . Escudero-De Los Rios P . \nHern\u00e1ndez-Avila M . Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico . Int J \nGyn ecol Cancer 2005 Sep -Oct;15(5 ):938 -45.  \n \n161) Commonly asked questions on human papillomavirus vaccine. Chan PKS. H K. Hong Kong J Dermatol \nVenereol 2008;16(1):12- 7. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n162) Comparison of detailed and succinct cohort modelling appr oaches in a multi -regional evaluation of cervical \ncancer vaccination. Debicki D, Ferko N, Demarteau N, et al. Vaccine 2008 15Sep;26(Suppl 5):F16 -F28. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n163) Comparison of the immunogenicity and safety of Cervarix (TM) and Gar dasil (R) human papillomavirus \n(HPV) cervical cancer   vaccines in healthy  women aged 18 -45 years. Einstein MH. Baron M. et al. Human \nVaccines 2009; 5(10): 705 -719. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n164) Comparison of two different educational methods on tea chers' knowledge, beliefs and behaviors regarding \nbreast cancer screening. Avci IA. et al. Eur J Oncol Nurs 2009;13(2):94 -101 \n                Trabajo (s) citado (s): \n Ortega-Altamirano D. L\u00f3pez-Carrillo L.  L\u00f3pez-Cervantes M.  Estrategias para la ense\u00f1anza del autoexamen del \nseno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 \u201325. \n \n165) Comparison of two PCR-based human papillomavirus genotyping methods. Castle PE, Porras C, Quint WG, et \nal. J Clin Microbiol 2008 Oct;46(10):3437- 45. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazca no-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n166) Complement Receptor 1 (A(3650)G RsaI and Intron 27 HindIII) Polymorphisms and Risk of Gallbladder  \n167) Cancer in North Indian Population. Srivastava A, Mittal B. Scand J Immunol 2009 Dec;70(6):614- 20. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n168) Complexes of Human Papillomavirus Type 16 E6 Proteins Form Pseudo -Death -Inducing Signaling Complex \nStructures during Tumor Necrosis Factor -Mediated Apoptosis. Filippova M, Filippov VA, Ka goda M, et al. J \nVirol 2009 1Jan;83(1):210 -27. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC . Estrada RA . Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n169) Conglomerados de c\u00e1ncer g\u00e1strico en el estado de M\u00e9rida, Venezuela. Alonso-Amelot ME. Avenda\u00f1o-Meza M. \nInterciencia 2009 Sep;34(9):617- 22 \n                Trabajo (s) citado (s):  \n36 \n Ward MH. L\u00f3pez-Carrillo L.  Dietary Factors and the Risk of Gastric Cancer in Mexico City.  Am J Epidemiol \n1999;149(10):925- 32. \n \n170) Conocimientos,  aceptabilidad y actitudes sobre la vacuna contra el VPH en m\u00e9dicos generales, ginec\u00f3logos y \npediatras en Colombia. Pi\u00f1eros M. Cort\u00e9s C, et al. Rev Colomb Cancerol 2009;13(2):88- 98 \n                Trabajo (s) citado (s): \n Franco EL . Tsu V. Herrero R . Lazcano-Ponce E . Hildesheim A . Mun\u00f3z N . Murillo R . S\u00e1nchez GI . Andrus JK . \nIntegration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the \nCaribbean . Vaccine 2008 19 Aug;26(Suppl 11):L88-L95.     \n171)  \nConquering sexually transmitted diseases. Starnbach MN, Roan NR. Nat Rev Immunol 2008 Apr;8(4):313- 7. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n172) Conservative Treatment With Progestin and Pregnancy Outcomes in Endometrial Cancer . Hahn HS, Yoon SG, \nHong JS, et al. Int J Gynecol Cancer 2009 Aug;19(6):1068- 73. \n                Trabajo (s) citado (s): \n Salazar -Martinez E . Lazcano-Ponce EC.  Lira-Lira GG . Escudero-De los Rios P . Salmeron-Castro J . Hern\u00e1ndez-\nAvila M . Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico . \nCancer Res 1999 1Aug;59(15):3658- 62. \n \n173) Consumption of sweet foods and breast cancer risk: a case-control study of women on Long Island, New York . \nBradshaw PT, Sagiv SK, Kabat GC, et al. Cancer Causes Control 2009 Oct;20(8):1509- 15. \n                Trabajo (s) citado (s): \n Lajous M.  Willett W . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM , Hernandez-Avila M , Romieu I . Glycemic load, \nglycemic index, and the risk of breast cancer among Mexican women . Cancer Causes Control 2005 \nDec;16(10):1165-9.  \n \n174) Control of cervical cancer in Colombia: the perspective of the health system . Wiesner-Ceballos C, Moreno \nRHM, Petersen MP, et al. Rev Panam Salud Publica 2009 Jan;25(1):1- 8. \n                Trabajo (s) citado (s): \n Lazcano-Ponce EC . Najera Aguilar P . Buiatti E. Alonso De Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The \ncervical cancer screening program in Mexico: problems with access and coverage .  Cancer Causes Control 1997 \nSep;8(5):698 -704. \n \n175) Correcting serum concentrations of organochlorine compounds by lipids: Alternatives to the organochlorine / \ntotal lipids ratio. Porta M. et al. Environ Int 2009;35:1080-5 \n                Trabajo (s) citado (s): \n Verner MA. Charbonneau M. L\u00f3pez-Carrillo L.  Haddad S. Physiologically based pharmacokinetic modeling of \npersistent organic pollutants for lifetime exposure assessment: a new tool in breast cancer epidemiologic studies. \nEnviron Health Perspect. 2008;116(7):886 \u2013892. \n \n176) Correlation between Cholelithiasis and Gallbladder Carcinoma in Surgical and Autopsy Specimens.  Mlinaric-\nVrbica S, Vrbica Z. Collegium Antropologicum 2009 Jun;33(2):533- 7. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n177) Correlation Between IL-10 Gene Expression and HPV Infection in Cervical Cancer: A Mechanism for Immune \nResponse Escape . Bermudez -Morales VH, Gutierrez LX, Alcocer -Gonzalez JM, et al.  Cancer Invest \n2008;26(10):1037 -43. \n                Trabajo (s) citado (s): \n Hern\u00e1ndez -Gir\u00f3n C . Smith JS . Lorincz A . Lazcano E. . Hern\u00e1ndez-Avila M . Salmeron J . High-risk human \npapillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico . Sex \nTransm Dis 2005 Oct;32(10):613-8.  \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n178) Cost -effectiveness analysis of a cervical cancer vaccine in five Latin  American countries. Colantonio L, Gomez \nJA, Demarteau N, et al. Vaccine 2009 4Sep;27(40):5519 -29. \n                Trabajo (s) citado (s):  \n37 \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Insinga RP. Dasbach EJ. Elbasha EH. Puig A. Reynales-Shigematsu LM.  Cost-effectiveness of quadrivalent human \npapillomavirus (HPV) vaccination in Mexico: a transmission dynamic model based evaluation. Vaccine 2007, \n26:128-139. \n Salmeron J . Lazcano-Ponce E.  Lorincz A . Hernandez M . Hern\u00e1ndez P . Leyva A . Uribe M . Manzanares H . Antunez \nA. Carmona E . Ronnett BM . Sherman ME . Bishai D . Ferris D . Flores Y . Yunes E . Shah KV . Comparison of HPV-\nbased assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexi co. Cancer Causes \nControl 2003 Aug;14(6):505-12.  \n Flores -Luna L . Salazar-Martinez E . Escudero-De los Rios P . Gonzalez-Lira G . Zamora-Mu\u00f1\u00f3z S . Lazcano -Ponce \nEC. Prognostic factors related to cervical cancer survival in Mexican women . Int J Gynecol Obstet 2001 \nOct;75(1):33-42.  \n \n179) Cost -effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme \nin Switzerland. Szucs TD, Largeron N, Dedes KJ, et al. Curr Med Res Opin 2008 May;24(5):1473-83. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n180) Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women . Kwon JS, Lu KH. \nObstet Gynecol 2008 Jul;112(1):56 -63. \n                Trabajo (s) citado (s): \n Salazar -Martinez E . Lazcano-Ponce E . Lira-Lira GG . Escudero-De los Rios P . Salmeron-Castro J . Larrea F . \nHernandez-Avila M .Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer \namong Mexican women . Cancer Causes Control 2000 Sep;11(8):707- 11. \n \n181) Cost -effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in \nAustria .  Zechmeister I. et al. Vaccine 2009 Aug;27(37):5133- 41 \n                Trabajo (s) citado (s): \n Insinga RP. Dasbach EJ. Elbasha EH. Puig A. Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human \npapillomavirus (HPV) vaccination in Mexico: a transmission dynamic model based evaluation. Vaccine 2007, \n26:128-139. \n \n182) Cost -Effectiveness analysis of human papillomavirus Vaccination in the Netherlands . de Kok IM. et al. J Natl \nCancer Inst 2009;101(15):1083- 92. \n                Trabajo (s) citado (s): \n Insinga RP. Dasbach EJ. Elbasha EH. Puig A. Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human \npapillomavirus (HPV) vaccination in Mexico: a transmission dynamic model based evaluation. Vaccine 2007, \n26:128-139. \n \n183) Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United \nStates.  Kim JJ, Goldie SJ. BMJ 2009 8Oct;339 Article Number: b3884 \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n184) Cost -effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. \nBergeron C, Largeron N, McAllister R, et al. Int J Technol Assess Health Care 2008 Win;24(1):10- 9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n185) Cost -Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium. Annemans L, \nRemy V, Oyee J, et al. Pharmaeconomics 2009;27(3):231- 45. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n186) Cost -effectiveness of breast cancer screening policies in Mexico . Valencia -Mendoza A, Sanchez -Gonzalez G, \nBautista -Arredondo S, et al. Salud Publica Mex 2009 51(Supl 2):S296 -S304.  \n                Trabajo (s) citado (s):  \n38 \n Flores -Luna L . Salazar-Martinez E . Duarte-Torres RM . Torres-Mejia G . Alonso-Ruiz P . Lazcano -Ponce E.  \nPrognostic factors related to breast cancer survival . Salud Publica Mex 2008 Mar-Apr;50(2):119-25.  \n187)  \nCost -effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 \nvaccination. Goldhaber-Fiebert JD, Stout NK, Salomon JA, et al. J Natl Cancer Inst 2008 5Mar;100(5):308- 20. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n188) Cost -Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older \nThan 30 Years in the United States. Kim JJ, Ortendahl J, Goldie SJ. Ann Intern Med 2009 20Oct;151(8):538- 45. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n189) Cost -effectiveness of human papillomavirus vaccination in Belgium: Do not forget about cervical cancer \nscreening. Thiry N, De Laet C, Hulstaert F, et al. Int J Tech Assess Health Care 2009 Apr;25(2):161-70 - \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n190) Cost -effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to \nHPV types 16 and 18 using a transmission dynamic model. Usher C, Tilson L, Olsen J, et al. Vaccine 2008 \n16Oct;26(44):5654- 61. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Insinga RP. Dasbach EJ. Elbasha EH. Puig A. Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human \npapillomavirus (HPV) vaccination in Mexico: a transmission dynamic model based evaluation. Vaccine 2007, \n26:128-139. \n \n191) Cost -effectiveness of vaccination against cervical cancer: A multi-regional analysis assessing the impact of \nvaccine characteristics and alternative vaccination scenarios. Suarez E, Smith JS, Bosch FX, et al. Vaccine 2008 \n15Sep;26(Suppl 5):F29-F45. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n192) Cost of screening and treatment of cervical dyskaryosis in Germany. Petry KU, Breugelmans JG, Benard S, et \nal. Eur J Gynaecol Oncol 2008;29(4):345- 9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n193) Costo institucional del infarto agudo del miocardio en en el Instituto de Cardiolog\u00eda y Cirug\u00eda Cardiovascular. \nFern\u00e1ndez-Garcia A. et al. Rev Cub Salud Publica;43(4):1-7 \n                Trabajo (s) citado (s): \n Reynales-Shigematsu L . Ju\u00e1rez-M\u00e1rquez S. Valdez-Salgado R . Costo de atenci\u00f3n m\u00e9dica atribuible al tabaquismo \nen el IMSS, Morelos. Salud P\u00fablica Mex 2005; 47: 451- 7. \n \n194) Costs and benefits of HAART for patients with HIV in a public hospital in Mexico . Aracena -Genao B, Navarro \nJO, Lamadrid -Figueroa H, et al. AIDS 2008 Jul;22(Suppl 1) :S141 -S148.  \n                Trabajo (s) citado (s): \n Flores -Luna L . Mun\u00f3z SZ . Salazar-Mart\u00ednez E . Lazcano-Ponce EC.  Methodology in survival studies. The case of \ncervical cancer among Mexican women . Salud Publica Mex 2000 May-Jun;42(3):242- 51. \n195)  \nCoverage of Cervical Cytology and Related Factors in Four Departments of Colombia . Cendales R. Pi\u00f1eros M. \nWiesner C. et al. Rev Colomb Cancerol 2008 ;12(3):119 -125  \n                Trabajo (s) citado (s): \n Murillo R . Almonte M  Pereira A . Ferrer E . Gamboa OA . Jeronimo J . Lazcano-Ponce E. Cervical Cancer Screening \nPrograms in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48.  \n \n196) Country recommendations on the inclusion of HPV vaccines in national immunization programmes among \nhigh -income countries, June 2006 -January 2008. Koulova A, Tsui J, Irwin K, et al. Vaccine 2008 \n2Dec;26(51):6529 -41.  \n39                 Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n197) Current challenges and future perspectives in the medical treatment of solid tumours.  Sobrero A, Di Benedetto \nM.  Eur JCancer SUPPLEMENTS 2008 Oct;6(14):91-3.    \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n198) Current issues in ad olescent immunization. Brabin L, Greenberg DP, Hessel L, et al. Vaccine 2008 \n5Aug;26(33):4120 -34. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Rivera L. Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n199) Current prophylactic HPV vaccines and gynecologic premalignancies. Harper DM. Curr Opin Obstet Gynecol \n2009 Dec;21(6):457- 64. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n200) Current status of gynecological cancer in China. Kim K, Zang R, Choi SC, et al. J Gynecol Oncol 2009 \nJun;20(2):72 -6. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A . Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n201) Current Understanding of Risk Factors for Ovarian Cancer .  Sueblinvong T, Carney ME. Curr Treat Opt Oncol \n2009 Apr;10(1-2):67- 81. \n                Trabajo (s) citado (s): \n Salazar -Mart\u00ednez E . Lazcano-Ponce E.  Lira-Lira GG . Escudero-De los Rios P . Hern\u00e0ndez-Avila M . Nutritional \ndeterminants of epithelial ovarian cancer risk: A case-control study in Mexico . Oncology 2002;63(2):151-7.  \n \n202) Currently approved prophylactic HPV vaccines. Harper DM. Expert Rev Vaccines 2009 Dec;8(12):1663- 79. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n203) Cutting human papillomavirus infection in men. Chin-Hong PV. J Infect Dis 2008 15Mar;197(6):781- 3. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n204) Cytokine polymorphisms and gastric cancer risk. Schneider BG. et al. Cancer Biol Ther 2008;7(2):157- 62 \n                Trabajo (s) citado (s): \n Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Gastric cancer risk in a Mexican population: \nrole of  Helicobacter pylori CagA positive infection and polymorphisms in interleukin -1 and -10 genes. Int. J. \nCancer. 118:649 \u2013657. \n \n40  \n205) DDT and breast cancer. Tarone RE. Environ Health Perspect 2008 Apr;116(4):A153  \n                Trabajo (s) citado (s): \n L\u00f3pez -Cervante s M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez -Carrillo L . 2004. Dichlorodiphenyldichloroethane burden \nand breast cancer risk: A meta -analysis of the epidemiologic evidence. Environ. Health Perspect. 112:207 \u2013214. \n \n206) DDT and breast cancer: Cohn et al. respond . Cohn BA, Cirillo PM, Sholtz RI, et al. Environ Health Perspect \n2008 Apr;116(4):A153-A154. \n                Trabajo (s) citado (s): \n Romieu I . Hernandez-Avila M . Lazcano- Ponce E. . Weber JP . Dewailly E . Breast cancer, lactation history, and \nserum organochlorines . Am J Epidemiol 2000 15Aug;152(4):363- 70. \n \n207) Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination. \nHowlett RI, Miller AB, Pasut G, et al. . Prev Med 2009 May;48(5):432- 7. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n208) Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among \nwomen with oncogenic human papillomavirus infection . Harris TG, Miller L, Kulasingam SL, et al. Am J \nObstet Gynecol 2009 May;200(5):Article 489.e1. \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n209) Detection, management, and follow-up of pre-malignant cervical lesions and the role for human \npapillomavirus. Van Harmont D, Bekkers RLM, Massuger LFAG, et al. Rev Med Virol 2008 Mar-Apr;18(2):117-\n32. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n210) Detection of human papillomavirus from self-collected vaginal samples of women in Chiang Mai, Thailand. \nWongworapat K. Keawvichit R. et al. Sex Transm Dis 2008; 35(2): 172- 173. \n                Trabajo (s) citado (s): \n Dzuba IG. Yunes -D\u00edaz E. Allen B.  Leonard YF. Lazcano- Ponce EC.  et al. The Acce ptability of Self -collected \nSamples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women\u2019s \nHealth & Gender -Based Medicine, 2002;11(3):265 -275. \n \n211) Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda . \nSafaeian M, Kiddugavu M, Gravitt PE, et al. Cancer Epidemiol Biomarkers Prev 2008 Jun;17(6):1300- 7. \n                Trabajo (s) citado (s): \n Salmeron J . Lazcano-Ponce E.  Lorincz A . Hernandez M . Hern\u00e1ndez P . Leyva A . Uribe M . Manzanares H . Antunez \nA. Carmona E . Ronnett BM . Sherman ME . Bishai D . Ferris D . Flores Y . Yunes E . Shah KV . Comparison of HPV-\nbased assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico . Cancer Causes \nControl 2003 Aug;14(6):505-12.  \n \n212) Determinants of Newly Detected Human Papillomavirus Infection in HIV-Infected and HIV-Uninfected \nInjection Drug Using Women . Phelan DF, Gange SJ, Ahdieh-Grant L, et al. Sex Transm Dis 2009 Mar;36(3):149-\n56. \n                Trabajo (s) citado (s): \n Hern\u00e1ndez -Gir\u00f3n C . Smith JS . Lorincz A . Lazcano E. . Hern\u00e1ndez-Avila M . Salmeron J . High-risk human \npapillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico . Sex \nTransm Dis 2005 Oct;32(10):613-8.  \n \n213) Developing a Nigerian-specific food and nutrient coding database. Day RS. et al. J Food Composit Anal 2008 \nFeb;21(Suppl 1):S109-S114 \n                Trabajo (s) citado (s): \n Bonilla-Fernandez P. L\u00f3pez-Cervantes M. Torres-S\u00e1nchez LE.  Tortolero-Luna G. L\u00f3pez-Carrillo L.  Nutritional \nfactors and breast cancer in Mexico. Nutr Cancer 2003;45(2):148 \u2013155. \n Galv\u00e1n-Portillo M. Torres-S\u00e1nchez L. L\u00f3pez-Carrillo L.  Dietary and reproductive factors associated with benign \nbreast disease in Mexican women. Nutr Cancer 2002;43(2):133- 40 \n \n \n41 214) Development of an Adenoviral Vaccine Against E6 and E7 Oncoproteins to Prevent Growth of Human \nPapillomavirus-Positive Cancer.  Lee DW, Anderson ME, Wu S, et al. Arch Otolaryngol Head Neck Surg 2008 \nDec;134(12):1316- 23. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n215) Development of nutritionally enhanced tortillas . Scazzina F, Del Rio D, Serventi L, et al. Food Biophys 2008 \nJun;3(2):235- 40. \n                Trabajo (s) citado (s): \n Lajous M . Willett W . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM , Hernandez-Avila M , Romieu I . Glycemic load, \nglycemic index, and the risk of breast cancer among Mexican women . Cancer Causes Control 2005 \nDec;16(10): 1165-9.  \n \n216) Diabetes and endometrial cancer: An evaluation of the modifying effects of other known risk f actors .  \nSaltzman BS, Doherty JA, Hill DA, et al. Am J Epidemiol 2008 1Mar;167(5):607 -14. \n                Trabajo (s) citado (s): \n Salazar -Martinez E . Lazcano-Ponce E . Lira-Lira GG . Escudero- De los Rios P . Salmeron-Castro J . Larrea F . \nHernandez-Avila M .Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer \namong Mexican women . Cancer Causes Control 2000 Sep;11(8):707- 11. \n \n217) Diagnosis of Helicobacter pylori. Granstrom  M. et al. Helicobacter 2008;13 (Suppl 1):7 -12 \n                Trabajo (s) citado (s): \n Ornelas IJ. Galvan-Potrillo M. L\u00f3pez-Carrillo L . Protective effect of yoghurt consumption on Helicobacter pylori \nseropositivity in a Mexican population. Public Health Nutr 2007;10:1283 \u20137. \n \n218) Diagnosis of Helicobacter pylori Infection . Monteiro L, Oleastro M, Lehours P, et al. Helicobacter 2009 \nSep; 14(Suppl 1):8-14  \n                Trabajo (s) citado (s): \n Camorlinga -Ponce M . Flores-Luna L.  Lazcano -Ponce E.  Herrero R.  Bernal-Sahagun F . Abdo-Francis JM . Aguirre-\nGarcia J . Mun\u00f3z N . Torres J .  Age and severity of mucosal lesions influence the performance of serologic markers \nin Helicobacter pylori-associated gastroduodenal Pathologies . Cancer Epidemiol Biomarkers Prev 2008 \nSep;17(9):2498-2504.. \n \n219) Dichlorodiphenyldichloroethylene concentrations in umbilical cord of newborns and determinant maternal \nfactors. Barraza -Vazquez A, Borja -Aburto VH, Bassol -Mayagoitia S, et al. J Appl Toxicol 2008 Jan;28(1):27 -34. \n                Trabajo (s) citado (s): \n Romieu I . Hernandez-Avila M . Lazcano- Ponce E. . Weber JP . Dewailly E . Breast cancer, lactation history, and \nserum organochlorines . Am J Epidemiol 2000 15Aug;152(4):363- 70. \n L\u00f3pez -Carrillo L . Blair A. L\u00f3pez -Cervantes M. Cebrian M. Rueda C.  Reyes R et al (1997) \ndichlorodiphenyltrichloroethane serum levels and breast cancer risk: a case -control study from Mexico. Cancer \nRes 57:3728 \u20133732  \n \n220) Diet and breast cancer in Latin -America . Torres -Sanchez L, Galvan -Portillo M, Lewis S, et al. Salud Publica \nMex 2009;51(Supl 2):S181 -S190.  \nTrabajo (s) citado (s): \n Ortiz -Rodriguez SP . Torres-Mejia G . Mainero-Ratchelous F . Angeles-Llerenas A . Lopez-Caudana AE . Lazcano-\nPonce E . Romieu I .  Physical activity and breast cancer risk in Mexican women . Salud Publica Mex 2008 Mar-\nApr;50(2):126-35.  \n Lajous M . Willett W . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM , Hernandez-Avila M , Romieu I . Glycemic load, \nglycemic index, and the risk of breast cancer among Mexican women . Cancer Causes Control 2005 \nDec;16(10):1165-9.  \n Lajous M . Lazcano-Ponce E.  Hern\u00e1ndez-Avila M . Willett W . Romieu I . Folate, vitamin B-6, and vitamin B- 12 \nintake and the risk of breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2006 \nMar;15(3):443-8.   \n Romieu I . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Willett W . Hern\u00e1ndez-Avila M . Carbohydrates and the risk \nof breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2004 Aug;13(8):1283-9.  \n \n221) Dietary consumption of phytochemicals and breast cancer risk in Mexican women . Torres -Sanchez L, Galvan -\nPortillo M, Wolff MS, et al. Public Health 2009 Jun;12(6):825.31.  \n                Trabajo (s) citado (s): \n Romieu I . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Willett W . Hern\u00e1ndez-Avila M . Carbohydrates and the risk \nof breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2004 Aug;13(8):1283-9.   \n42 \n Lajous M . Lazcano-Ponce E.  Hern\u00e1ndez-Avila M . Willett W . Romieu I . Folate, vitamin B-6, and vitamin B- 12 \nintake and the risk of breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2006 \nMar;15(3):443-8.   \n222)  \nDietary fiber and stomach cancer risk: a case \u2013control study from Italy. Bravi F. et al. Cancer Causes Control \n2009;20(6):847- 53 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L . L\u00f3pez-Cervantes M. Ward MH. Bravo-Alvarado J. Ram\u00edrez-Espitia A. Nutrient intake and \ngastric cancer in Mexico. Int J Cancer 1999; 83: 601- 605 \n \n223) Dietary fiber intake and risk of breast cancer in postmenopausal women: the National Institutes of Health \u2013\nAARP Diet and Health Study. Park Y. et al . Am J Clin Nutr 2009;90:664 -7 \n                Trabajo (s) citado (s): \n Lajous M.  Boutron-Ruault MC. Fabre A. Clavel-Chapelon F. Romieu I . Carbohydrate intake, glycemic index, \nglycemic load, and risk of postmenopausal breast cancer in a prospective study of French women. Am J Clin Nutr. \n2008;87(5):1384 \u20131391.  \n \n224) Dietary fibre and cancer prevention. Johnson IT. Agro Foof Ind Hi-Tech 2009  May-Jun:20(3):9- 12 \n                Trabajo (s) citado (s): \n Lajous M.  Boutron-Ruault MC. Fabre A. Clavel-Chapelon F. Romieu I . Carbohydrate intake, glycemic index, \nglycemic load, and risk of postmenopausal breast cancer in a prospective study of French women. Am J Clin Nutr. \n2008;87(5):1384 \u20131391.  \n \n225) Dietary glycaemic index, glycaemic load and breast cancer risk: a systematic review and meta-analysis. \nMulholland HG. et al. Br J Cancer 2008;99(7):1170.5 \n                Trabajo (s) citado (s): \n Lajous M.  Boutron-Ruault MC. Fabre A. Clavel-Chapelon F. Romieu I . Carbohydrate intake, glycemic index, \nglycemic load, and risk of postmenopausal breast cancer in a prospective study of French women. Am J Clin Nutr. \n2008;87(5):1384 \u20131391.  \n \n226) Dietary glycaemic index, glycaemic load and breast cancer risk: a systematic review and meta-analysis .  \nMulholland HG, Murray LJ, Cardwell CR, et al. Br J Cancer 2008 30Sep;99(7):1170- 5. \n                Trabajo (s) citado (s): \n Lajous M . Willett W . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM , Hernandez-Avila M , Romieu I . Glycemic load, \nglycemic index, and the risk of breast cancer among Mexican women . Cancer Causes Control 2005 \nDec;16(10):1165-9.  \n \n227) Dietary Glycemic Index, Glycemic Load, and Risk of Cancer: A Prospective Cohort Study. George SM. et al. \nAm J Epidemiol 2009;169(4):462-72.  \n                Trabajo (s) citado (s): \n Lajous M.  Boutron-Ruault MC. Fabre A. Clavel-Chapelon F. Romieu I . Carbohydrate intake, glycemic index, \nglycemic load, and risk of postmenopausal breast cancer in a prospective study of French women. Am J Clin Nutr. \n2008;87(5):1384 \u20131391.  \n \n228) Dietary intake of carotenoids and retinol and endometrial cancer risk in an Italian case -control study . Pelucchi \nC, Dal Maso L, Montella M, et al. Cancer Causes Control 2008 Dec;19(10):1209 -15. \n                Trabajo (s) citado (s): \n Salazar -Martinez E .Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Gonz\u00e1lez-Lira G . Escudero-De Los Rios P . \nHern\u00e1ndez-Avila M . Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico . Int J \nGynecol Cancer 2005 Sep -Oct;15(5 ):938 -45.  \n \n229) Dietary Intake of Folate, Vitamin B2, Vitamin B6, Vitamin B12, Genetic Polymorphism of Related Enzymes, \nand Risk of Breast Ca ncer: A Case -Control Study in Japan. Ma Enbo. et al. Nutr Cancer 2009;61(4):447 -56 \n                Trabajo (s) citado (s): \n Lajous M. Romieu I.  Sabia S. Boutron-Ruault MC. Clavel-Chapelon F. Folate, vitamin B12 and postmenopausal \nbreast cancer in a prospective study of French women. Cancer Causes Control 17, 1209 \u20131213, 2006. \n Lajous M. Lazcano-Ponce E.  Hern\u00e1ndez-Avila M . Willett W . Romieu I . Folate, vitamin B-6, and vitamin B- 12 \nintake and the risk of breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2006 \nMar;15(3):443-8.   \n230) Dietary intake of folate, vitamin B-6, and vitamin B-12, genetic polymorphism of related enzymes, and risk of \nbreast cancer: a case-control study in Brazilian women. Ma Enbo. et al. BMC Cancer 2009 24Apr;9:122 \n                Trabajo (s) citado (s): \n Lajous M. Romieu I.  Sabia S. Boutron-Ruault MC. Clavel-Chapelon F. Folate, vitamin B12 and postmenopausal \nbreast cancer in a prospective study of French women. Cancer Causes Control 17, 1209 \u20131213, 2006.  \n43 \n Lajous M . Lazcano-Ponce E.  Hern\u00e1ndez-Avila M . Willett W . Romieu I . Folate, vitamin B-6, and vitamin B- 12 \nintake and the risk of breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2006 \nMar;15(3):443-8.   \n \n231) Dietary intake of selected micronutrients and gastric cancer risk: an Italian case-control study. Pelucchi C. et al. \nAnn Oncol 2009;20:160-5 \n                Trabajo (s) citado (s): \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pe z-Carrillo L.  et al. Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T \nand A1298C polymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n \n232) Dietary intakes of omega -6 and omega -3 polyunsaturat ed fatty acids and the risk of breast cancer. Thiebaut \nACM. et al. Int J Cancer 2009 15Feb;124(4):924 -931 \n                Trabajo (s) citado (s): \n Lajous M. Romieu I.  Sabia S. Boutron-Ruault MC. Clavel-Chapelon F. Folate, vitamin B12 and postmenopausal \nbreast cancer in a prospective study of French women. Cancer Causes Control 17, 1209 \u20131213, 2006. \n \n233) Dietary patterns and breast cancer risk in Asian American women . Wu AH, Yu MC, Tseng CC, et al. Am J Clin \nNutr 2009 1Apr;89(4):1145- 54. \n                Trabajo (s) citado (s): \n Romieu I . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Willett W . Hern\u00e1ndez-Avila M . Carbohydrates and the risk \nof breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2004 Aug;13(8):1283-9.  \n \n234) Dietary Spices in health and diseases. (II). Kochhar KP. Indian J Physiol Pharmacol 2008;52(4):327 -54 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L.  Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case-\ncontrol study. Am J Epidemiol 1994;139:263- 71. \n \n235) Differences in the risk of cervical cancer and human papillomavirus infection by education level. Franceschi S, \nPlummer M, Clifford G, et al. Br J Cancer 2009 25Aug;101(5):865-70. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n Murillo R . Almonte M  Pereira A . Ferrer E . Gamboa OA . Jeronimo J . Lazcano-Ponce E. Cervical Cancer Screening \nPrograms in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48.  \n \n236) Differential effects exerted on human mammary epithelial cells by environmentally relevant organochlorine \npesticides either individually or in combination. Valer\u00f3n PF. Et al. Chem Biol Interact 2009;180:485- 91  \n                Trabajo (s) citado (s): \n L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez -Carrillo L . 2004. Dichlorodiphenyldichloroethane burden \nand breast cancer risk: A meta -analysis of the epidemiologic evidence. Environ. Health Perspect. 112:207 \u2013214. \n \n237) Dioxin -like activity in plasma among Danish pregnant women:  Diet ary predictors, birth weigh tand infant \ndevelopment. Halldorsson T. et al, Environ Res 2009;109:22 -8 \n                Trabajo (s) citado (s): \n Verner MA. Charbonneau M. L\u00f3pez-Carrillo L.  Haddad S. Physiologically based pharmacokinetic modeling of \npersistent organic pollutants for lifetime exposure assessment: a new tool in breast cancer epidemiologic studies. \nEnviron Health Perspect. 2008;116(7):886 \u2013892. \n \n238) Discussions about self -obtained samples for HPV testing as an alternative for cervical cancer prevention. \nBarata PC.  Mai V. J  Psychosom Obstet Gynecol 2008; 29(4): 251 -257. \n                Trabajo (s) citado (s): \n Dzuba IG. Yunes -D\u00edaz E. Allen B.  Leonard YF. Lazcano- Ponce EC.  et al. The Acceptability of Self -collected \nSamples for HPV Testing vs. the Pap Test as A lternatives in Cervical Cancer Screening. Journal of Women\u2019s \nHealth & Gender -Based Medicine, 2002;11(3):265 -275. \n \n239) Disinhibition and Risk Compensation Scope, Definitions, and Perspective. Hogben M. Liddon N. Sex Transm \nDis 2008;35(12): 1009-1010. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n  \n44 240) Distribution of HPV-16 Intratypic Variants among Women with Cervical Intraepithelial Neoplasia and \nInvasive Cervical Cancer in Mongolia. Chimeddorj B, Pak CY, Damdin A, et al. Asian Pac J Cancer Prev \n2008;9(4):563- 8. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy .  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n241) Distribution of human papillomavirus genotypes in invasive cervical cancer in Italy: A representative, single \ninstitution case series. Sideri M, Cristoforoni P, Casadio C, et al. Vaccine 2009 29May;27(Suppl 1):A30-A33. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n242) Distribution of Human Papillomavirus Type 58 Variants in Progression of Cervical Dysplasia in Korean \nWomen. Bae JH, Cheung JLK, Lee SJ, et al. J Microbiol Biotechnol 2009 Sep;19(9).1051- 4. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n243) Distribution of human papillomavirus types in anogenital warts of men. Chan PKS, Luk ACS, Luk TNM,et al. \nJ Clin Virol 2009 Feb;44(2):111- 4. \n                Trabajo (s) citado (s): \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n244) Distribution of human papillomavirus types in cervical cancers in Hong Kong: Current situation and changes \nover the last decades. Chan PKS, Ho WCS, Yu MY, et al. Int J Cancer 2009 1Oct;125(7):1671- 7. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n245) Do you approve of spending $300 million on HPV vaccination?: no. Lippman A. Boscoe M. Scurfield C. Can \nFam Physician 2008 Feb;54(2):175,177, 179,181.  \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n246) Drinking-Water Arsenic Exposure Modulates Gene Expression in Human Lymphocytes from a U.S. \nPopulation. Andrew AS. et al. Environ Health Perspect 2008 Apr;116(4):524- 31 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessment \nof lymphocyte subpopulations and cytokine secretion in chil dren exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n247) Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant \nmammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition. Coyne CP. et al. J \nDrug Targeting 2009;17(6):474- 89 \n                Trabajo (s) citado (s): \n Bernstein J. L\u00f3pez-Carrillo L.  Wang L. Epidemiology of Her-2/neu and P53 in breast cancer. Salud Publica Mex \n1999; 41: suppl 2:114-123. \n \n248) Dynamic Spectral Imaging: Improving Colposcopy. Soutter WP, Diakomanolis E, Lyons D, et al. Clin Cancer \nRes 2009 1Mar;15(5):1814- 20. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n249) Early Experience with Human Papillomavirus Vaccine Introduction in the United States, Canada and Australia. \nShefer A, Markowitz L, Deeks S, et al. Vaccine 2008 19Aug;26(Suppl 10):K68-K75. \n                Trabajo (s) citado (s):  \n45 \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n250) Ecological Studies Of Ultraviolet B, Vitamin D And Cancer Since 2000 . Grant WB, Mohr SB. Ann Epidemiol \n2009 Jul;19(7):446 -54. \n                Trabajo (s) citado (s): \n Salazar -Mart\u00ednez E . Lazca no-Ponce E.  Lira-Lira GG . Escudero-De los Rios P . Hern\u00e0ndez-Avila M . Nutritional \ndeterminants of epithelial ovarian cancer risk: A case-control study in Mexico . Oncology 2002;63(2):151-7.  \n \n251) Economic Evaluation of Human Papillomavirus Vaccination in Developed Countries. Brisson M, Van de Velde \nN, Boily MC. . Public Health Genom 2009;12(5-6):343- 51. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n252) Economic evaluation of human papillomavirus vaccination in the United Kingdom. Jit M, Choi YH, Edmunds \nWJ. BMJ 2009 9Aug;337(7665): Article:a769. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n253) Economic evaluations of massive HPV vaccination: Within-study and between study variations in incremental \ncost per QALY gained . Puig-Junoy J. Prev Med 2009 May;48(5)444-8 \n                Trabajo (s) citado (s): \n Insinga RP. Dasbach EJ. Elbasha EH. Puig A. Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human \npapillomavirus (HPV) vaccination in Mexico: a transmission dynamic modelbased evaluation. Vaccine 2007, \n26:128-139. \n \n254) Edible compounds as antitumor agents. Mohammad A. et al. Indian J Sci Technol 2009;2(5):62- 74 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L.  Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case-\ncontrol study. Am J Epidemiol 1994;139:263- 71. \n \n255) Educational level and cervical cancer screening programs in a Venezuelan urban area . N\u00fanez -Troconis J, \nVelasquez J, Mindiola R, et al. Invest Clin 2008 Sep;49(3):331 -9. \n                Trabajo (s) citado (s): \n Lazcano-Ponce EC . Najera Aguilar P . Buiatti E. Alonso De Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The \ncervical cancer screening program in Mexico: problems with access and coverage .  Cancer Causes Control 1997 \nSep;8(5):698 -704. \n Torres -Mejia G . Salmeron-Castro J . Tellez-Rojo MM . Lazcano-Ponce E.  Juarez-Marquez SA . Torres-Torija I . Gil-\nAbadie L . Characteristics of respondents to a cervical cancer screening program in a developing country . Arch \nMed Res 2002 May-Jun;33(3):295-300.  \n \n256) Effect of arsenic on tegulatory T Cells. Hern\u00e1ndez -Castro B. et al, J Clin Immunol 2009;29:461 -9 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessment \nof lymphocyte sub populations and cytokine secretion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n257) Effect of Barley on Variation of Blood Glucose and Lipid Metabolism. Yeun -Seok Y. et al. Korean J Fam Med \n2009;30:790 -5 \n                Trabajo (s) citado (s): \n Lajous M.  Boutron-Ruault MC. Fabre A. Clavel-Chapelon F. Romieu I . Carbohydrate intake, glycemic index, \nglycemic load, and risk of postmenopausal breast cancer in a prospective study of French women. Am J Clin Nutr. \n2008;87(5):1384 \u20131391.  \n \n258) Effect of capsaicin on glucose metabolism studied in experimental lung carcinogenesis. Anandakumar P. et al. \nNat Prod Res 2009;23(8):763- 74 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L.  Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case-\ncontrol study. Am J Epidemiol 1994;139:263- 71. \n  \n46 259) Effect of Genetic Predisposition on the Risk of Gallbladder Cancer in Hungary. Kimura A, Tsuchiya Y, Lang I, \net al. Asian Pac J Cancer Prev 2009;9(3):391- 6. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n260) Effect of Male Circumcision on the Prevalence of High-Risk Human Papillomavirus in Young Men: Results of \na Randomized Controlled Trial Conducted in Orange Farm, South Africa. Auvert B, Sobngwi-Tambekou J, \nCutler E, et al. . J Infect Dis 2009 1Jan;199(1):14- 9. \n                Trabajo (s) citado (s): \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n Aguilar LV . Lazcano-Ponce E.  Vaccarella S . Cruz A . Hern\u00e1ndez P . Smith JS . Munoz N . Kornegay JR . Hern\u00e1ndez-\nAvila M . Franceschi S . Human papillomavirus in men: comparison of different genital sites. Sex Transm Infect \n2006 1Feb;82(1):31- 3. \n \n261) Effect of Second Pregnancy on Maternal Carriage and Outcome of High -Risk Human Papillomavirus (HPV) . \nSarkola ME, Grenman SE, Rintala MAM, et al. Gynecol Obstet Invest 2009;67(3):208 -16. \n                Trabajo (s) citado (s): \n Hern\u00e1ndez -Gir\u00f3n C . Smith JS . Lorincz A . Lazcano E. . Hern\u00e1ndez-Avila M . Salmeron J . High-risk human \npapillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico . Sex \nTransm Dis 2005 Oct;32(10):613-8.  \n \n262) Effect of Transgenic PPase Gene on Potato Inorganic Pyrophosphatase Activity and Inorganic Phosphorus \nContent. Chunfeng Z. et al. Molecular Plant Brreding 2009;7(3):586- 90 \n                Trabajo (s) citado (s): \n Oliva G. Romero I. Ayala G. Barrios-Jacobo I . Celis H (2000) Characterization of the inorganic pyrophosphatase \nfrom the pathogenic bacterium Helicobacter pylori. Arch Microbiol 174: 104 \u2013110. \n \n263) Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine A Systematic Review . Marra F. et al. \nPharmaeconomics 2009;27(2):127- 47 \n                Trabajo (s) citado (s): \n Insinga RP. Dasbach EJ. Elbasha EH. Puig A. Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human \npapillomavirus (HPV) vaccination in Mexico: a transmission dynamic model based evaluation. Vaccine 2007, \n26:128-139. \n \n264) Effectiveness of Cultivando La Salud: A Breast and Cervical Cancer Screening Promotion Program for Low-\nIncome Hispanic Women . Fernandez ME, Gonzales A, Tortolero-Luna G, et al. Am J Public Health 2009 \nMay;99(5):936-43. \n                Trabajo (s) citado (s): \n Aguilar -Perez JA . Leyva-L\u00f3pez AG . Angulo-Najera D . Salinas A . Lazcano-Ponce EC . Cervical cancer screening: \nknowledge of Pap smear benefits and utilization in Mexico .. Rev Saude Publica 2003 Feb;37(1):100-6.  \n \n265) Effectiveness of cytology -based cervical cancer screening in the Colombian health system . Murillo R,  Cendales \nR, Wiesner C, et al. Biomedica 2009 Se p;29(3):354 -61. \n                Trabajo (s) citado (s): \n Lazcano-Ponce EC.  Moss S . de Ruiz PA . Castro JS . Avila MH .Cervical cancer screening in developing countries: \nWhy is it ineffective? The case of  Mexico . Arch Med Res 1999 May-Jun;30(3):240-50.  \n Hern\u00e1ndez -Avila M . Lazcano EC . de Ruiz PA . Romieu I . Evaluation of the cervical cancer screening programme \nin Mexico: a population-based ca se-control study . Int J Epidemiol 1998 Jun;27(3):370- 6. \n \n266) Effects of in utero arsenic exposure on child immunity and morbidity in rural Bangladesh. Raqib R. et al. \nToxicol Lett 2009 Mar;185(3):197-202 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Lun a AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessment \nof lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n267) Effects of Information Framing on Human Papillomavirus Vaccination. Leader AE.  Weiner JL. et al. J Womens \nHealth 2009; 18(2): 225- 233. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);2 01-9. \n  \n47 268) Effects of Peer and Group Education on Knowledge, Beliefs and Breast Self -Examination Practice among \nUniversity Students in Turkey. Karayurt O. et al. Turk J Med Sci 2009;39(1):59 -66 \n                Trabajo (s) citado (s): \n Ortega-Altamirano D. L\u00f3pez-Carrillo L.  L\u00f3pez-Cervantes M.  Estrategias para la ense\u00f1anza del autoexamen del \nseno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 \u201325. \n \n269) Effects of the organochlorines p,p ' -DDE and lindane on gilthead seabream leucocyte immune parameters and \ngene expression . Cuesta A, Meseguer J, Esteban MA. Fish Shellf Immunol 2008 Nov;25(5):682 -8. \n                Trabajo (s) citado (s): \n Romieu I . Hernandez-Avila M . Lazcano- Ponce E. . Weber JP . Dewailly E . Breast cancer, lactation history, and \nserum organochlorines . Am J Epidemiol 2000 15Aug;152(4):363- 70. \n \n270) Efficacy Data and HPV Vaccination Studies (Reply). Haug C. JAMA 2009 23Dec;302(24):2659 -60. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n271) Efficacy of Human Papillomavirus Vacc ines A Systematic Quantitative Review. Medeiros LR, Rosa DD, da \nRosa MI, et al. Int J Gynecol Cancer 2009 Oct;19(7):1166 -76. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n272) Efficacy, duration of immunity and cross protection after HPV vaccination: A review of the evidence. Bonanni \nP, Boccalini S, Bechini A. Vaccine 2009 29May;27(Suppl 1):A46-A53. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n273) El virus del papiloma humano y el c\u00e1ncer cervicouterino. Castellanos Morales MR. Rev Fac Med UNAM \n2004;47(1):35 -36. \n                Trabajo (s) citado (s): \n Dzuba IG. Yunes -D\u00edaz E. Allen B.  Leonard YF. Lazcano- Ponce EC.  et al. The Acceptability of Self -collected \nSamples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women\u2019s \nHealth & Gender -Based Medicine , 2002;11(3):265 -275. \n \n274) ELISA Test to Detect CDKN2A (p16(INK4a)) Expression in Exfoliative Cells A New S creening Tool for Cervical \nCancer . Ding L, Zou XJ, Ao JE, et al. Mol Diagn Ther 2008;12(6):395 -400. \n                Trabajo (s) citado (s): \n Lazcano-Ponce EC.  Moss S . de Ruiz PA . Castro JS . Avila MH .Cervical cancer screening in developing countries: \nWhy is it ineffective? The case of  Mexico . Arch Med Res 1999 May-Jun;30(3):240-50.  \n \n275) Endometrial hyperplasia, endometrial cancer and prevention: Gaps in existing research of modifiable risk \nfactors.   Linkov F, Edwards R, Balk J, et al. Eur J Cancer 2008 Aug;44(12):1632- 44. \n                Trabajo (s) citado (s): \n Salazar -Martinez E .Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Gonz\u00e1lez-Lira G . Escudero-De Los Rios P . \nHern\u00e1ndez-Avila M . Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico . Int J \nGynecol Cancer 2005 Sep -Oct;15(5 ):938 -45.  \n \n276) Enhancement of underused cervical cancer prevention services in rural Oaxaca, Mexico . Givaudan M, Leenen I, \nPick S, et al. Rev Panam Salud Publica 2008 Feb;23(2):135- 43. \n                Trabajo (s) citado (s): \n Lazcano-Ponce EC . Najera Aguilar P . Buiatti E. Alonso De Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The \ncervical cancer screening program in Mexico: problems with access and coverage .  Cancer Causes  Control 1997 \nSep;8(5):698 -704. \n Lazcano-Ponce EC.  Moss S . Cruz-Vald\u00e9z A.  de Ruiz PA . Casares-Queralt S . Martinez-Leon CJ . Hern\u00e1ndez-Avila \nM. Factors which determine participation in an early detection program of cervical cancer in the state of M orelos . \nSalud Publica Mex 1999 Jul-Aug;41(4):278- 85. \n \n277) ENT update seminar Comprehensive further training over 2 days. Ayazpoor U.  HNO 2009 Feb;57(2):178 -80. \n                Trabajo (s) citado (s): \n \n48 \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n278) Enteric infections, diarrhea, and their impact on function a nd development. Petri WA. et al. J Clin Invest 2008 \napr;118(4):1277 -90. \n                Trabajo (s) citado (s): \n Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Gastric cancer risk in a Mexican population: \nrole of Helicobacter pylori CagA po sitive infection and polymorphisms in interleukin -1 and -10 genes. Int. J. \nCancer. 118:649 \u2013657. \n \n279) Entire genome characterization of human papillomavirus type 16 from infected Thai women with different \ncytological findings. Lurchachaiwong W, Junyangdikul P, Payungporn S, et al. Virus Genes 2009 Aug;39(1):30-\n8. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n280) Environmental Chemicals and Breast Cancer Risk - A Structural Chemistry Perspective . Weyandt J, Ellsworth \nRE, Hooke JA, et al. Curr Med Chem 2008 Nov;15(26):2680-2701. \n                Trabajo (s) citado (s): \n Romieu I . Hernandez-Avila M . Lazcano- Ponce E. . Weber JP . Dewailly E . Breast cancer, lactation history, and \nserum organochlorines . Am J Epidemiol 2000 15Aug;152(4):363- 70. \n L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez -Carrillo L . 2004. Dichlorodiphenyldichloroethane burden \nand breast cancer risk: A meta -analysis of the epidemiologic evidence. Environ. Health Perspect. 112:207 \u2013214. \n L\u00f3pez -Carrillo L . Blair A. L\u00f3pez -Cervantes M. Cebrian M. Rueda C.  Reyes R et al (1997) \ndichlorodiphenyltrichloroethane serum levels and breast cancer risk: a case -control study from Mexico. Cancer \nRes 57:3728 \u20133732  \n \n281) Evolving Treatment Strategies for Gallbladder Cancer. Hueman MT, Vollmer CM, Pawlik TM. Ann Surg \nOncol 2009 Aug;16(8):2101- 15. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n282) Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical \nand systematic review of the literature in the development of an HPV dynamic transmission model . Insinga \nRP, Dasbach EJ, Elbasha EH. BMC Infect Dis 2009 29Jul;9(119):Artic 119. \n                Trabajo (s) citado (s): \n Flores -Luna L . Salazar-Martinez E . Escudero-De los Rios P . Gonzalez-Lira G . Zamora-Mu\u00f1\u00f3z S . Lazcano -Ponce \nEC. Prognostic factors related to cervical cancer survival in Mexican women . Int J Gynecol Obstet 2001 \nOct;75(1):33-42.  \n \n283) Epidemiologic Risk Profile of Infection With Different Groups of Human Papillomaviruses. Chan PKS, Ho \nWCS, Wong MCS, et al. J Med Virol 2009 Sep;81(9):1635- 44. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A . Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n284) Epidemiological and Genetic Factors Associated With Ovarian Cancer . McLemore MR, Miaskowski C, \nAouizerat BE, et al. Cancer Nurs 2009 Jul-Aug;32(4):281- 8. \n                Trabajo (s) citado (s): \n Salazar -Mart\u00ednez E . Lazcano-Ponce E.  Lira-Lira GG . Escudero-De los Rios P . Hern\u00e0ndez-Avila M . Nutritional \ndeterminants of epithelial ovarian cancer risk: A case-control study in Mexico . Oncology 2002;63(2):151-7 .  \n \n285) Epidemiological, clinical and viral determinants of the increased prevalence of high-risk human \npapillomavirus (HPV) infections in elderly women. Syrjanen K, Kulmala SM, Shabalova I, et al. Eur J \nGynaecol Oncol 2008 29(2):114-22. \n                Trabajo (s) citado (s): \n \n49 \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Lazcano- Ponce E.  Herrero R. Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n286) Epidemiology and cost of treatment of genital warts in Spain. Castellsague X, Cohet C, Puig-Tintore LM, et al. \nEur J Public Health 2009 Jan;19(1):106- 110. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n287) Epidemiology and costs associated with genital warts in Canada . Marra F. et al. Sex Transm Infect 2009 \nApr;85(2):111 -15 \n                Trabajo (s) citado (s): \n Insinga RP. Dasbach EJ. Elbasha EH. Puig A. Reynales -Shigematsu LM. Cost -effectiveness of quadrivalent human \npapillomavirus (HPV) vaccination in Mexico: a transmission dynamic model based evaluation. Vaccine 2007, \n26:128-139. \n \n288) Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in \nCervical Neoplasia . Bosch FX, Burchell AN, Schiffman M, et al. Vaccine 2008 19Aug;26(Suppl 10):K1-K16. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n289) Epidemiology and Prevention of Human Papillomavirus and Cervical Cancer in China and Mongolia . Shi JF, \nQiao YL, Smith JS, et al. Vaccine 2008 19Aug;26(Suppl 12):M53-M59. \n                Trabajo (s) citado (s): \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n290) Epidemiology of biliary tract cancers: an update. Randi G, Malvezzi M, Levi F, et al. Ann Oncol 2009 \nJan;20(1):146- 59. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n291) Epidemiology of Mucosal Human Papillomavirus Infection and Associated Diseases . Trottier H, Burchell AN. \nPublic Health Genom 2009;12(5-6): 291-307.  \n                Trabajo (s) citado (s): \n Giuliano AR . Lazcano- Ponce E . Villa LL . Flores R . Salmeron J . Lee JH . Papenfuss MR . Abrahamsen M . Jolles E. \nNielson CM . Baggio ML. Silva R . Quiterio M . The human papillomavirus infection in men study: Human \npapillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States . \nCancer Epidemiol Biomarkers Prev 2008 Aug;17(8):2036-43. \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n292) Espacios 100% libres de humo : una realidad en el Distrito Federal. Guillermo-Tenorio X. Salud Publica Mex \n2008;50(Supll 3):S384-S390 \n                Trabajo (s) citado (s): \n Reynales- Shigematsu L . Rodr\u00edguez-Bola\u00f1os RA. Jim\u00e9nez JA. Ju\u00e1rez-M\u00e1rquez S. Castro-R\u00edos A. Hern\u00e1ndes-\u00c1vila \nM. Costo de atenci\u00f3n m\u00e9dica atribuible al tabaquismo en el Instituto Mexicano del Seguro Social. Salud P\u00fablica \nMex 2006; 48(supl 1):S48-S64 \n \n293) Estimating the Long-Term Clinical Impact of Cervical Cancer Vaccination in Taiwan. Yen MS, You SL, Ferko \nN, et al. Int J Gynecol Cancer 2009 Feb;19(2):281- 8. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.   \n50  \n294) Estudio piloto: costos directos atribuibles al tabaquismo en dos hospitales de Santiago. Mart\u00ednez-Guti\u00e9rrez \nMS. et al. Rev Med Chile 2008;136:1281-7 \n                Trabajo (s) citado (s): \n Reynales-Shigematsu L . Ju\u00e1rez-M\u00e1rquez S. Valdez-Salgado R . Costo de atenci\u00f3n m\u00e9dica atribuible al tabaquismo \nen el IMSS, Morelos. Salud P\u00fablica Mex 2005; 47: 451- 7. \n \n295) Ethical and social implications of the introduction of the vaccine against the human papilloma virus in Mexico: \nReflections on a proposed intervention. de la Rosa AP, Delgado CG, Klip DF, et al. Acta Bioethica \n2008;14(2):157-65. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n296) Ethical behaviours in clinical practice hmong mexican Elath care workers.  Valdez -Martinez E, Lavielle P, \nBedolla M, et al. Nurs Ethics 2008 Nov;15(6):729 -44. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E. Angeles-Llerenas A . Alvarez-del Rio A . Salazar-Martinez E . Allen B . Hernandez-Avila M . \nKraus A .Ethics and communication between physicians and their patients with cancer, HIV/AIDS, and \nrheumatoid arthritis in Mexico . Arch Med Res 2004 Ene-Feb;35(1):66- 75.  \n \n297) Ethnic di fferences in cytokine gene polymorphisms: potential implications for cancer development. Zabaleta J. \net al. Cancer Immunol Immunother 2008;57:107- 14 \n                Trabajo (s) citado (s): \n Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Gastric cancer risk in a Mexican population: \nrole of Helicobacter pylori CagA positive infection and polymorphisms in interleukin -1 and -10 genes. Int. J. \nCancer. 118:649 \u2013657. \n \n298) EUROGIN 2008 roadmap on cervical cancer prevention .  Franceschi S, Cuzick J, et al. Int J Cancer 2009 \n15Nov;125(10):2246 -2255.  \n Trabajo (s) citado (s): \n Franco EL . Tsu V . Herrero R . Lazcano- Ponce E . Hildesheim A.  Mun\u00f3z N . Murillo R . S\u00e1nchez GI . Andrus JK . \nIntegration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the \nCaribbean . Vaccine 2008 19 Aug;26(Suppl 11):L88-L95.   Supplement: Suppl. 11 Published: AUG 19 2008.  \n \n299) EUROGIN 2007 roadmap - Conclusion. Wheeler CM, Franceschi S. Vaccine 2008 14Mar;26(Suppl 1):A28-A31. \n         Trabajo (s) citado(s):  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n300) Evaluating the impact of human papillomavirus vaccines. Chang YL, Brewer NT, Rinas AC, et al. Vaccine 2009 \n9Jul;27(32):4355- 62. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n301) Evaluating the potential benefits of universal worldwide human papillomavirus vaccination. Bosch FX. de \nSanjos\u00e9 S. Castellsagu\u00e9 X. Evaluating Therapy 2008:5(3):305- 312. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n302) Evaluation of systemic and mucosal anti -HPV16 and anti -HPV18 antibody responses from vaccinated women. \nKemp TJ, Garcia -Pineres A, Falk RT, et al. Vaccine 2008 4Jul;26(29 -30):3608 -16. \n                Trabajo (s) citado(s):  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):19 15-27.  \n \n303) Evaluation of the \"Early detection and opportune attention of cervicouterine cancer\" program . Llanos AA, Salas \nMM. Atencion Primaria 2009 Jun;41(6):300- 5. \n                Trabajo (s) citado (s): \n Lazcano-Ponce EC.  Moss S . Cruz-Vald\u00e9z A.  de Ruiz PA . Casares-Queralt S . Martinez-Leon CJ . Hern\u00e1ndez-Avila \nM. Factors which determine participation in an early detection program of cervical cancer in the state of Morelos . \nSalud Publica Mex 1999 Jul-Aug;41(4):278- 85. \n  \n51 304) Evolution of the health economics of cervical cancer vaccination. Ferko N, Postma M, Gallivan S, et al. Vaccine \n2008 15Sep;26(Suppl 5):F3-F15. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions. NEJM 2007 10May;356(19):1915-27.  \n \n305) Expression of 25-Hydroxyvitamin D-3- 24-Hydroxylase in Benign and Malignant Ovarian Cell Lines and Tissue . \nFischer D, Thome M, Becker S, et al. Anticancer Res 2009 Sep;29(9):3635- 9. \n                Trabajo (s) citado (s): \n Salazar -Mart\u00ednez E . Lazcano-Ponce E.  Lira-Lira GG . Escudero-De los Rios P . Hern\u00e0ndez-Avila M . Nutritional \ndeterminants of epithelial ovarian cancer risk: A case-control study in Mexico . Oncology 2002;63(2):151-7.  \n \n306) Expression of the p16(INK4a) gene product in premalignant and malignant epithelial lesions of the \ngallbladder. Lynch BC, Lathrop SL, Ye DM, et al. Ann Diagn Pathol 2008 Jun;12(3);161- 4. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n307) Factors affecting utilization of cervical cancer prevention services in low-resource settings. Bingham A. Bishop \nA. Coffey P. et al. Salud Publica Mex 2003;45 Suppl 3:S408- 16 \n                Trabajo (s) citado (s): \n Dzuba IG. Yunes -D\u00edaz E. Allen B.  Leonard YF. Lazcano- Ponce EC.  et al. The Acceptability of Self -collected \nSamples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women\u2019s \nHealth & Gender -Based Medicine, 2002;11(3):265 -275. \n \n308) Factors Associated with Acquisition and Clearance of Human Papillomavirus Infection in a Cohort of US Men: \nA Prospective Study. Lu B, Wu Y, Nielson CM, et al. J Infect Dis 2009 1Feb;199(3):362- 71. \n                Trabajo (s) citado (s): \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n309) Factors associated with the risk of progression to precursor lesions or cervical cancer in women with negative \ncytologic findings . Girianelli VR, Silva GAE, Thuler LCS. Int J Gynecol Obstet 2009 D ec;107(3):228 -231.  \n                Trabajo (s) citado (s): \n Flores YN . Bishai DM . Shah KV . Lazcano -Ponce E . Lorincz A . Hern\u00e1ndez M . Ferris D . Salmeron J . Risk factors for \ncervical cancer among HPV positive women in Mexico . Salud Publica Mex 2009 Jan-Feb;50(1):49- 58. \n \n310) False -Positive Results in Cancer Epidemiology: A Plea for Epistemological Modesty. Boffetta P. et al. J N atl \nCancer  Inst 2008 16Jul;100(4):988 -95.  \n                Trabajo (s) citado (s): \n L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez -Carrillo L . 2004. Dichlorodiphenyldichloroethane burden \nand breast cancer risk: A meta -analysis of the epidemiologic evid ence. Environ. Health Perspect. 112:207 \u2013214. \n \n311) Family history and the risk of gastric cancer. Yaghoobi M. et al. Br J Cancer 2009 Nov [On Line]  \n                  Trabajo (s) citado (s): \n Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Gastric  cancer risk in a Mexican population: \nrole of Helicobacter pylori CagA positive infection and polymorphisms in interleukin -1 and -10 genes. Int. J. \nCancer. 118:649 \u2013657. \n \n312) Feasibility of collecting self-sampled vaginal swabs by mail: quantity and quality of genomic DNA. Baay. MF. \nVerhoeven DV. et al. Eur J Clin Microbiol Infect Dis 2009; 28(11): 1285-1289. \n                Trabajo (s) citado (s): \n Dzuba IG. Yunes -D\u00edaz E. Allen B.  Leonard YF. Lazcano- Ponce EC.  et al. The Acceptability of Self -collected \nSamples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women\u2019s \nHealth & Gender -Based Medicine, 2002;11(3):265 -275. \n \n313) Female reproductive disorders: the roles of endocrine disrupting compounds and developmental timing. Crain \nDA. Et al.  Fertil Steril 2008 Oct;90(4):911- 40 \n                Trabajo (s) citado (s):  \n52 \n L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez -Carrillo L . 2004. Dichlorodiphenyldichloroethane burden \nand breast cancer risk: A meta -analysis of the epidemiologic ev idence. Environ. Health Perspect. 112:207 \u2013214. \n \n314) First Breast Cancer Mammography Screening Program in Me xico: Initial Results 2005 -2006 . Rodriguez -Cuevas \nS, Guisa -Hohenstein F, Labastida -Almendaro S. Breast J 2009 Nov -Dec;15(6):623 -31. \n                Trabajo (s) citado (s): \n Tovar -Guzman V . Hern\u00e1ndez-Gir\u00f3n C . Lazcano -Ponce E.  Romieu I . Avila MH . Breast cancer in Mexican women: \nan epidemiological study with cervical cancer control . Rev Saude Publica 2000 Apr;34(2):113-9.  \n \n315) Folate and one -carbon metabolism nutrients from supplements and diet in relation to breast cancer risk. \nMaruti SS. et al. Am J Clin Nutr 2009 1Feb;89(2):624 -633  \n                Trabajo (s) citado (s): \n Lajous M. Romieu I.  Sabia S. Boutron-Ruault MC. Clavel-Chapelon F. Folate, vitamin B12 and postmenopausal \nbreast cancer in a prospective study of French women. Cancer Causes Control 17, 1209 \u20131213, 2006. \n Lajous M . Lazcano-Ponce E.  Hern\u00e1ndez-Avila M . Willett W . Romieu I . Folate, vitamin B-6, and vitamin B- 12 \nintake and the risk of breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2006 \nMar;15(3):443-8.   \n316)  \nFolate, cancer risk, and the Greek god, Proteus: a tale of two chameleons . Mason JB. Nutr Rev 2009 \nApr;77(4): 206-12. \n                Trabajo (s) citado (s): \n Lajous M . Lazcano-Ponce E.  Hern\u00e1ndez-Avila M . Willett W . Romieu I . Folate, vitamin B-6, and vitamin B- 12 \nintake and the risk of breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2006 \nMar;15(3):443-8.   \n317)  \nFolate Intake and Prostate Cancer Risk: A Case-Control Study. Shannon J, Phoutrides E, Palma A, et al.  Nutr \nCancer 2009;61(5):617 -28. \n                Trabajo (s) citado (s): \n Lajous M . Lazcano-Ponce E.  Hern\u00e1ndez-Avila M . Willett W . Romieu I . Folate, vitamin B-6, and vitamin B- 12 \nintake and the risk of breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2006 \nMar;15(3):443-8.   \n318)  \nFolate Intake, Methylenetetrahydrofolate Reductase Polymorphisms, and Breast Cancer Risk in Women from \nthe Malmo\u00a8 Diet and Cancer Cohort. Ericson U. Cancer Epidemiol Biomarkers Prev 2009;18(4):11 01-10  \n                Trabajo (s) citado (s): \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carrillo L.  et al. Meta - and pooled analyses of the methylenetetrahydrofolate reduct ase C677T \nand A1298C polymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n \n319) Folate Status and Aberrant DNA Methylation Are Associated With HPV Infection and Cervical Pathogenesis . \nFlatley JE, McNeir K, Balasubramani L, et al. Cancer Epidemiol Biomarkers Prev 2009 Oct;18(10): 2782- 9.  \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Snijders PJF . Dai M . Thomas JO . Hieu NT . Ferreccio C . Matos E.  Posso H . de Sanjose S . \nShin HR . Sukvirach S . Lazcano-Ponce E. Mun\u00f3z N . Meijer CJLM . Franceschi S . Smoking and human \npapillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence \nSurveys. Int J Epidemiol 2008 Jun;37(3):536- 46.  \n \n320) Food groups and alcoholic beverages and the risk of stomach cancer: a case-control study in Italy. Lucenteforte \nE. et al. Nutr Cancer 2008;60(5):577- 84 \n                Trabajo (s) citado (s): \n Ward MH. L\u00f3pez-Carrillo L.  Dietary Factors and the Risk of Gastric Cancer in Mexico City.  Am J Epidemiol \n1999;149(10):925- 32. \n \n321) Food groups and endometrial cancer risk: a case-control study from Italy . Bravi F, Scotti L, Bosetti C, et al. Am J \nObstet Gynecol 2009 Mar;200(3): Article: 293.e1. \n                Trabajo (s) citado (s): \n Salazar -Martinez E .Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Gonz\u00e1lez-Lira G . Escudero-De Los Rios P . \nHern\u00e1ndez-Avila M . Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico . Int J \nGynecol Cancer 2005 Sep-Oct;15(5):938-45.  \n \n322) Fraction of cervical neoplasias due to human papillomavirus 16 and 18 in vaccine trials. Franceschi S, Clifford \nGM. Int J Cancer 2008 1Feb;122(3):719- 20. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.   \n53  \n323) From Causality to Prevention - The Example of Cervical Cancer: My Personal Contribution to This Fascinating \nHistory. Mun\u00f3z N. Public Health Genom 2009;12(5- 6):368-71. \nTrabajo (s) citado (s): \n Franco EL . Tsu V . Herrero R . Lazcano- Ponce E . Hildesheim A.  Mun\u00f3z N . Murillo R . S\u00e1nchez GI . Andrus JK . \nIntegration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the \nCaribbean . Vaccine 2008 19 Aug;26(Suppl 11):L88-L95.     \n \n324) Fumonisin exposure and the sphinganine/sphingosine ratio in uri ne, serum and buccal cells in adults from \nBurkina Faso, West Africa. Nikiema PA. et al. World Mycotoxin J 2008 Nov;1(4):483 -91 \n                Trabajo (s) citado (s): \n Gong YY. Torres -S\u00e1nchez L. L\u00f3pez -Carrillo L. Peng JH. Sutcliffe AE. White KL. Humpf HU. Tur ner PC. Wild CP. \n(2008) Association between tortilla consumption and human urinary fumonisin B1 levels in a Mexican population. \nCancer Epidemiol Biomarkers Prev 17:688 \u2013694 \n \n325) Fumonisins determination in urine by LC -MS-MS. Silva LJG. et al. Anal Bioanal Chem 2009               \n                Trabajo (s) citado (s): \n Gong YY. Torres -S\u00e1nchez L. L\u00f3pez -Carrillo L. Peng JH. Sutcliffe AE. White KL. Humpf HU. Turner PC. Wild CP. \n(2008) Association between tortilla consumption and human urinary fumonisin B1 levels in a Mexican population. \nCancer Epidemiol Biomarkers Prev 17:688 \u2013694 \n \n326) Functional polymorphisms of the cyclooxygenase (PTGS2) gene and risk for gallbladder cancer in a North \nIndian population. Srivastava K, Srivastava A, Pandey SN, et al. J Gastroenterol 2009 Ju l;44(7):774 -80. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF. Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n327) Gallbladder Cancer (GBC): 10-Year Experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). Duffy A, \nCapanu M, Abou-Alfa GK, et al. J Surg Oncol 2008 1Dec;98(7):485- 9. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n328) Gallbladder cancer a comprehensive review. Lai ECH, Lau WY. Surgeon Journal of the Royal Colleges of \nSurgeons of Edinburgh and Ireland 2008 Apr;6(2):101- 10. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n329) Gallbladder cancer incidence among American Indians and Alaska Natives, US, 1999-2004. Lemrow SM, \nPerdue DG, Stewart SL, et al. Cancer 2008 1Sep;113(5):1266- 73. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n330) Gallbladder cancer. Gourgiotis S, Kocher HM, Solaini L, et al. Am J Surg 2008 Aug;196(2):252 -64. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n331) Gallbladder cancer: a morphological and molecular update. Goldin RD, Roa JC. Histopathology 2009 \nAug;55(2):218-29. \n                Trabajo (s) citado (s): \n Lazcano -Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n332) Gallstone disease: From genes to evidence-based therapy. Lammert F, Miquel JF. J Hepatol 2008;48(Suppl \n1):S124-S135. \n                Trabajo (s) citado (s):  \n54 \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n333) Gastric cancer in relation to the intake of nutrients involved in one-carbon metabolism among MTHFR 677 TT \ncarriers . Galvan -Portillo MV, Cantoral A, Onate -Ocana LF, et al. Eur J Cancer 2009 Aug;48(5):269 -76. \n                Trabajo (s) citado (s): \n Torres J . L\u00f3pez-Carrillo L. Lazcano E. Camorlinga M . Flores-Luna L . Munoz O . Trends in Helicobacter pylori \ninfection and gastric cancer in Mexico . Cancer Epidemiol Biomarkers Prev 2005 Aug;14(8():1874-7.  \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. G raziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carrillo L.  et al. Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T \nand A1298C polymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008;167(5):505 -516. \n \n334) Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Andre T, Reyes -Vidal JM, \nFartoux L, et al. Br J Cancer 2008 9Sep;99(6):862 -7. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n335) Gene Expression Patterns Induced by HPV-16 L1 Virus-Like Particles in Leukocytes from Vaccine Recipients. \nGarcia-Pineres AJ, Hildesheim A, Dodd L, et al. J Immunol 2009 1Feb;182(3):1706- 29. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n336) Generalized cost -effectiveness of preventive interventions against cervical cancer in Mexican women: Results \nof a Markov model from the public sector perspective . Gutierrez -Delgado C, Baez -Mendozo C, Gonzalez -Pier \nE, et al. Salud Publica Mex 2008 Mar -Apr;50(2):107 -18. \n                Trabajo (s) citado (s): \n Salmeron J . Lazcano-Ponce E.  Lorincz A . Hernandez M . Hern\u00e1ndez P . Leyva A . Uribe M . Manzanares H . Antunez \nA. Carmona E . Ronnett BM . Sherman ME . Bishai D . Ferris D . Flores Y . Yunes E . Shah KV . Comparison of HPV-\nbased assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico . Cancer Causes \nControl 2003 Aug;14(6):505-12.  \n Lazcano- Ponce EC. Castro R . Allen B . Najera P . De Ruiz PA. Hern\u00e1ndez-Avila M . Barriers to early detection of \ncervical-uterine cancer in Mexico . J Womens Health 1999 Apr;8(3):399- 408. \n \n337) Genetic changes of p53, K-ras and microstatellite instability in gallbladder carcinoma in high-incidence areas \nof Japan and Hungary. Nagahashi M, Ajioka Y, Lang I, et al. World J Gastroenterol  2008 7Jan;14(1):70- 5. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n338) Genetic Susceptibility to cancer: The role of polymorphisms in candidate genes. Dong LM. et al. JAMA \n2008;299(20):2423- 6. \n                Trabajo (s) citado (s): \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carrillo L.  et al. Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T \nand A1298C polymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n \n339) Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway. Hazra A. et al. \nHum Mol Genet 2009  \n                Trabajo (s) citado (s): \n Galv\u00e1n -Portillo MV . Cant oral A. O\u00f1ate -Oca\u00f1a LF. Chen J.  Herrera -Goepfert,R. Torres - S\u00e1nchez L. Hern\u00e1ndez -\nRamirez RU. Palma -Coca O.  L\u00f3pez -Carrillo L.  (2009) Gastric cancer in relation to the intake of nutrients involved \nin one -carbon metabolism among MTHFR 677 TT carriers. Eur. J. Nutr. 48,269 -276 \n \n340) Genomic medicine in Mexico: Initial steps and the road ahead. Jim\u00e9nez -S\u00e1nchez G. et al. Genome Res 2008 \nAug;18(8):1191 -8 \n                Trabajo (s) citado (s): \n Lacasa\u00f1a-Navarro M. Galv\u00e1n-Portillo M . Chen J. L\u00f3pez-Cervantes M. L\u00f3pez-Carrillo L. \nMethylenetetrahydrofolate reductase 677C>T polymorphism and gastric cancer susceptibility in Mexico. Eur J \nCancer 2006;42:528- 533. \n  \n55 341) Genotype Prevalence and Allele Frequencies of 5,10-Methylenetetrahydrofolate Reductase (MTHFR) C677T \nand A1298C Polymorphisms in Italian Newborns. Zappacosta B. et al. Lab Medicine2009 Dec;40(12):732-6 \n                Trabajo (s) citado (s): \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carril lo L.  et al. Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T \nand A1298C polymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n \n342) Genotype x diet interactions in mice predisposed to mammary cancer: II. Tumors and metastasis . Gordon RR, \nHunter KW, La Merrill M, et al. Mammalian Genome 2008 Mar;19(3):179- 89. \n                Trabajo (s) citado (s): \n Salazar -Martinez E .Lazcano-Ponce E. S\u00e1nchez-Zamorano LM.  Gonz\u00e1lez-Lira G . Escudero-De Los Rios P . \nHern\u00e1ndez-Avila M . Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico . Int J \nGynecol Cancer 2005 Sep -Oct;15(5 ):938 -45.  \n \n343) Geographic Variation in the Prevalence of Kaposi Sarcoma-Associated Herpesvirus and Risk Factors for \nTransmission . de Sanjose S, Mbisa G, Perez-Alvarez S, et al. J Infect Dis 2009 15May;199(10):1449-56. \n                Trabajo (s) citado (s): \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n344) Geographic variation of gallbladder cancer mortality and risk factors in Chile: A population-based ecologic \nstudy. Andia ME, Hsing AW, Andreotti G, et al. Int J Cancer 2008 15Sep;123(6):1411- 6. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n345) Global access to HPV vaccination: what are we waiting for?  Clifford GM. Lancet 2009 12Dec;374(9706):1948- 9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n346) Global effects of inorganic arsenic on gene expression profile in human Macrophages. Bourdonnay E. et al. \nMol Immunol 2009 feb;46(4):649- 56 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessment \nof lymphocyte subpopulations and cytokine secretion in children exposed to ar senic. FASEB J 20(6):779 \u2013781. \n \n347) Global Epigenetic Screening Technologies: a Novel Tool to Address Cancer Health Disparities in High-Risk \nPopulation Groups. Guerrero-Preston R. P R Health Sci J 2008 Dec;27(4):350- 6. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n348) Glycemic index, glycemic load, and cancer risk: a meta -analysis . Gnagnarella P, Gandini S, La Vecchia C, et  al. \nAm J Clin Nutr 2008 Jun;87(6):1793 -1801.  \n                Trabajo (s) citado (s): \n Lajous M . Willett W . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM , Hernandez-Avila M , Romieu I . Glycemic load, \nglycemic index, and the risk of breast cancer among Mexican women . Cancer Causes Control 2005 \nDec;16(10):1165-9.  \n \n349) Glycemic index, glycemic load and thyroid cancer risk . Randi G, Ferraroni M, Talamini R, et al. Ann Oncol 2008 \nFeb;19(2):380 -3. \n                Trabajo (s) citado (s): \n Lajous M . Willett W . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM , Hernandez-Avila M , Romieu I . Glycemic load, \nglycemic index, and the risk of breast cancer among Mexican women . Cancer Causes Control 2005 \nDec;16(10):1165-9.  \n \n350) Glycemic load, glycemic index and breast cancer risk in a prospective cohort of Swedish women. Larsson SC. et \nal. Int J Cancer 2009;125:153- 7. \n                Trabajo (s) citado (s):  \n56 \n Lajous M.  Boutron-Ruault MC. Fabre A. Clavel-Chapelon F. Romieu I . Carbohydrate intake, glycemic index, \nglycemic load, and risk of postmenopausal breast cancer in a prospective study of French women. Am J Clin Nutr. \n2008;87(5):1384 \u20131391.  \n \n351) Guideline for management of postmeal glucose . Ceriello A, Colagiuri S, Gerich J, et al. Nutr Metab Cardiovasc \nDis 2008 May;18(4):S17-S33. \n                Trabajo (s) citado (s): \n Lajous M . Willett W . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM , Hernandez-Avila M , Romieu I . Glycemic load, \nglycemic index, and the risk of breast cancer among Mexican women . Cancer Causes Control 2005 \nDec;16(10):1165-9.  \n \n352) Good girls do ... get vaccinated: HPV, mass marketing and moral dilemmas for sexually active young women. \nPolzer J, Knabe S. J Epidemiol Commun Health 2009 Nov;63(11):869- 70. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n353) Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Mennini FS, Rossi PG, \nPalazzo F, et al. Gynecol Oncol 2009 Feb;112(2):370- 6. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n354) Health and economic implications of HPV vaccination in the United States. Kim JJ, Goldie SJ. NEJM 2008 \n21Aug;359(8):821- 32. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n355) Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI -eligible countries. Goldie SJ, O'Shea M, \nCampos NG, et al. Vaccine 2008 29Jul;26(32):4080 -93. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n356) Health insurance and cervical cancer screening among older women in Latin American and Caribbean citie s. \nReyes -Ortiz CA, Velez LF, Camacho ME, et al. Int J Epidemiol 2008 Aug;37(4):870 -8. \n                Trabajo (s) citado (s): \n Aguilar -Perez JA . Leyva-L\u00f3pez AG . Angulo-Najera D . Salinas A . Lazcano-Ponce EC . Cervical cancer screening: \nknowledge of Pap smear benefits and utilization in Mexico .. Rev Saude Publica 2003 Feb;37(1):100-6.  \n Hern\u00e1ndez -Avila M . Lazcano EC . de Ruiz PA . Romieu I . Evaluation of the cervical cancer screening programme \nin Mexico: a population-based case-control study . Int J Epidemiol 1998 Jun;27(3):370- 6. \n \n357) Health systems and immunization financing for human papillomavirus vaccine introduction in low -resource \nsettings. Biellik R, Levin C, Mugis ha E, et al. Vaccine 2009 19Oct;27(44):6203 -9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n358) Helicobacter pylori and Non-malignant Diseases . Furuta T, Delchier JC. Helicobacter 2009 Sep;14(Suppl 1):29-\n35.    \n                Trabajo (s) citado (s): \n Trejo -de la OA . Torres J . P\u00e9rez-Rodr\u00edguez M . Camorlinga-Ponce M . Flores- Luna L . Abdo-Francis JM . Lazcano-\nPonce E.  Maldonado-Bernal C . TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine \npatterns in Mexican patients with Helicobacter pylori-associated gastroduodenal diseases . Clin Immunol 2008 \nNov;129(2) :333-340.  \n \n359) Helicobacter Pylori associated global gastric cancer burden. Mbulaiteye SM. et al. Front Biosci 2009;14(4):1490-504  \n                Trabajo (s) citado (s): \n Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Gastric cancer risk in a Mexican population: \nrole of Helicobacter pylori CagA positive infection and polymorphism s in interleukin -1 and -10 genes. Int. J. \nCancer. 118:649 \u2013657. \n \n360) Helicobacter pylori-negative duodenal ulcer disease . Gisbert JP, Calvet X. Aliment Pharmacol Ther  2009 \nOct;30(8):791-815.  \n57                 Trabajo (s) citado (s): \n Camorlinga -Ponce M . Flores-Luna L . Lazcano-Ponce E . Herrero R . Bernal-Sahagun F . Abdo-Francis JM . Aguirre-\nGarcia J. Mun\u00f3z N . Torres J .  Age and severity of mucosal lesions influence the performance of serologic markers \nin Helicobacter pylori-associated gastroduodenal Pathologies . Cancer Epidemiol Biomarkers Prev 2008 \nSep;17(9):2498-2504.. \n \n361) Helicobacter Pylori's Plasticity Zones Are Novel Transposable Elements . Kersulyte D, Lee W, Subramaniam D, \net al. PLoS One 2009 3Sep;4(9):Article e6859. \n                Trabajo (s) citado (s): \n Romo -Gonzalez C . Salama NR . Burgeno-Ferreira J . Ponce-Castaneda V . Lazcano-Ponce EC.  Camorlinga-Ponce M . \nTorres J . Differences in Genome Content among Helicobacter pylori Isolates from Patients with Gastritis, \nDuodenal Ulcer, or Gastric Cancer Reveal Novel Disease-Associated Genes . Infect Immun 2009 May;77(5):2201- 11. \n \n362) Helicobacter species in cancers of the gallbladder and extrahepatic biliary tract .  de Martel C, Plummer M, \nParsonnet J, et al. Br J Cancer 2009 13 Jan;100(1):194- 9. \n                Trabajo (s) citado (s): \n Camorlinga-Ponce M . Flores-Luna L . Lazcano-Ponce E . Herrero R . Bernal-Sahagun F . Abdo-Francis JM . Aguirre-\nGarcia J. Mun\u00f3z N . Torres J .  Age and severity of mucosal lesions influence the performance of serologic markers \nin Helicobacter pylori-associated gastroduodenal Pathologies . Cancer Epidemiol Biomarkers Prev 2008 \nSep;17(9):2498-2504..  \n \n363) Hexavalent Chromium, Yellow Water, and Cancer A Convoluted Saga. Smith A. Epidemiology 2008;19:24-6 \n                Trabajo (s) citado (s): \n Tovar -Guzm\u00e1n V. Hern\u00e1ndez -Gir\u00f3n C.  Barquera S. Rodr\u00edguez -Salgado N. L\u00f3pez -Carrillo L.. Epidemiologic \npanorama of stomach cancer mortality in Mexico. Arch Med Res 2001;32:312 \u2013 7. \n \n364) High frequency of multiple HPV types in cervical specimens from Danish women. Mejlhede N, Bonde J, \nFomsgaard A, A PMIS 2009 Feb;117(2):108 -14. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n365) High prevalence of human papillomavirus infection in the female population of Guatemala. Valles X, Murga \nGB, Hernandez G, et al. Int J Cancer 2009 1Sep;125 (5):1161 -7. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A . Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n P\u00e9rez G . Lazcano -Ponce E.  Hern\u00e1ndez-Avila M . Garcia PJ. Mun\u00f3z N . Villa LL . Bryan J . Taddeo FJ . Lu S . Esser MT . \nVuoco S . Sattler C . Barr E . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, \n11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8.  \n Vaccarella S . Franceschi S . Herrero R. Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n366) High-risk HPV DNA detected in less than 2% of over 25,000 cytology negative imaged liquid-based Pap test \nsamples from women 30 and older. Bansal M, Austin RM, Zhao CQ. Gynecol Oncol 2009 Nov;115(2).257- 61. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n367) Higher Intakes of Vegetables and Vegetable-Related Nutrients Are Associated with Lower Endometrial Cancer \nRisks . Yeh M, Moysich KB, Jayaprakash V, et al. J Nutr 2009 Feb;139(2).317- 22. \n                Trabajo (s) citado (s): \n Salazar -Martinez E .Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Gonz\u00e1lez-Lira G . Escudero-De Los Rios P . \nHern\u00e1ndez-Avila M . Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico . Int J \nGynecol Cancer 2005 Sep -Oct;15(5 ):938 -45.  \n \n368) HIV -infected patients with anal carcinoma who subsequently developed oral squamous cell carcinoma: report \nof 2 cases. Chaiyachati K. Cinti SK. et al. J Int Assoc Physicians AIDS Care 2008 Nov-Dec;7(6):306- 10 \n                Trabajo (s) citado (s):  \n58 \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n369) Hormone replacement therapy and ovarian cancer risk: A meta-analysis . Zhou B, Sun QM, Cong RH, et al. \nGynecol Oncol 2008 Mar;108(3):641- 51. \n                Trabajo (s) citado (s): \n Salazar -Martinez E . Lazcano-Ponce EC.  Lira-Lira GG . Escudero-De los Rios P . Salmeron-Castro J . Hern\u00e1ndez-\nAvila M . Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico . \nCancer Res 1999 1Aug;59(15):3658- 62. \n \n370) Hormones and gallbladder cancer in women. Barreto SG. Haga H. Shukla PJ. Indian J Gastroenterol 2009 Jul -\nAug;28(4):126 -30. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal for Clinicians 2001 Nov-\nDec;51(6):349-64.  \n \n371) How many CIN2+lesions can be avoided through HPV 16/18 vaccination?  Eskild A, Sjoborg KD. Acta Obstet \nGynecol Scand 2009;88(7):859- 60. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n372) How much will it hurt? HPV vaccine side effects and influence on completion of the three-dose regimen  Reiter \nPL, Brewer NT, Gottlieb SL, et al. Vaccine 2009 16Nov;27(49): 6840 -4. \n                Trabajo (s) citado (s): \n P\u00e9re z G. Lazcano- Ponce E . Hern\u00e1ndez-Avila M . Garcia PJ . Mun\u00f3z N . Villa LL. Bryan J . Taddeo FJ . Lu S . Esser MT . \nVuoco S. Sattler C . Barr E . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, \n11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8.  \n \n373) How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands. Coupe VMH, de Melker HE, \nSnijders PJF, et al. Vaccine 2009 13Aug;27(37):5111- 9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n374) HPV and cancer. Carcopino X, Bretelle F, Boubli L. Med Malad Infect 2008 Jun;38(Suppl 2):S47-S48. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n375) HPV and cervical cancer: screening or vaccination? Bosch FX, Castellsague X, de Sanjose S. Br J Cancer 2008 \n8Jan;98(1):15- 21. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n376) Hpv and Cervical Cancer Prevention. Ursic-Vrscaj M. Baskovic M. et al. Zdravniski Vestnik-Slovenian Medical \nJournal 2009; 78: 39- 42. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n377) HPV & HPV vaccination: Issues in developing countries.  Bharadwaj M, Hussain S, Nasare V, et al. Ind J Med \nRes 2009 Sep;130(3):327 -33. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n378) HPV vaccine acceptability in a rural Southern area. Fazekas KI. Brewer NT. et al. J Womens Health 2008; 17(4): \n539-548. \n                Trabajo (s) citado (s): \n \n59 \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n379) HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV \nvaccine. Joura EA, Kjaer SK, Wheeler CM, et al. Vaccine 2008 2Dec;26(52):6844- 51. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Giuliano AR . Lazcano -Ponce E.  Villa L . Nolan T . Marchant C . Radley D . Golm G .  McCarroll K . Yu J . Esser MT . \nVuocolo SC . Barr E Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) \nhuman papillomavirus virus-like-particle vaccine .. J Infect Dis 2007 15Oct;196(8):1153- 62. \n \n380) HPV as a Model for the Development of Prophylactic and Therapeutic Cancer Vaccines. Samara RN, Khleif \nSN. Curr Mol Med 2009 Aug;9(6):766- 73. \n                Trabajo (s) citado (s): \n Villa LL, et al. (The Future II Study Group, Lazcano-Ponce E.).  Quadrivalent vaccine against human papillomavirus \nto prevent high-grade cervical lesions. NEJM 2007 10May;356(19):1915-27.  \n \n381) HPV genotype prevalence in cytologically abnormal cervical samples from women living in south Italy. Capra \nG, Giovannelli L, Bellavia C, et al. Virus Re s 2008 May;133(2):195 -200. \n                Trabajo (s) citado (s): \n Vaccar ella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n382) HPV immunization for the prevention of cervical cancer. Mougin C, Bourgault-Villada I, Coursaget P.Press \nMed 2009 Dec;38(12):1750- 68. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n383) HPV in men . D'Hauwers KWM, Tjalma WAA. Eur J Gynaecol Oncol 2008;29(4):338 -40. \n                Trabajo (s) citado (s): \n Aguilar LV . Lazcano-Ponce E.  Vaccarella S . Cruz A . Hern\u00e1ndez P . Smith JS . Munoz N . Kornegay JR . Hern\u00e1ndez-\nAvila M . Franceschi S . Human papillomavirus in men: comparison of different genital sites. Sex Transm Infect \n2006 1Feb;82(1):31- 3. \n \n384) HPV infection in Europe. De Vuyst H, Clifford G, Li N, et al. Eur J Cancer 2009 Oct;45(15):2632-9. Sp. Iss. SI. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n385) HPV infection in women with and without cervical cancer in Conakry, Guinea. Keita N, Clifford GM, \nKoulibaly M, et al. Br J Cancer 2009 30Jun;101(1):202- 8. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n386) HPV information needs, educational messages and channel of delivery preferences: views from developing \ncountry with multiethnic populations. Wong LP. Vaccine 2009 25Feb;27(9):1410- 5. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Rivera L. Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n387) HPV p revalence among healthy Italian male sexual partners of women with cervical HPV infection . Benevolo \nM, Mottolese M, Marandino F, et al. J Med Virol 2008 Jul;80(7):1275 -81. \n \n60                 Trabajo (s) citado (s): \n Lazcano- Ponce E. Herrero R . Munoz N . Hernandez-Avila M . Salmeron J. Leyva A . Meijer CJLM . Walboomers \nJMM . High prevalence of human papillomavirus infection in Mexican males - Comparative study of penile-\nurethral swabs and urine samples . Sex Transm Dis 2001 May;28(5):277-80.  \n \n388) HPV prevalence in Colombian women with cervical cancer: implications for  vaccination in a developing  \ncountry.  Murillo R. Molano M. Infect Dis Obstet Gynecol 2009;2009:653598. Epub 2009 Dec 20  \n                Trabajo (s) citado (s): \n Franco EL . Tsu V. Herrero R . Lazcano- Ponce E . Hildesheim A . Mun\u00f3z N . Murillo R . S\u00e1nchez GI . Andrus JK . \nIntegration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the \nCaribbean . Vaccine 2008 19 Aug;26(Suppl 11):L88-L95  \n389) HPV Prophylactic Vaccines and the Potential Prevention of Noncervical Cancers in Both Men and Women. \nGillison ML, Chaturvedi AK, Lowy DR. Cancer 2008 15Nov;113(10):3036-46. Suppl. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n390) HPV -related Carcinogenesis: Basic Concepts, Viral Types and Variants. Lizano M, Berumen J, Garcia -Carranca \nA. Arch Med Res 2009 Aug;40(6):428 -34. Sp. Iss. SI.  \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n391) HPV Vaccination for the Prevention of Cervical Intraepithelial Neoplasia. Kahn JA. NEJM 2009 \n16Jul;361(3):271- 8. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n392) HPV vaccination: Counselling of young sexually active women. Schmalfeldt B, Seifert-Klauss V, Paepke S, et \nal. Geburtshilfe Und Frauenheilkunde 2008 Jan;68(1):27- 30. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n393) HPV-vaccination for the prevention of cervical cancer in Austria: a model based long-term prognosis of cancer \nepidemiology. Zechmeister I. et al. J Public Health Online Aug 2009 \n                Trabajo (s) citado (s): \n Insinga RP. Dasbach EJ. Elbasha EH. Puig A. Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human \npapillomavirus (HPV) vaccination in Mexico: a transmission dynamic model based evaluation. Vaccine 2007, \n26:128-139. \n \n394) HPV vaccination: the beginning of the end of cervical cancer? A Review. Lepique AP, Rabachini T, Villa LL. \nMem Inst Oswaldo Cruz 2009 Feb;104(1):1- 10. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n395) HPV vaccination: the promise & problems. Sankaranarayanan R.  Ind J Med Res 2009 Sep;130(3):322- 6. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n \n61 396) HPV Vaccine Acceptability by Latino Parents: A Comparison of US and Salvadoran Populations. Podolsky R, \nCremer M, Atrio J, et al. J Pediatr Adole s Gynecol 2009 Aug;22(4):205 -15. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Rivera L. Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n \n397) HPV Vaccine Acceptance among Latina Mothers by HPV Status. Sanderson M, Coker AL, Eggleston KS, et al. J \nWomens Health 2009 Nov;18(11):1793- 9. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Rivera L . Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n \n398) HPV vaccines and cervical cancer. Bosch FX. Ann Oncol 2008;19(Suppl 5):48- 51. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n399) HPV vaccines: are they the answer?.  Stanley M. Br Med Bull 2008 Dec;88(1):59-74. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n400) HPV Vaccines: Preclinical Development . Gissmann L. Arch Med Res 2009 Aug;40(6):466-70. Sp. Iss. SI.  \n                Trabajo (s) citado (s): \n Giuliano AR . Lazcano -Ponce E.  Villa L . Nolan T . Marchant C . Radley D . Golm G .  McCarroll K . Yu J . Esser MT . \nVuocolo SC . Barr E Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) \nhuman papillomavirus virus-like-particle vaccine .. J Infect Dis 2007 15Oct;196(8):1153- 62. \n \n401) HPV Vaccines: Today and in the Future. Moscicki AB. J Adoles Health 2008 Oct;43(S4):S26-S40. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n402) HPV16/18 vaccination to prevent cervical cancer in The Netherlands: Model-based cost-effectiveness. Coupe \nVMH, van Ginkel J, de Melker HE, et al. Int J Cancer 2009 15Feb;124(4):970- 8. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n403) Human Leukocyte Antigens I and II Haplotypes Associated With Human Papillomavirus 16-Positive Invasive \nCervical Cancer in Mexican Women . Hernandez -Hernandez DM, Cerda -Flores RM, Juarez -Cedillo T, et al. Int J \nGynecol Cancer 2009  Aug;19(6):1099 -1106.  \n                Trabajo (s) citado (s): \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA . Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J. Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n404) Human papilloma virus - Prevention and treatment .  Diaz ML. Obstet Gynecol Clin North Am 2008 \nJun;35(2):199+. \n                Trabajo (s) citado (s): \n \n62 \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n405) Human papilloma virus and esophageal carcinoma in a Latin -American region . Herrera -Goepfert R, Lizano M, \nAkiba S, et al. World J Gastroen terol 2009 7Jul;15(23): 3142- 7.  \n                Trabajo (s) citado (s): \n Flores YN . Bishai DM . Shah KV . Lazcano -Ponce E . Lorincz A . Hern\u00e1ndez M . Ferris D . Salmeron J . Risk factors for \ncervical cancer among HPV positive women in Mexico . Salud Publica Mex 2009 Jan-Feb;50(1):49- 58. \n Giuliano AR . Lazcano- Ponce E . Villa LL . Flores R . Salmeron J . Lee JH . Papenfuss MR . Abrahamsen M . Jolles E. \nNielson CM . Baggio ML. Silva R . Quiterio M . The human papillomavirus infection in men study: Human \npapillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United Stat es. \nCancer Epidemiol Biomarkers Prev 2008 Aug;17(8):2036-43.  \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n406) Human papillomavirus and genital cancer. Rapose A. Ind J Dermatol Venereol Leprol 2009 May-Jun;75(3):236-\n44. \n                Trabajo (s) citado (s): \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n \n407) Human papilloma virus in adolescence . Christopoulos P, Papadias K, Panoulis K, et al. Clin Exp Obstet \nGynecol 2008;35(4): 248-51.  \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Snijders PJF . Dai M . Thomas JO . Hieu NT . Ferreccio C . Matos E.  Posso H . de Sanjose S . \nShin HR . Sukvirach S . Lazcano-Ponce E. Mun\u00f3z N . Meijer CJLM . Franceschi S . Smoking and human \npapillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence \nSurveys. Int J Epidemiol 2008 Jun;37(3):536- 46.  \n Lazcano- Ponce E.  Rivera L. Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n \n408) Human papilloma virus (HPV) infection in child ren and adolescents. Mammas IN, Sourvinos G, Spandidos \nDA. Eur J Pediatr 2009 Mar;168(3):267 -73. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n409) Human papillomavirus-associated diseases in HIV-infected men who have sex with men . Kreuter A, Wieland \nU. Curr Opin Infect Dis 2009 Apr;22(2):109- 14.  \n                Trabajo (s) citado (s): \n Giuliano AR . Lazcano- Ponce E.  Villa LL . Flores R . Salmeron J . Lee JH . Papenfuss MR . Abrahamsen M . Jolles E. \nNielson CM . Baggio ML . Silva R . Quiterio M . The human papillomavirus infection in men study: Human \npapillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States . \nCancer Epidemiol Biomarkers Prev 2008 Aug;17(8):2036-43.  \n \n410) Human Papilloma Virus Associated with Genital Infection. Ljubojevic S, Lipozencic J, Grgec DL, et al. \nCollegium Antropologicum 2008 Sep;32(3):989- 97. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n411) Human papilloma virus infection and cervical cancer: a public health perspective . Torres -Poveda KJ, Burguete \nA, Bermudez -Morales VH, et al. Rev Invest Clin 2008 Sep -Oct;60(5):414 -20. \n                Trabajo (s) citado (s): \n Flores Y . Bishai D . Lazcano E.  Shah K . Lorincz A . Hernandez M . Salmeron J. Improving cervical cancer screening \nin Mexico: Results from the Morelos HPV Study . Salud Publica Mex 2003;54(Suppl 3):S388-S398.  \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n \n63 412) Human Papilloma Virus Infection and Prevention in the Adolescent Population. Hager WD. J Pediatr Adoles \nGynecol  2009 Aug;22(4):197- 204. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n413) Human Papilloma Virus (HPV) in head and neck region: review of literature. Mannarini L, Kratochvil V, \nCalabrese L, et al. Acta Otorhino laryngol Ital 2009 Jun;29(3):119 -26. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents. Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n414) Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, \nNational Immunization Survey-Adult 2007. Jain N, Euler GL, Shefer A, et al. Prev Med 2009 May;48(5):426- 31. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n415) Human papillomavirus (HPV) vaccination and the development of public policies. Lippman A. J Epidemiol \nCommun Health 2008 Jul;62(7):570- 1. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n416) Human Papillomavirus and Cervical Cancer - Current Status of Vaccination Against Human Pathogenic \nPapillomavirus In Reply.  Loning M, Hillemanns P. Deutsches Arzteblatt Int 2008 7Jan;105(1-2):23- 4. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n417) Human Papillomavirus and Cervical Cancer - Current Status of Vaccination Against Human Pathogenic \nPapillomavirus Low Efficacy . Hirte M, Rabe S, Schmidt-Troschke S.  Deutsches Arzteblatt Int 2008 7Jan;105(1-\n2):22. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n418) Human papillomavirus and cervical disease in adole scents. Guido R. Clin Obstet Gynecol 2008 Jun;51(2):290 -\n305. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n419) Human papillomavirus and vaccination. Huang CM. Mayo Clin Proceed 2008 Jun;83(6):701 -7. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n420) Human papillomavirus disease and vaccines. Hutchinson DJ, Klein KC. Am J Health Syst Pharm 2008 \n15Nov;65(22):2105- 12. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL. Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n421) Human Papillomavirus Genotype Distribution in Cervical Cancer in India: Results from a Multi-center Study. \nBasu P, Roychowdhury S, Bafna UD, et al. Asian Pac J Cancer Prev 2009;10(1):27-34. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n \n64 422) Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and \ncomparison with CIN2/3 and invasive cervical cancer - The EDiTH III study. Pretet JL, Jacquard AC, Saunier \nM, et al. Gynecol Oncol 2008 Aug;110(2):179- 84. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n423) Human papillomavirus genotypes and HPV16 variants in penile carcinoma. Tornesello ML, Duraturo ML, \nLosito S, et al. Int J Cancer 2008 1Jan;122(1):132- 7. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n424) Human papillomavirus (HPV) genotype 84 infection of the male genitalia: Further evidence for HPV tissue \ntropism?   Castle PE. J Infect Dis 2008 1Mar;197(5):776- 8. \n                Trabajo (s) citado (s): \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n425) Human papillomavirus in cervical and head-and-neck cancer.  Psyrri A, DiMaio D. Nat Clin Pract Oncol 2008 \nJan;5(1):24- 31. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n426) Human Papillomavirus in HNSCC: Recognition of a Distinct Disease Type . Vidal L, Gillison ML. Hematol \nOncol Clin North Am 2008 Dec;22(6): 1125.   \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Snijders PJF . Dai M . Thomas JO . Hieu NT . Ferreccio C . Matos E.  Posso H . de Sanjose S . \nShin HR . Sukvirach S . Lazcano-Ponce E. Mun\u00f3z N . Meijer CJLM . Franceschi S . Smoking and human \npapillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence \nSurveys. Int J Epidemiol 2008 Jun;37(3):536- 46.  \n \n427) Human papillomavirus: molecular and cytologic/histotogic aspects related to cervical intraepithelial neoplasia \nand carcinoma. Thomison J, Thomas LK, Shroyer KR. Hum Pathol 2008 Feb;39(2):154- 66. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n428) Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United \nStates, 2003-2005. Datta SD, Koutsky LA, Ratelle S, et al. Ann Intern Med 2008 1Apr;148(7):493-500. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677- 2684.   \n \n429) Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Lowy DR, \nSolomon D, Hildesheim A, et al. Cancer 2008 1Oct;113(7):1980 -93. Sp. Iss. SI.  \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A . Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Vaccarella S . Franceschi S . Herrero R. Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior , \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n430) Human papillomavirus infection in Beijing, People's Republic of China: a population-based study . Zhao R, \nZhang WY, Wu MH, et al. Br J Cancer 2009 27Oct;101(9):1635- 40.  \n                Trabajo (s) citado (s):  \n65 \n Vaccarella S . Herrero R . Snijders PJF . Dai M . Thomas JO . Hieu NT . Ferreccio C . Matos E.  Posso H . de Sanjose S . \nShin HR . Sukvirach S . Lazcano-Ponce E. Mun\u00f3z N . Meijer CJLM . Franceschi S . Smoking and human \npapillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence \nSurveys. Int J Epidemiol 2008 Jun;37(3):536- 46.  \n Vaccarella S . Franceschi S . Herrero R. Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n431) Human papillomavirus infection in honduran women with normal cytology. Tabora N, Bakkers JMJE, Quint \nWGV, et al. Cancer Causes Control 2009 Nov;20(9):1663- 70. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n432) Human Papillomavirus Infection Low -Risk and High -Risk Genotypes in Women in Catania, Sicily. Agodi A, \nBarchitta M, La Rosa N, et al. Int J Gynecol Cancer 2009 Aug;19(6):1094 -8. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n433) Human Papillomavirus Infection in Solid Organ Transplant Recipients.  Kwak EJ, Julian K. Am J Transpl 2009 \nDec;9(Suppl 4):S151-S160. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions. NEJM 2007 10May;356(19):1915-27.  \n \n434) Human papillomavirus infection in Ulaanbaatar, Mongolia: A population-based study . Dondog B, Clifford \nGM, Vaccarella S, et al. Cancer Epidemiol Biomarkers Prev 2008 Jul;17(7):1731- 8. \n                Trabajo (s) citado (s): \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n435) Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. Bardin A, \nVaccarella S, Cliffoyd GM, et al. Eur J Cancer 2008 Mar;44(4):557-64. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS. Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n436) Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for \ncervical cancer. Onuki M, Matsumoto K, Satoh T, et al. Cancer Sci 2009 Jul;100(7):1312- 6. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group , Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n \n66 437) Human Papillomavirus Infections and Vulvar Disease Development. Garland SM, Insinga RP, Sings HL, et al. \nCancer Epidemiol Biomarkers Prev 2009 Jun;18(6):1777- 84. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n438) Human papillomavirus profile of women in Belize City, Belize: correlation with cervical cytopathologic \nfindings. Cathro HP, Loya T, Dominguez F, et al. Hum Pathol 2009 Jul;40(7):942- 9. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n439) Human Papillomavirus Quadrivalent Vaccine: A Look Behind The Numbers. Flaherty DK, Alkhateeb FM. Ann \nPharmacother 2009 Apr;43(4):740- 4. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n440) Human papillomavirus type 16 variants in cervical cancer from an admixtured population in Brazil. Junes-Gill \nK, Sichero L, Maciag PC, et al. . J Med Virol 2008 Nov;80(9):1639- 45. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n441) Human papillomavirus vaccination - Reasons for caution. Haug CJ. NEJM 2008 21Aug;359(8):861- 2. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n442) Human papillomavirus vaccination coverage on YouTube. Ache KA, Wallace LS. Am J Prev Med 2008 \nOct;35(4):389- 92. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Rivera L. Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n \n443) Human Papillomavirus Vaccination in the Prevention of Cervical Neoplasia. Astbury K, Turner MJ. Int J \nGynecol Cancer 2009 Dec;19(9):1610- 13. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n444) Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate \nwomen older than 26? Skinner SR, Garland SM, Stanley MA, et al. Med J Austr 2008 18Feb;188(4):238- 42. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n445) Human papillomavirus vaccination: Attitude to a consultation on a therapeutic novelty.  Gonzalez CA, Ascanio \nADC. Atencion Primaria 2008 Apr;40(4):205- 8. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n446) Human papillomavirus vaccination: Expected impacts and unresolved issues. Dempsey AF, Freed GL. J Pediatr \n2008 Mar;152(3):305- 9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.   \n67  \n447) Human papillomavirus vaccine. Kim KH. J Kor Med Assoc 2008 Feb;51(2):144- 57. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n448) Human Papillomavirus Vaccine Acceptability Among Young Adult Men. Gerend MA, Barley J. Sex Transm \nDis 2009 Jan;36(1):58- 62. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n449) Human papillomavirus vaccine and adolescents . Dempsey AF. Zimet GD. Curr Opin Obstetr Gynecol 2008 \nOct;20(5):447- 54 \n                Trabajo (s) citado (s): \n Insinga RP. Dasbach EJ. Elbasha EH. Puig A. Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human \npapillomavirus (HPV) vaccination in Mexico: a transmission dynamic model based evaluation. Vaccine 2007, \n26:128-139. \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents. Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n P\u00e9rez G . Lazcano- Ponce E . Hern\u00e1ndez-Avila M . Garcia PJ . Mun\u00f3z N . Villa LL. Bryan J . Taddeo FJ . Lu S . Esser MT . \nVuoco S. Sattler C . Barr E . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, \n11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n450) Human papillomavirus vaccine and cervical cancer prevention. Oaknin A, Barretina MP. Clin Transl Oncol \n2008 Dec;10(12):804- 11. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n451) Human papillomavirus vaccine decision -making in Da Nang, Vietnam: Perceived spousal and adolescent -\nparent concordance. Breitkopf, C. R., H. C. Pearson, et al. Vaccine 2009; 27(17): 2367 -2371.  \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL . Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n452) Human papillomavirus vaccine efficacy: Aligning expectations with reality. Smith-McCune KK. Gynecol \nOncol 2008 Oct;III(1):1- 2. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n453) Human Papillomavirus Vaccine Initiation in an Area with Elevated Rates of Cervical Cancer. Gottlieb SL. \nBrewer NT. et al. Journal of Adolescent Health 2009; 45(5): 430-437. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n454) Human Papillomavirus Vaccine Safety in Pediatric Patients: An Evaluation of the Vaccine Adverse Event \nReporting System. Borja-Hart NL, Benavides S, Christensen C. Ann Pharmacother 2009 Feb;43(2):356- 9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus- like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n455) Human Papillomavirus Vaccine Uptake, Predictors of Vaccination, and Self-Reported Barriers to Vaccination. \nConroy K, Rosenthal SL, Zimet GD, et al. J Womens Health 2009 Oct;18(10):1679-86. \n \n68                 Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n456) Human papillomavirus vaccine: a paradigm shift for pediatricians. Jenson HB. Curr Opin Pediatr 2009 \nFeb;21(1):112- 21. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n457) Human papillomavirus vaccine: optimism versus prudence . Martinez-Gonzalez MA, Carlos S, de Irala J Med \nClin 2008 6Sep;131(7):256- 63. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n458) Human papillomavirus vaccine:  recommendations, issues and controversias. Fisher R. et al. Curr Opin Pediatr \n2008 Aug;20(4):441 -5 \n                Trabajo (s) citado (s): \n Insinga RP. D asbach EJ. Elbasha EH. Puig A. Reynales -Shigematsu LM. Cost -effectiveness of quadrivalent human \npapillomavirus (HPV) vaccination in Mexico: a transmission dynamic model based evaluation. Vaccine 2007, \n26:128-139. \n \n459) Human papillomavirus vaccine. Statement of  the Advisory Committee of Immunizations on Behalf of the \nChilean Infectious Diseases Society. September 2008. Abarca K, Valenzuela MT, Vergara R, et al. Rev Med \nChile 2008 Nov;136(11):1485 -92. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n P\u00e9rez G . Lazcano- Ponce E . Hern\u00e1ndez-Avila M . Garcia PJ . Mun\u00f3z N . Villa LL. Bryan J . Taddeo FJ . Lu S . Esser MT . \nVuoco S. Sattler C . Barr E . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, \n11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n460) Human papillomavirus vaccine. Statement of the Consultive Committee of Immunizations on behalf of The \nChilean Infectious Disea ses Society. September 2008. Katia AV, Valenz uela MT, Rodrigo VF, et al. Rev Chil \nInfectol 2008 Dec 25(6):428 -34. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n P\u00e9rez G . Lazcano- Ponce E . Hern\u00e1ndez-Avila M . Garcia PJ . Mun\u00f3z N . Villa LL. Bryan J . Taddeo FJ . Lu S . Esser MT . \nVuoco S. Sattler C . Barr E . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, \n11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8.  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions. NEJM 2007 10May;356(19):1915-27.  \n \n461) Human papillomavirus vaccines versus cervical cancer screening. Stantey M. Clin Oncol 2008 Aug;20(6):388- 94. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n \n69 462) Human papillomavirus vaccines. Satyaprakash A, Creed R, Ravanfar P, et al. Dermatol Ther 2009 Mar-\nApr;22(2):150- 7. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n463) Human papillomavirus vaccines: an outsider's point of view. Trollfors B. Expert Rev Vaccines 2008 \nOct;7(8):1131- 3. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n P\u00e9rez G . Lazcano- Ponce E . Hern\u00e1ndez-Avila M . Garcia PJ . Mun\u00f3z N . Villa LL. Bryan J . Taddeo FJ . Lu S . Esser MT . \nVuoco S. Sattler C . Barr E . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, \n11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8.  \n \n464) Human papillomavirus vaccines: An update for gynecologists. Ault KA. Clin Obstetr Gynecol 2008 \nSep;51(3):527- 32. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n465) Human papillomavirus vaccines: current issues & future. Kawana K, Yasugi T, Taketani Y. Ind J Med Res 2009 \nSep;130(3):341- 7. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n466) Human papillomavirus, cervical cancer, and the vaccines. Tovar JM, Bazaldua OV, Varga s L, et al. Postgrad \nMed 2008 Jul;120(2):79 -84. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n467) Human papillomavirus, genital warts, and vaccines. Hsueh PR. J Microbiol Immunol Infect 2009 Apr;42(2):101-\n6.  \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n468) Human Papillomaviruses and genital co -infections in gynaecological outpatients . Verteramo R, Pierangeli A, \nMancini E, et al. BMC Infect Dis 2009 12Feb;9:Article 16. \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n Vaccarella S . Franceschi S . Herrero R. Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2) :326-33.  \n \n469) Human papillomaviruses (HPV) vaccines: implementation and communication issues. Kane MA. J Fam Plann \nReprod Health Care 2008 Jan;34(1):3- 4. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n470) Human Papillomavirus-Related Diseases: Oropharynx Cancers and Potential Implications for Adolescent HPV \nVaccination. Gillison ML. J Adolesc Health 2008 Oct;43(4):S52-S60. Suppl. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n70  \n471) Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and \napoptosis. Zehbe I, Richard C, DeCarlo CA, et al. Virology 2009 5Jan;383(1):69- 77. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n472) Human papillomavirus 16E6 oncogene mutation in cervical cancer. Sun F, Ha XQ, Lv TD, et al. Chin J Cancer \nRes 2009 Jun;21(2):97 -101. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n473) Human Rights In Health Equity: Cervical Cancer and HPV Vaccines . Erdman JN. Am J Law Med 2009;35(2-\n3):365- 87.  \n                Trabajo (s) citado (s): \n Winkler JL . Wittet S . Bartolini RM . Creed-Kanashiro HM . Lazcano-Ponce E . Lewis-Bell K . Lewis MJ . Penny ME . \nDeterminants of Human Papillomavirus Vaccine Acceptability in Latin America and the Caribbean . Vaccine 2008 \n19Aug;26(Suppl 11):L73-L79.  \n \n474) IL-1 gene polymorphisms and genetic susceptibility of gallbladder cancer in a north Indian population.  \nVishnoi M, Pandey SN, Choudhuri G, et al. Cancer Genet Cytogenet 2008 15Oct;186(2):63- 8. \n                Trabajo (s) citado (s): \n Lazcano -Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n475) Immune responses to human papilloma viruses. Stanley MA. Ind J Med Res 2009 Sep;130(3):266- 76. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n476) Immune Therapy for Cancer. Dougan M, Dranoff G. Annu Rev Immunol 2009;27:83- 117. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high- grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n477) Immunogenicity and Safety of Human Papillomavirus (HPV) -16/18 AS04 -Adjuvanted Vaccine in Healthy Boys \nAged 10 -18 Years. Petaja T, Keranen H, Karppa T, et al. J Adolesc Health 2009 Jan;44(1):33 -40. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n478) Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in \nwomen aged 15-55 years. Schwarz TF, Spaczynski M, Schneider A, et al. Vaccine 2009 22Jan;27(4):581- 7. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n479) Immunohistochemical expression of Ki-67 as a marker of proliferation in gallbladder mucosa samples with or \nwithout cancer. Roa I, Elorza X, Lantadilla S, et al. Rev Med Chile 2009 Jul;137(7):881- 7. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n480) Immunotherapy in Acute Leukemia. Leung W. Semin Hematol 2009 Jan;46(1):89- 99. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n481) Immunotoxicity and biodistribution analysis of arsenic trioxide in C5 7Bl/6 mice following a 2 -week inhalation \nexposure. Burchiel SW. et al. Toxicol Appl Pharmacol 2009 Dec;241(3):253 -9 \n \n71                 Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Asse ssment \nof lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n482) Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus -like particle vaccine \nin a sexually active populati on of North American women. Barr E, Gause CK, Bautista OM, et al. Am J Obstet \nGynecol 2008 Mar;198(3): Article: 261.e1.  \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n483) Impact of a Quadrivalent HPV6/11/16/18 Vaccine in Mexican Women: Public Health Implications for th e \nRegion.  Lazcano- Ponce E, Perez G, Cruz -Valdez A, et al. Arch Med Res 2009 Aug;40(6):514 -24. Sp. Iss. SI.  \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n484) Impact of endocrine disruptor chemicals in gynaecology. Caserta D. Maranghi L, Mantovani A, et al. et al. Hum \nReprod Update 2008 Jan-Feb;14(1): 59-72 \n                Trabajo (s) citado (s): \n L\u00f3pez -Carrillo L . Blair A. L\u00f3pez -Cervantes M. Cebrian M. Rueda C.  Reyes R et al (1997) \ndichlorodiphenyltrichloroethane serum levels and breast cancer risk: a c ase-control study from Mexico. Cancer \nRes 57:3728 \u20133732  \n Romieu I . Hernandez-Avila M . Lazcano- Ponce E. . Weber JP . Dewailly E . Breast cancer, lactation history, and \nserum organochlorines . Am J Epidemiol 2000 15Aug;152(4):363- 70. \n \n485) Implicaciones \u00e9ticas y sociales de la introducci \u00f3n de la vacuna contra el virus del papiloma humano en M\u00e9xico: \nreflexiones sobre una propuesta de i ntervenci\u00f3n. Prieto de la Rosa A. Guti\u00e9rrez -Delgado C. et al.  Acta Bioethica \n2008;14(2):157 -65.  \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n486) Improvement of women's health - HPV vaccination after 16 years of age?  Mogensen O. Acta Obstet Gynecol \nScand 2009;88(7): 756-7. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n487) In silico analysis of protein neoplastic biomarkers for ce rvix and uterine cancer . Rodriguez -Perez MA, Medina -\nAunon A, Encarnacion -Guevara SM, et al. Clin Translat Oncol 2008 Oct;10(10):604 -17.  \n                Trabajo (s) citado (s): \n Palacio -Mejia LS . Rangel-G\u00f3mez G . Hern\u00e1ndez-Avila M . Lazcano-Ponce E.  Cervical cancer, a disease of poverty: \nMortality differences between urban and rural areas in Mexico . Salud Publica Mex 2003;45(Suppl 3):S315 -S325.  \n Lazcano-Ponce EC . Rasc\u00f3n-Pacheco RA . Lozano-Ascencio R . Velasco-Mondrag\u00f3n HE . Mortality from cervical \ncarcinoma in Mexico - Impact of screening, 1980- 1990. Acta Cytol 1996 May-Jun;40(3):506- 12. \n \n488) In vitro and in vivo induction of apoptosis by capsaicin in pancreatic cancer cells is mediated through ROS \ngeneration and mitochondrial death pathway. Zhang R. et al. Apoptosis 2008;13:1465- 78 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L.  Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case-\ncontrol study. Am J Epidemiol 1994;139:263- 71. \n \n489) In vitro Hepatic and Skin Metabolism of Capsaicin. Chanda  S. et al. Drug Metab Disposition 2008 \napr;36(4):670 -5 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L.  Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case-\ncontrol study. Am J Epidemiol 1994;139:263- 71. \n \n490) Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix. Chen J, Macdonald OK, \nGaffney DK. Obstet Gynecol 2008 Jun;111(6):1394- 1402.  \n \n72                 Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E.  Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n491) Increased Risk of Oncogenic Human Papillomavirus Infections and Incident High-Grade Cervical \nIntraepithelial Neoplasia Among Smokers Experience From the Latin American Screening Study . Sarian LO, \nHammes LS, Longatto A, et al. Sex Transm Dis 2009 Apr;36(4):241- 8. \n                Trabajo (s) citado (s): \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n492) Incomplete pregnancy and risk of ovarian cancer: results from two Australian case-control studies and \nsystematic review . Dick MLB, Siskind V, Purdie DM, et al. Cancer Causes Control 2009 Nov;20(9):1571- 85. \n                Trabajo (s) citado (s): \n Salazar -Martinez E . Lazcano-Ponce EC.  Lira-Lira GG . Escudero-De los Rios P . Salmeron-Castro J . Hern\u00e1ndez-\nAvila M . Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico . \nCancer Res 1999 1Aug;59(15):3658- 62. \n \n493) Inequalities in breast and cervical cancer screening among urban Mexican women . Couture MC, Nguyen CT, \nAlvarado BE, et al. Prev Med 2008 Nov;47(5):471- 6.  \n                Trabajo (s) citado (s): \n Lazcano-Ponce EC . Najera Aguilar P . Buiatti E. Alonso De Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The \ncervical cancer screening program in Mexico: problems with access and coverage .  Cancer Causes Control 1997 \nSep;8(5):698 -704. \n Hern\u00e1ndez -Avila M . Lazcano EC . de Ruiz PA . Romieu I . Evaluation of the cervical cancer screening programme \nin Mexico: a population-based case-control study . Int J Epidemiol 1998 Jun;27(3):370- 6. \n \n494) Infection, inflammation and gastric cancer.   Fuentes-Panana E, Camorlinga-Ponce M, Maldonado-Bernal C.  \nSalud Publica Mex 2009 Sep-Oct;51(5):427-433.  \n                Trabajo (s) citado (s): \n Trejo -de la OA . Torres J . P\u00e9rez-Rodr\u00edguez M . Camorlinga-Ponce M . Flores- Luna L . Abdo-Francis JM . Lazcano-\nPonce E.  Maldonado-Bernal C . TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine \npatterns in Mexican patients with Helicobacter pylori-associated gastroduodenal diseases . Clin Immunol 2008 \nNov;129(2) :333-340.  \n Tovar -Guzm\u00e1n V. Hern\u00e1ndez -Gir\u00f3n C.  Barquera S . Rodr\u00edguez -Salgado N. L\u00f3pez -Carrillo L.. Epidemiologic \npanorama of stomach cancer mortality in Mexico. Arch Med Res 2001;32:312 \u2013 7. \n \n495) Infections and cancer: Established associations and new hypotheses . de Martel C, Franceschi S. Crit Rev Oncol \nHematol 2009 Jun;70(3):183- 94. \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n Vaccarella S . Herrero R . Snijders PJF. Dai M . Thomas JO . Hieu NT . Ferreccio C . Matos E . Posso H . de Sanjose S . \nShin HR . Sukvirach S . Lazcano-Ponce E . Mun\u00f3z N . Meijer CJLM . Franceschi S . Smoking and human \npapillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence \nSurveys. Int J Epidemiol 2008 Jun;37(3):536- 46.  \n \n496) Influence of Loop Electrosurgical Excision Procedure on Subsequent Acquisition of New Human \nPapillomavirus Infections . Castle PE, Kreimer AR, Wacholder S, et al. J Infect Dis 2009 1Jun;199(11): 1612-20.  \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Snijders PJF . Dai M . Thomas JO . Hieu NT . Ferreccio C . Matos E.  Posso H . de Sanjose S . \nShin HR . Sukvirach S . Lazcano-Ponce E. Mun\u00f3z N . Meijer CJLM . Franceschi S . Smoking and human \npapillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence \nSurveys. Int J Epidemiol 2008 Jun;37(3):536- 46.  \n \n497) Influenza virus-like particle vaccines. Haynes JR. Expert Rev Vaccines 2009 Apr;8(4).435- 45. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al. Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n73  \n498) Informing adolescents about human papillomavirus vaccination: What will parents allow?  Vallely LA, Roberts \nSA, Kitchener HC, et al. Vaccine 2008 24 Apr;26(18):2203-10.  \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n499) Initial lessons learned in HPV vaccination. Herzog TJ, Huh WK, Downs LS, et al. Gynecol Oncol 2008 \nMay;109(2):S4-S11. Suppl. 1. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n500) Inorganic Arsenic Activates Reduced NADPH Oxidase in Human Primary Macrophages through a Rho \nKinase/p38 Kinase Pathway. Lemarie A.  et al. J Immunol 2008;180:6010-7  \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessment \nof lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n501) Inorganic Arsenic Induces Necrosis of Human CD34 -Positive Haematopoietic Stem Cells. Vernhe t L. et al. \nEnviron Toxicol 2008;23(2):263 -8 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessment \nof lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n502) Insufficient Milk Supply and Breast Cancer Risk: A Systematic Review . Cohen JM, Hutcheon JA, Julien SG, et \nal. PLoS One 2009 14Dec;4(12):Article e8237. \n                Trabajo (s) citado (s): \n Romieu I . Hern\u00e1ndez-Avila M . Lazcano E.  L\u00f3pez L . Romero-Jaime R . Breast cancer and lactation history in \nMexican women . Am J Epidemiol 1996 15Mar;143(6):543-52.  \n \n503) Insulin -like growth factor -I (IGF -I) serum concentrations in healthy children and adolescents: Relationship to \nlevel of contamination by DDT -derivative pesticides. Zumbado M. et al. Growth Horm IGF Res 2009  \n                Trabajo (s) citado (s): \n L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez -Carrillo L . 2004. Dichlorodiphenyldichloroethane burden \nand breast cancer risk: A meta -analysis of the epidemiologic evidence. Environ. Health Perspect. 112:207 \u2013214. \n \n504) Intention of parents to have male children vaccinated with the human papillomavirus vaccine. Ogilvie GS, \nRemple VP, Marra F, et al. Sex Transm Infect 2008 1Aug;84(4):318- 23. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n Aguilar LV . Lazcano-Ponce E.  Vaccarella S . Cruz A . Hern\u00e1ndez P . Smith JS . Munoz N . Kornegay JR . Hern\u00e1ndez-\nAvila M . Franceschi S . Human papillomavirus in men: comparison of different genital sites. Sex Transm Infect \n2006 1Feb;82(1):31- 3. \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n505) Integration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the \nCaribbean. Franco EL, Tsu V, Herrero R, et al.  Vaccine 2008 19Aug;26(Suppl 11):L88 -L95.  \n                Trabajo (s) citado (s): \n Murillo R . Almonte M  Pereira A . Ferrer E . Gamboa OA . Jeronimo J. Lazcano-Ponce E . Cervical Cancer Screening \nPrograms in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48.  \n \n506) Integrazione tra vaccinazione e screening di popolazione. Costa S. Formelli G. et al. Riv It Ost Gin 2008;19  \nSp:920 -24. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n507) Interaction between polymorphisms of the Human Leukocyte Antigen and HPV-16 Variants on the risk of \ninvasive cervical cancer.  Souza PSD, Maciag PC, Ribeiro KB, et al. BMC Cancer 2008 22Aug;8: Artic 246. \n                Trabajo (s) citado (s): \n \n74 \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n508) Interdisciplinary review for correlation between the plant origin capsaicinoids, non-steroidal antiinflammatory \ndrugs, gastrointestinal mucosal damage and prevention in animals and human beings. Mozsik G. et al. \nInflammopharmacol 2009 Jul;17(3):113- 50 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L.  L\u00f3pez-Cervantes M. Robles-D\u00edaz G. Ram\u00edrez-Espitia A. Mohar-Betancourt A. Meneses-Garc\u00eda A. \nL\u00f3pez-Vidal Y. Blair A. Capsaicin consumption, helicobacter pylori positivity and gastric cancer in Mexico. Int J \nCancer 2003;106(2):277- 82 \n \n509) Interleukin 1-beta gene polymorphisms and risk of gastric cancer in Sweden. Persson C. et al. Scand J \nGastroenterol 2009;44(3):339- 49 \n                Trabajo (s) citado (s): \n Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Gastric cancer risk in a Mexican population: \nrole of Helicobacter pylori CagA positive infection and polymorphisms in interleukin -1 and -10 genes. Int. J. \nCancer. 118:649 \u2013657. \n \n510) Interleukin10 -592 Promoter Polymorphism Associated with Gastric Cancer Among Asians: A Meta -Analysis of \nEpidemiologic Studies. Zhuang W. et al. Dig Dis Sci 2009;  \n                Trabajo (s) citado (s): \n Sicinschi LA. L\u00f3pez-Carrillo L . Constanza-Camargo M. et al. 2006. Gastric cancer risk in a Mexican population: \nrole of Helicobacter pylori CagA positive infection and polymorphisms in interleukin -1 and -10 genes. Int. J. \nCancer. 118:649 \u2013657. \n \n511) International correlation between human papillomavirus prevalence and cervical cancer incidence. Maucort-\nBoulch D, Franceschi S, Plummer M. Cancer Epidemiol Biomarkers Prev 2008 Mar;17(3):717- 20. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A . Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n512) Interpretaci\u00f3n del desempe\u00f1o operativo de las pruebas de tamizaje y de diagn\u00f3stico en enfermedades en \nobstetricia y ginecolog\u00eda. Gait\u00e1n_Duarte H. Rubio -Romero JA. G\u00f3mez -Chantraine M: Rev Colom Obstet \nGinecol 2009;60(4):365 -76. \nTrabajo (s) citado (s): \n Lazcano- Ponce E.  Palacio-Mejia LS . Allen-Leigh B . Yunes-Diaz E . Alonso P . Schiavon R . Hern\u00e1ndez-Avila M . \nDecreasing cervical cancer mortality in Mexico: Effect of Papanicolaou coverage, birthrate and the importance of \ndiagnostic validity of cytology . Cancer Epidemiol Biomarkers Prev 2008 Oct;17(10):2808- 17. \n \n513) Introducing human papillomavirus vaccines - questions remain. Paavonen J, Lehtinen M. Ann Med 40(3):162- 6. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n514) Inverse association between a pro -inflammatory geneti c profile and Helicobacter pylori seropositivity among \npatients with chronic atrophic gastritis: Enhanced elimination of the infection during disease progression?. \nGao L. et al Eur J Cancer 2009 Nov;45(16):2860 -6 \n                Trabajo (s) citado (s): \n Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Gastric cancer risk in a Mexican population: \nrole of Helicobacter pylori CagA positive infection and polymorphisms in interleukin -1 and -10 genes. Int. J. \nCancer. 118:649 \u2013657. \n \n515) Invited commentary: Is monitoring of human papillomavirus infection for viral persistence ready for use in \ncervical cancer screening? Castle PE. Am J Epidemiol 2008 15Jul;168(2):138- 44. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n516) Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug \nsensitivity using the NCI-60 panel as a model. Charasson V. et al. Eur J Cancer 2009;45:2931-2401  \n75                 Trabajo (s) citado (s): \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao  CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carrillo L.  et al. Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T \nand A1298C polymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n \n517) Is folic acid good for everyone?  Smith AD, Kim YI, Refsum H. Am J Clin Nutr 2008 Mar;87(3):517-3 3. \n                Trabajo (s) citado (s): \n Lajous M . Lazcano-Ponce E.  Hern\u00e1ndez-Avila M . Willett W . Romieu I . Folate, vitamin B-6, and vitamin B- 12 \nintake and the risk of breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2006 \nMar;15(3):443-8.   \n518)  \nIs viral status needed before vaccination? Wright TC, Bosch FX. Vaccine 2008 14Mar;26(Suppl 1):A12-A15. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n519) Isolation and functional analysis of five HPVE6 variants with respect to p53 degradation. Hiller T, \nStubenrauch F, Iftner T. J Med Virol 2008 Mar;80(3):478- 83. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n520) Kinoids: a novel generation of specific immune therapy against cytokines. Bensussan A, Bizzini B, Pouletty P, \net al. Medecine Sciences 2008 Mar;24(3):306- 13. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n521) Knowledge about cervical cancer screening among family p hysicians: cross -sectional survey . Gonzalez -Losa \nMD, Gongora -Marfil GK, Puerto -Solis M. J Eval Clin Res 2009 Apr;15(2):289 -91. \n                Trabajo (s) citado (s): \n Arillo-Santillan E . Lazcano-Ponce E.  Peris M. Salazar-Martinez E . Salmeron-Castro J . Alonso-De Ruiz P . \nKnowledge of healthcare professionals on cervical cancer prevention. Alternatives for medical education.  Salud \nPublica Mex 2000 Jan -Feb;42(1):34 -42. \n Lazcano- Ponce EC.  Buiatti E . Najera-Aguilar I . Alonso- de-Ruiz P . Hernandez-Avila M . Evaluation model of the \nMexican national program for early cervical cancer detection and proposals for a new approach . Cancer Causes \nControl 1998 May;9(3):241- 51. \n Hern\u00e1ndez -Avila M . Lazcano EC . de Ruiz PA . Romieu I . Evaluation of the cervical cancer screening programme \nin Mexico: a population-based case-control study . Int J Epidemiol 1998 Jun;27(3):370- 6. \n Lazcano-Ponce EC . Rasc\u00f3n-Pacheco RA . Lozano-Ascencio R . Velasco-Mondrag\u00f3n HE . Mortality from cervical \ncarcinoma in Mexico - Impact of screening, 1980- 1990. Acta Cytol 1996 May-Jun;40(3):506- 12. \n \n522) Knowledge about infection with human papillomavirus: A systematic review. Klug SJ, Hukelmann M, Blettner \nM. Prev Med 2008 Feb;46(2):87- 98. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Rivera L. Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n \n523) Knowledge and interest of Turkish women about cervical cancer and HPV vaccine. Baykal C, Al A, Ugur MG, \net al. Eur J Gynaecol Oncol 2008;29(1):76- 9. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Rivera L. Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n524) Knowledge, Attitude and Practice of screening for cervical cancer among female students of a tertiary  \ninstitution in south earsten Nigeria.  Akujobi CN, Ikechebelu JI, Onunkwo I, et al. Niger J Clin Pract 2008 \nSep;11(3):216- 9. \n                Trabajo (s) citado (s):  \n76 \n Lazcano-Ponce EC. Moss S . Cruz-Vald\u00e9z A. de Ruiz PA . Martinez-Le\u00f3n CJ . Casares-Queralt S . Hern\u00e1ndez-Avila \nM. The positive experience of screening quality among users of a cervical cancer detection center : Arch Med Res \n2002 Mar-Apr;33(2):186-92.   \n \n525) Knowledge of Cervical Cancer Screening, Human Papillomavirus, and HPV Vaccine Among Midwestern \nGynecology Patients. Hild-Mosley KA, Patel DM, Markwell S, et al. J Low Genit Tract Dis 2009 Oct;13(4):200- 6. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n526) Knowledge of Pap screening and human papillomavirus among women attending clinics in Medellin, \nColombia . Hanisch R, Gustat J, Hagensee ME, et al. Int J Gynecol Cancer 2008 Sep-Oct;18(5):1020-6.  \n                Trabajo (s) citado (s): \n Flores Y . Bishai D . Lazcano E.  Shah K . Lorincz A . Hernandez M . Salmeron J. Improving cervical cancer screening \nin Mexico: Results from the Morelos HPV Study . Salud Publica Mex 2003;54(Suppl 3):S388-S398.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n527) La dieta y su asociaci\u00f3n con lesiones preneopl\u00e1sicas y c\u00e1ncer g\u00e1strico en una zona de alto riesgo para c\u00e1ncer \ng\u00e1strico en Colombia I, 2000-2006. Mart\u00ednez T. et al. Rev Colomb Cancerol 2008;12(2):74- 88 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L.  Torres-L\u00f3pez J. Galv\u00e1n-Portillo M . Mu\u00f1oz L. L\u00f3pez-Cervantes M. Helicobacter pylori-CagA \nseropositivity and nitrite and ascorbic acid food intake as predictors for gastric cancer. Eur J Cancer. \n2004;40(11):1752- 9. \n Ward MH. L\u00f3pez-Carrillo L.  Dietary Factors and the Risk of Gastric Cancer in Mexico City.  Am J Epidemiol \n1999;149(10):925- 32. \n \n528) La inflamaci\u00f3n y su papel en el desarrollo del c\u00e1ncer g\u00e1strico. Alpizar-Alpizar W. et al. Acta Med Costarric 2009 \nAbr-Jun;51(2):77- 82 \n                Trabajo (s) citado (s): \n Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Gastric cancer risk in a Mexican population: \nrole of Helicobacter pylori CagA positive infection and polym orphisms in interleukin -1 and -10 genes. Int. J. \nCancer. 118:649 \u2013657. \n \n529) La mujer \u00edndigena, vulnerable a c\u00e1ncer c\u00e9rvicouterino: Pespectiva desde modelos conceptuales de salud \np\u00fablica. Torres-Poveda KJ. Arredondo-L\u00f3pez AA. Duarte-G\u00f3mez MB. Madrid-Marina V. Salud en Tabasco \n2008 Sep-Dic;14(3) \n                Trabajo (s) citado (s): \n Palacio -Mejia LS . Rangel-G\u00f3mez G . Hern\u00e1ndez-Avila M . Lazcano-Ponce E.  Cervical cancer, a disease of poverty: \nMortality differences between urban and rural areas in Mexico . Salud Publica Mex 2003;45(Supl 3):S315-S325. \n \n530) Lack of Effects on Fertility and Developmental Toxicity of a Quadrivalent HPV Vaccine in Sprague-Dawley \nRats. Wise LD, Wolf JJ, Kaplanski CV, et al. Birth Defects Res B Dev Reprod Toxicol 2008 Dec;83(6):561- 72. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n531) Legume intake and the risk of cancer: a multisite case \u2013control study in Uruguay. Aune D. et al. Cancer Causes \nControl 2009;20:1605-1615 \n                Trabajo (s) citado (s): \n Ward MH. L\u00f3pez-Carrillo L.  Dietary Factors and the Risk of Gastric Cancer in Mexico City.  Am J Epidemiol \n1999;149(10):925- 32. \n \n532) Lifestyle conditions related to global cardiovascular risk among univ ersity workers in the State of Mexico . \nCerecero P, Hernandez B, Aguirre D, et al. Salud Publica Mex 2009 Nov -Dec;51(6): 465-73. \n                Trabajo (s) citado (s): \n Ortiz -Rodriguez SP . Torres-Mejia G . Mainero-Ratchelous F . Angeles-Llerenas A . Lopez-Caudana AE . Lazcano-\nPonce E.  Romieu I .  Physical activity and breast cancer risk in Mexican women . Salud Publica Mex 2008 Mar-\nApr;50(2):126-35.  \n \n533) Lifestyle and gout . Hak AE, Choi HK Curr Opin Rheumatol 2008 Mar;20(2):179- 86.  \n                Trabajo (s) citado (s): \n Romieu I . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Willett W . Hern\u00e1ndez-Avila M . Carbohydrates and the risk \nof breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2004 Aug;13(8):1283-9.  \n  \n77 534) Lignans and breast cancer risk in pre- and post-menopausal women: meta-analyses of observational studies. \nVelentzis LS. et al. Br J Cancer 2009;100:1492-8 \n                Trabajo (s) citado (s): \n Torres -S\u00e1nchez L. Galv\u00e1n -Portillo M. Wolff MS.  L\u00f3pez -Carrillo L.  (2008) Dietary consumption of phytochemicals \nand breast cancer risk in Mexican women. Public Health Nutr 23:1-7 \n \n535) Linking Exposure to Polychlorinated Biphenyls With Fatty Fish Consumption and Reduced Fetal Growth \nAmong Danish Pregnant Women: A Cause for Concern? Halldorsson TI. et al. Am J Epidemiol 2008 15 \nOct;168(8):958- 65 \n                Trabajo (s) citado (s): \n Verner MA. Charbonneau M. L\u00f3pez-Carrillo L.  Haddad S. Physiologically based pharmacokinetic modeling of \npersistent organic pollutants for lifetime exposure assessment: a new tool in breast cancer epidemiologic studies. \nEnviron Health Perspect. 2008;116(7):886 \u2013892. \n \n536) Long -term dietary calcium intake and breast cancer risk in a prospective cohort of women. Larsson SC. et al. \nAm J Clin Nutr 2009;89(1):277 -82 \n                Trabajo citado: \n Galv\u00e1n-Portillo M. Torres-S\u00e1nchez L. L\u00f3pez-Carrillo L.  Dietary and reproductive factors associated with benign \nbreast disease in Mexican women. Nutr Cancer 2002;43(2):133- 40 \n \n537) Long-term effect of folic acid therapy in heart transplant recipients: Follow-up analysis of a randomized study . \nPotena L, Grigioni F, Masetti M, et al. Transplantation 2008 27Apr;85(8):1146- 50. \n                Trabajo (s) citado (s): \n Lajous M . Lazcano-Ponce E.  Hern\u00e1ndez-Avila M . Willett W . Romieu I . Folate, vitamin B-6, and vitamin B- 12 \nintake and the risk of breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2006 \nMar;15(3):443-8.   \n538)  \nLonger term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine . Rowhani-Rahbar A, \nMao C, Hughes JP, et al. Vaccine 2009 18Sep;27(41):5612- 9.  \n                Trabajo (s) citado (s): \n P\u00e9rez G. Lazcano -Ponce E.  Hern\u00e1ndez-Avila M . Garcia PJ. Mun\u00f3z N . Villa LL . Bryan J . Taddeo FJ . Lu S . Esser MT . \nVuoco S . Sattler C . Barr E . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, \n11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8.  \n \n539) Long-Term Survival After Fertility-Sparing Surgery for Epithelial Ovarian Cancer . Schlaerth AC, Chi DS, \nPoynor EA, et al. Int J Gynecol Cancer 2009 Oct;19(7):1199-1204. \n                Trabajo (s) citado (s): \n Gonzalez -Lira G . Escudero-De los Rios P . Salazar-Mart\u00ednez E . Lazcano-Ponce EC.  Conservative surgery for \novarian cancer and effect on fertility . Int J Gynecol Obstet  1997 Feb;56(2):155- 62. \n \n540) Low dose mixture effects of endocrine disrupters: implications for risk assessment and epidemiology. \nKortenkamp A. Int J Androl 2008;31(2):233- 40 \n                Trabajo (s) citado (s): \n L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez -Carrillo L . 2004. Dichlorodiphenyldichloroethane burden \nand breast cancer  risk: A meta -analysis of the epidemiologic evidence. Environ. Health Perspect. 112:207 \u2013214. \n \n541) Macronutrients, fatty acids and cholesterol intake and stomach cancer risk. Lucenteforte E. et al. Ann Oncol \n2009;20:1434 -8 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L . L\u00f3pez-Cervantes M. Ward MH. Bravo-Alvarado J. Ram\u00edrez-Espitia A. Nutrient intake and \ngastric cancer in Mexico. Int J Cancer 1999; 83: 601- 605 \n \n542) Macronutrients, fatty acids and cholesterol intake and endometrial cancer . Lucenteforte E, Talamini R, \nMontella M, et al. Ann Oncol 2008 Jan;19(1):168 -72. \n                Trabajo (s) citado (s): \n Salazar -Martinez E .Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Gonz\u00e1lez-Lira G . Escudero-De Los Rios P . \nHern\u00e1ndez-Avila M . Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico . Int J \nGynecol Cancer 2005 Sep -Oct;15(5 ):938 -45.  \n \n543) Major clinical research advances in gynecologic cancer 2009. Kim K.  Ryu SY. Journal of Gynecologic Oncology \n2009; 20(4): 203-209. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E.).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n \n78 544) Making the case for cervical cancer prevention: what about equity?  Tsu VD, Levin CE. Reprod Health Matt 2008 \nNov;16(32):104- 12. \n                Trabajo (s) citado (s): \n Palacio -Mejia LS . Rangel-G\u00f3mez G . Hern\u00e1ndez-Avila M . Lazcano-Ponce E.  Cervical cancer, a disease of poverty: \nMortality differences between urban and rural areas in Mexico . Salud Publica Mex 2003;45(Suppl 3):S315 -S325.  \n \n545) Male Circumcision and Serologically Determined Human Papillomavirus Infection in a Birth Cohort. Dickson \nNP, Ryding J, van Roode T, et al. Cancer Epidemiol Biomarkers Prev 2009 Jan;18(1):177- 83. \n                Trabajo (s) citado (s): \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n546) Male circumcision for preventing HPV infection . Gray RH. Nat Rev Urol 2009 Jun;6(6):298- 9. \n                Trabajo (s) citado (s): \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n \n547) Male Circumcision for the Prevention of HSV-2 and HPV Infections. Tobian AAR, Serwadda D, Gray RH.  \nNEJM 2009 16Jul;361(3):307- 308.  \n                Trabajo (s) citado (s): \n Giuliano AR . Lazcano E.  Villa LL . Flores R . Salmeron J . Lee JH . Papenfuss M . Abrahamsen M . Baggio ML . Silva R . \nQuiterio M . Circumcision and sexual behavior: Factors independently associated with human papillomavirus \ndetection among men in the HIM study . Int J Cancer 2009 Mar;124(6):1251- 7. \n \n548) Male circumcision, human papillomavirus and cervical cancer: from evidence to intervention. Bosch FX, Albero \nG, Castellsague X. J Fam Plann Reprod Health Care 2009 Jan;35(1):5- 7. \n                Trabajo (s) citado (s): \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n \n549) Management of Adolescents Who Have Abnormal Cytology and Histology. Moscicki AB. Obstet Gynecol Clin \nNorth Am 2008 Dec;35(4):633+. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n550) Managing cancer risk and decision making after kidney transplantation. Webster AC, Wong G, Craig JC, et al. \nAm J Transpl 2008 Nov;8(11):2185- 91. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n551) Marketing HPV Vaccine Implications for Adolescent Health and Medical Professionalism.  Rothman SM, \nRothman DJ. JAMA 2009 19Aug;302(7):781- 6. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n552) Mass psychogenic response to human papillomavirus vaccination. Buttery JP, Madin S, Crawford NW, et al. \nMed J Austr 2008 1Sep;189(5):261- 2. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n \n79 553) Mast Cells Mediate the Immune Suppression Induced by Dermal Exposure to JP-8 Jet Fuel. Lim\u00f3n-Flores AY. \net al. Toxicol Sci 2009;112(1):144- 52 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessm ent \nof lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n554) Mathematical Models of Cervical Cancer Prevention in Latin America and the Caribbean . Goldie SJ. et aL. \nVaccine 2008 Aug;26(Suppl 11):L59 -L72 \n                Trabajo (s) citado (s): \n Insinga RP. Dasbach EJ. Elbasha EH. Puig A. Reynales -Shigematsu LM. Cost -effectiveness of quadrivalent human \npapillomavirus (HPV) vaccination in Mexico: a transmission dynamic model based evaluation. Vaccine 2007, \n26:128-139. \n \n555) Menopausal Hormone Therapy and Risk of Clinical Breast Cancer Subtypes . Slanger TE. et al. Cancer \nEpidemiol Biomarkers Prev 2009 Apr; 18(4) :1188 -1196  \n                Trabajo (s) citado(s):  \n Fabre A. Fournier A. Mesrine S.Gompel A. Desreux J. Berrino F. Boutron MC. Romieu I.  Clavel F. et al. \nProgestagens use before menopause and breast cancer risk according to histology and hormone -receptors. Cancer \nEpidemiol Biomarkers Prev 2008;17:2723 \u20138. \n \n556) Men's Attitudes Toward Receiving the Human Papillomavirus Vaccine.  Ferris DG, Waller JL, Miller J, et al. J \nLow Genit Tract Dis 2008 Oct;12(4):276- 81. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n557) Meta- and Pooled Analyses of the Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphisms \nand Gastric Cancer Risk: A Huge-GSEC Review. Boccia S. et al. Am J Epidemiol 2009 \n                Trabajo (s) citado (s): \n Lacasa\u00f1a-Navarro M. Galv\u00e1n-Portillo M . Chen J. L\u00f3pez-Cervantes M. L\u00f3pez-Carrillo L.  \nMethylenetetrahydrofolate reductase 677C>T polymorphism and gastric cancer susceptibility in Mexico. Eur J \nCancer 2006;42:528- 533. \n \n558) Meta-analysis of intrauterine device use and risk of endometrial cancer . Beining RM, Dennis LK, Smith EM, et \nal. Ann Epidemiol 2008 Jun;18(6):492- 9. \n                Trabajo (s) citado (s): \n Salazar -Martinez E . Lazcano-Ponce EC.  Lira-Lira GG . Escudero-De los Rios P . Salmeron-Castro J . Hern\u00e1ndez-\nAvila M . Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico . \nCancer Res 1999 1Aug;59(15):3658- 62. \n \n559) Methylenetetrahydrofolate reductase polymorphisms and susceptibility to gastric cancer in Chinese \npopulations: a meta -analysis. Sun L. et al. Eur J Cancer Prev 2008;17:446 -52 \n                Trabajo (s) citado(s):  \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carrillo L.  et al. Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T \nand A1298C polymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n Lacasa\u00f1a -Navarro M. Galv\u00e1n -Portillo M . Chen J. L\u00f3pez -Cervantes M. L\u00f3pez -Carrillo L.  \nMethylenetetrahydrofolate reductase 677C>T polymorphism and gastric cancer susceptibility in M exico. Eur J \nCancer 2006;42:528 -533. \n \n560) MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders. Maes OC. et al. Curr \nGenomics 2009 May:10(3):154 -68 \n                Trabajo (s) citado (s): \n Ruiz -Ramos R. L\u00f3pez -Carrillo L. Rios -P\u00e9rez AD. De Vi zcaya -Ru\u00edz A. Cebrian ME. Sodium arsenite induces ROS \ngeneration, DNA oxidative damage, HO -1 and c -Myc proteins, NF -kappaB activation and cell proliferation in \nhuman breast cancer. MCF -7 cells. Mutat Res. 2009 Mar 31;674(1 -2):109 -15. \n \n561) Misinformation and lack of knowledge hinder cervical cancer prevention. Moodley J, Harries J, Barone M. \nSouth Afr Med J 1999 Mar;99(3):128. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n562) Modification of Gastric Mucin Oligosaccharide Expression in Rhesus Macaques After Infection With \nHelicobacter pylori . Cooke CL, An HJ, Kim J, et al. Gastroenterology 2009 Sep;137(3):1 061-71.   \n80                 Trabajo (s) citado (s): \n Camorlinga -Ponce M . Flores-Luna L.  Lazcano -Ponce E.  Herrero R.  Bernal-Sahagun F . Abdo-Francis JM . Aguirre-\nGarcia J . Mun\u00f3z N . Torres J .  Age and severity of mucosal lesions influence the performance of serologic markers \nin Helicobacter pylori-associated gastroduodenal Pathologies . Cancer Epidemiol Biomarkers Prev 2008 \nSep;17(9):2498-2504.. \n \n563) Molecular diagnosis of human papillomavirus in the development of cervical cancer .  Gutierrez -Xicotenc atl L, \nPlett -Torres T, Madrid -Gonzalez CL, et al. Salud Publica Mex 2009;51(Suppl 3):S479 -S488.  \n                Trabajo (s) citado (s): \n Flores Y . Shah K . Lazcano E.  Hern\u00e1ndez M . Bishai D . Ferris DG . Lorincz A . Hern\u00e1ndez P . Salmeron J . Design and \nmethods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study . \nSalud Publica Mex 2002 Jul-Aug. 44(4):335- 44. \n Lazcano- Ponce E.  Alonso P . Ruiz-Moreno JA . Hern\u00e1ndez-Avila M . Recommendations for cervical cancer \nscreening programs in developing countries. The need for equity and technological development . Salud Publica \nMex 2003;45(Suppl 3):S449-S462.  \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n564) Molecular epidemiology of human papillomavirus. Hoory T, Monie A, Gravitt P, et al. J Formos Med Assoc \n2008 Mar;107(3):198 -217.  \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Salmeron J . Lazcano-Ponce E.  Lorincz A . Hernandez M . Hern\u00e1ndez P . Leyva A . Uribe M . Manzanares H . Antunez \nA. Carmona E . Ronnett BM . Sherman ME . Bishai D . Ferris D . Flores Y . Yunes E . Shah KV . Comparison of HPV-\nbased assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico . Cancer Causes \nControl 2003 Aug;14(6):505-12.  \n \n565) Molecular pathogenesis of head and neck cancers. Singh B. J Surg Oncol 2008 15Jun;97(8):634- 9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n566) Molecular  targets for cancer chemoprevention. William WN, Heymach JV, Kim ES, et al. Nat Rev Drug Discov \n2009 Mar;8(3):213- 25. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n567) Mon itoring HPV vaccination. Stanley M, Villa LL. Vaccine 2008 14Mar;26(Suppl 1):A24 -A27.  \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n568) Mothers' and Adolescents' Beliefs about Risk Compensation following HPV Vaccination. Marlow LAV, Forster \nAS, Wardle J, et al. J Adoles Health 2009 May;44(5):446- 51. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n569) Mothers' Intention for Their Daughters and Themselves to Receive  the Human Papillomavirus Vaccine: A \nNational Study of Nurses. Kahn JA, Ding LL, Huang B, et al. Pediatrics 2009 Jun;123(6):1439 -45. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n570) MTHFR C677T Polymorphism and Risk of HCC in Patients With Liver Cirrhosis: Role of Male Gender and \nAlcohol Consumption. Fabris C. et al. Alcohol Clin Exp Res 2009 Jan;33(1):102 -7 \n                Trabajo (s) citado (s):  \n81 \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carrillo L.  et al. Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T \nand A1298C pol ymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n \n571) MTHFR polymorphisms, dietary folate intake and breast cancer risk in Chinese women. Gao CM.  Tang JH. et \nal. J Human Genet 2009; 54(7): 414- 418. \n                Trabajo (s) citado (s): \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carrillo L.  et al. Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T \nand A1298C poly morphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008;167(5):505 -516. \n \n572) MTHFR Polymorphisms Involved in Vitamin B12 Deficiency Associated with Atrophic Gastritis. Palladino M. \net al. Biochem Genet 2009 Oct;47(9-10):645- 50 \n                Trabajo (s) citado (s): \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carrillo L.  et al. Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T \nand A1298C  polymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n \n573) Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand \ncervical cancer early endpoints and determinants.  Wentzensen N, Schiffman M, Dunn T, et al. Int J Cancer \n2009 1Nov;125(9):2151- 8. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n574) Multiple-Type Human Papillomavirus Infection in Male Anogenital Sites: Prevalence and Associated Factors. \nNielson CM, Harris RB, Flores R, et al. Cancer Epidemiol Biomarkers Prev 2009 Apr;18(4):1077- 83. \n                Trabajo (s) citado (s): \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n575) Mutation of PIK3CA: Possible risk factor for cervical carcinogenesis in older women. Cui B, Zheng B, Zhang X, \net al. Int J Oncol 2009 Feb;34(2):409- 16. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n576) Mycotoxines : facteur de risque de cancers. Pfohl-Leszkowicz A. J Afr Cancer 2009;1:42- 55 \n                Trabajo (s) citado (s): \n Gong YY. Torres -S\u00e1nchez L. L\u00f3pez -Carrillo L. Peng JH. Sutcliffe AE. White KL. Humpf HU. Turner PC. Wild CP. \n(2008) Association between tortilla cons umption and human urinary fumonisin B1 levels in a Mexican population. \nCancer Epidemiol Biomarkers Prev 17:688 \u2013694 \n \n577) Natural history of gallbladder cancer. Analysis of biopsy specimens. Roa I, Munoz S, Ibacache G, et al. Rev \nMed Chile 2009 Jul;137(7):873 -80. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n578) Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a \nQuadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine. Garland SM, Steben M, Sings HL, et al. \nJ Infect Dis 2009 15Mar;199(6):805- 14. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n579) Natural History of Human Papillomavirus Infections, Cytologic and Histologic Abnormalities, and Cancer  \nWheeler CM. Obstet Gynecol Clin North Am 2008 Dec;35(4):519+.  \n82                 Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n580) Negative association between plasma levels of adiponectin and polychlorinated biphenyl 153 in \n581) obese women under non -energy -restrictive regi me. Mullerova D. et al. Int J Obes 2008;32:1875 -8 \n                Trabajo (s) citado (s): \n Verner MA. Charbonneau M. L\u00f3pez-Carrillo L.  Haddad S. Physiologically based pharmacokinetic modeling of \npersistent organic pollutants for lifetime exposure assessment: a new tool in breast cancer epidemiologic studies. \nEnviron Health Perspect. 2008;116(7):886 \u2013892. \n \n582) New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors. Syrjanen K. \nEur J Gynaecol Oncol 2008;29(3):205- 21. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Vaccare lla S. Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n583) New Quadrivalent HPV Vaccine Developments. Tovar JM, Bazaldua OV. Postgrad Med 2008 Nov;120(4):14- 6. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n584) New therapeutic strategies for human papillomavirus related an ogenital lesions in HIV patients: highly active \nantiretroviral therapy and HPV vaccines. Fuste P, Santamaria X, Carreras R. Med Clin 2008 7Jun;131(1):30 -4. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n585) News vaccines offering a larger spectrum of protection against acute otitis media: Will parents be willing to \nhave their children immunized?  Dube E. de WalsP. et al. Int J Pediat Otorhinolaryngol 2009; 73(7): 987-991. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n586) No association of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in susceptibility to \ngallbladder cancer. Srivastava A, Pandey SN, Pandey P, et al. DNA Cell Biol 2008 Mar;27(3):127- 32. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n587) Nobel price for vaccination against cervical cancer: Current data and guidelines. Hepburn HM, Kaufmann AM. \nInternist 2009 May;50(5):617- 26. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n588) Nutrient dietary patterns and the risk of breast and ovarian cancers . Edefonti V, Decarli A, La Vecchia C, et al. \nInt J Cancer 2008 1Feb;122(3):609 -13.  \n \n83                 Trabajo (s) citado (s): \n Lajous M . Lazcano-Ponce E.  Hern\u00e1ndez-Avila M . Willett W . Romieu I . Folate, vitamin B-6, and vitamin B- 12 \nintake and the risk of breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2006 \nMar;15(3):443-8.   \n Lajous M . Willett W . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM , Hernandez-Avila M , Romieu I . Glycemic load, \nglycemic index, and the risk of breast cancer among Mexican women . Cancer Causes Control 2005 \nDec;16(10):1165-9.  \n \n589) Obesity is associated with atypia in breast ductal lavage of women with proliferative breast disease. Djuric Z. \net al. Cancer Epidemiol 2009 Oct;33(3-4):242-8 \n                Trabajo (s) citado (s): \n Galv\u00e1n-Portillo M. Torres-S\u00e1nchez L. L\u00f3pez-Carrillo L.  Dietary and reproductive factors associated with benign \nbreast disease in Mexican women. Nutr Cancer 2002;43(2):133- 40 \n \n590) Obtenci\u00f3n de biopsia con laringoscopio flexible y canal de trabajo como m\u00e9todo diagn\u00f3stico de c\u00e1ncer de \nlaringe. Ponce-Belloc MB. et al. An Orl Mx 2009;54(2):67- 70 \n                Trabajo (s) citado (s): \n Tovar-Guzman VJ. Barquera S. L\u00f3pez-Antu\u00f1ano FJ . Tendencias de mortalidad por c\u00e1nceres atribuibles a tabaco \nen M\u00e9xico. Salud Publica Mex 2002;44:20- 24 \n \n591) One -carbon metabolism and  breast cancer: an epidemiological perspective. Xu XR. Chen J. J Genet Genom 2009 \nApr;36(4):204 -14 \n                Trabajo (s) citado (s): \n Lajous M. Romieu I.  Sabia S. Boutron-Ruault MC. Clavel-Chapelon F. Folate, vitamin B12 and postmenopausal \nbreast cancer in a prospective study of French women. Cancer Causes Control 17, 1209 \u20131213, 2006. \n \n592) Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer \nvaccination: A multi-regional health economic analysis. Rogoza RM, Ferko N, Bentley J, et al. Vaccine 2008 \n15Sep;26(Suppl 5):F46-F58. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n593) Oral contraceptives and clinical recurrence of human papillomavirus lesions and cervical intraepithelial \nneoplasia following treatment .  Frega A, Scardamaglia P, Piazze J, et al. Int J Gynecol Obstet 2008 \nFeb;100(2):175- 8. \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n594) Outcome of in-vitro fertilization treatment and DDT levels in serum and follicular fluid . Al-Saleh I, Coskun S, \nEl-Doush I, et al. Med Sci Monit 2009 Nov;15(11):BR320-BR333. \n                Trabajo (s) citado (s): \n Romieu I . Hernandez-Avila M . Lazcano- Ponce E. . Weber JP . Dewailly E . Breast cancer, lactation history, and \nserum organochlorines . Am J Epidemiol 2000 15Aug;152(4):363- 70. \n \n595) Overcoming Barriers and Ensuring Access to HPV Vaccines in Low-Income Countries. Tsu VD. Am J Law Med \n2009;35(2-3):401- 13. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Insinga RP. Dasbach EJ. Elbasha EH. Puig A. Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human \npapillomavirus (HPV) vaccination in Mexico: a transmission dynamic model based evaluation. Vaccine 2007, \n26:128-139. \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n596) Panorama epidemiol\u00f3gico de la mortalidad por c\u00e1ncer cervicouterino en M\u00e9xico (1980 -2004). Tovar -Guzm\u00e1n VJ. \nOrtiz -Contreras F. et al.  Rev Fac Med UNAM 2008 Mar -Abr;51(2):47 -51. \n                Traba jo(s) citado (s): \n Palacio -Mejia LS . Rangel-G\u00f3mez G . Hern\u00e1ndez-Avila M . Lazcano-Ponce E.  Cervical cancer, a disease of poverty: \nMortality differences between urban and rural areas in Mexico . Salud Publica Mex 2003;45(Supl 3):S315-S325. \n \n84  \n597) Pap smear receipt among Vietnamese immigrants: the importance of health care factors . Taylor VM, Yasui Y, \nNguyen TT, et al. Ethnicity Health  2009;14(6):575- 89. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC. Castro R . Allen B . Najera P . De Ruiz PA. Hern\u00e1ndez-Avila M . Barriers to early detection of \ncervical-uterine cancer in Mexico . J Womens Health 1999 Apr;8(3):399- 408. \n \n598) Papilloma Virus Vaccine Reply. Gonzalez CA, Ascanio AD. Atencion Primaria 2008 Nov;40(11):585- 6. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n599) Papillomas of the External Ear Canal: Report of Ten cases in Chinese Patients with HPV In Situ Hybridization. \nWang S. Yee H. et al. Head and Neck Pathol 2009 Sep;3(3):207 \u2013211 \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n600) Parental Response to Human Papillomavirus Vaccine Availability: Uptake and Intentions.  Gerend MA. \nWeibley E. et al. Journal of Adolescent Health 2009; 45(5): 528- 531. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n601) Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective \nimmunity in mice. Istrate C, Hinkula J, Charpilienne A, et al. Vaccine 2008 18Aug;26(35):4594- 601. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n602) Pathogenesis, clinical features and pathology of chronic arsenicosis. Ranjan -Sengupta S. et al. Indian J \nDermatol Venerol Leprol 2008;74(6):559 -70 \n                Trabajo (s) citado (s): \n Rosales-Castillo JA. Acosta-Saavedra LC. Torres R. Ochoa-Fierro J. Borja-Aburto VH. L\u00f3pez -Carrillo L,  et al . \nArsenic exposure and human papillomavirus response in non -melano ma skin cancer Mexican patients: a pilot \nstudy. Int Arch Occup Environ Health 2004;77:418 -23 \n \n603) Pathogenes is of Helicobacter pylori Infection . Costa AC, Figueiredo C, Touati E. Helicobacter 2009 \nSep;14(Suppl 1):15 -20. \n                Trabajo (s) citado (s): \n Romo -Gonzalez C . Salama NR . Burgeno-Ferreira J . Ponce-Castaneda V . Lazcano-Ponce EC.  Camorlinga-Ponce M . \nTorres J . Differences in Genome Content among Helicobacter pylori Isolates from Patients with Gastritis, \nDuodenal Ulcer, or Gastric Cancer Reveal Novel Disease-Associated Genes . Infect Immun 2009 May;77(5):2201- 11. \n \n604) Pediatricians are More Supportive of the Human Papillomavirus Vaccine than the General Public. Ishibashi \nKL, Koopmans J, Curlin FA, et al. South Med J 2008 Dec;101(12):1216- 21. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n605) Pediatricians' Intention to Recommend Human Papillomavirus (HPV) Vaccines to 11-to 12-Year-Old Girls \nPostlicensing . Feemster KA, Winters SE, Fiks AG, et al. J Adolesc Health 2008 Oct;43(4):408- 11. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n606) Penile cancer: epidemiology, pathogenesis and prevention. Bleeker MCG,  Heideman DAM, Snijders PJF, et al. \nWorld J Urol 2009 Apr;27(2):141 -50. \n                Trabajo (s) citado (s): \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior,  \n85 condom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n607) Pepper and Capsaicin (Capsicum and Piper species). Barceloux DG. Disease a Month 2009 Jun;55(6):380- 90 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L.  Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case-\ncontrol study. Am J Epidemiol 1994;139:263- 71. \n L\u00f3pez-Carrillo L.  L\u00f3pez-Cervantes M. Robles-D\u00ed az G. Ram\u00edrez-Espitia A. Mohar-Betancourt A. Meneses-Garc\u00eda A. \nL\u00f3pez-Vidal Y. Blair A. Capsaicin consumption, helicobacter pylori positivity and gastric cancer in Mexico. Int J \nCancer 2003;106(2):277- 82 \n \n608) Perinatal transmission of human papilomavirus DNA.  Rombaldi RL. Serafini EP. et al. Virology J  2009, 6:83 \n                Trabajo (s) citado (s): \n Hernandez -Gir\u00f3n C . Smith JS . Lorincz A . Chaidez EA . Lazcano E.  Hern\u00e1ndez-Avila M . Salmeron J . The \nprevalence of high-risk HPV infection in pregnant women from Morelos, Mexico . Salud Publica Mex 2005 Nov-\nDec;47(6):423-9.  \n \n609) Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms.  Szallasi A. \nGunthorpe MJ. Curr Pharm Des 2008;14(1):32- 41 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L.  Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case-\ncontrol study. Am J Epidemiol 1994;139:263- 71. \n \n610) Persistent Antibodies to HPV Virus-Like Particles Following Natural Infection Are Protective Against \nSubsequent Cervicovaginal Infection with Related and Unrelated HPV. Malik ZA, Hailpern SM, Burk RD. \nViral Immunol 2009 Dec;22(6):445- 9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n611) Perturbations in immune responses induced by concurrent subchronic exposure to arsenic and endosulfan. \nAggarwal M. et al. Toxicology 2008 29Sep;251(1-3):51- 60 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessment \nof lymphocyte subpopulations and cytoki ne secretion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n612) Pharmacogenetic relevance of MTHFR polymorphisms. Giuseppe Toffoli, Elena De Mattia. \nPharmacogenomics 2008 Sep;9(9):1195 -1206  \n                Trabajo (s) citado (s): \n Boccia S. Hung R. Ricci ardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carrillo L.  et al. Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T \nand A1298C polymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n \n613) Pharmacotherapy of recurrent respiratory papillomatosis: an expert opinion. Gallagher TQ, Derkay CS. Expert \nOpin Pharmacother 2009 Mar;10(4):645- 55. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n614) Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human \npapillomavirus 16 in end-stage cervical cancer patients shows lowtoxicity and robust immunogenicity. Kenter \nGG, Welters MJP, Valentijn ARPM, et al. Clin Cancer Res 2008 1Jan;14(1):169- 77. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions. NEJM 2007 10May;356(19):1915-27.  \n \n615) Physical activity, adiposity, and risk of endometrial cancer . Conroy MB, Sattelmair JR, Cook NR, et al. Cancer \nCauses Control 2009 Sep;20(7):1107- 15. \n                Trabajo (s) citado (s): \n Salazar -Martinez E . Lazcano-Ponce E . Lira-Lira GG . Escudero-De los Rios P . Salmeron-Castro J . Larrea F . \nHernandez-Avila M .Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer \namong Mexican women . Cancer Causes Control 2000 Sep;11(8):707- 11.  \n86  \n616) Physical activity, sedentary behavior, and endometrial cancer risk in the NIH-AARP Diet and Health Study . \nGierach GL, Chang SC, Brinton LA, et al. Int J Cancer 2009 1May;124(9):2139- 47. \n                Trabajo (s) citado (s): \n Salazar -Martine z E. Lazcano-Ponce E . Lira-Lira GG . Escudero-De los Rios P . Salmeron-Castro J . Larrea F . \nHernandez-Avila M .Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer \namong Mexican women . Cancer Causes Control 2000 Sep;11(8):707- 11. \n \n617) Physical exercise and sport for preventing and treating cancers . Fasching PA, Hubner J, Kleeberg UR. \nOnkologe 2009 Jul;15(7):696- 701. \n                Trabajo (s) citado (s): \n Salazar -Martinez E . Lazcano-Ponce E . Lira-Lira GG . Escudero-De los Rios P . Salmeron-Castro J . Larrea F . \nHernandez-Avila M .Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer \namong Mexican women . Cancer Causes Control 2000 Sep;11(8):707- 11. \n \n618) Physiologically based pharmacokinetic modeling of persistent organic pollutants for lifetime exposure \nassessment: A new tool in breast cancer epidemiologic studies . Verner MA, Charbonneau M, Lopez-Carrillo L, \net al. Environ Health Perspect 2008 Jul;116(7):886- 92. \n                Trabajo (s) citado (s): \n Romieu I . Hernandez-Avila M . Lazcano- Ponce E. . Weber JP . Dewailly E . Breast cancer, lactation history, and \nserum organochlorines . Am J Epidemiol 2000 15Aug;152(4):363- 70. \n L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez -Carrillo L . 2004. Dichlorodiphenyldichloroethane burden \nand breast cancer risk: A meta -analysis of the epidemiologic evidence. Environ. Health Perspect. 112:207 \u2013214. \n \n619) Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Mann \nCD. et al. Eur J Cancer Prev 2009 Feb;18(1):13 -25 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L.  Hern\u00e1ndez Avila M. Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case-\ncontrol study. Am J Epidemiol 1994;139:263- 71. \n \n620) Pitfalls in the epidemiologic classification of human papillomavirus types associated with cervical cancer \nusing polymerase chain reaction: driver and passenger. Matsukura T, Sugase M. Int J Gynecol Cancer 2008 Sep-\nOct;18(5):1042-50. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n621) Plasma carotenoids, retinol and tocopherol levels and the risk of ova rian cancer . Jeong NH, Song ES, Lee JM, et \nal. Acta Obstet Gynecol Scand 2009;88(4):457 -62. \n                Trabajo (s) citado (s): \n Salazar -Mart\u00ednez E . Lazcano-Ponce E.  Lira-Lira GG . Escudero-De los Rios P . Hern\u00e0ndez-Avila M . Nutritional \ndeterminants of epithelial ovarian cancer risk: A case-control study in Mexico . Oncology 2002;63(2):151-7.  \n \n622) Plasma folate, vitamin B -6, vitamin B -12, and risk of breast cancer in women. Lin J. et al. Am J Clin Nutr 2008 \nMar;87(3):734 -743 \n                Trabajo (s) citado (s): \n Lajous M. Romieu I.  Sabia S. Boutron-Ruault MC. Clavel-Chapelon F. Folate, vitamin B12 and postmenopausal \nbreast cancer in a prospective study of French women. Cancer Causes Control 17, 1209 \u20131213, 2006. \n Lajous M . Lazcano-Ponce E.  Hern\u00e1ndez-Avila M . Willett W . Romieu I . Folate, vitamin B-6, and vitamin B- 12 \nintake and the risk of breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2006 \nMar;15(3):443-8.   \n623)  \nPlasma organochlorine levels and subse quent risk of breast cancer among Japanese women: A nested case -\ncontrol study. Iwasaki M. et al. Sci Tot Environ 2008 1Sep;402(2 -3):176 -83 \n                Trabajo (s) citado (s): \n L\u00f3pez -Carrillo L . Blair A. L\u00f3pez -Cervantes M. Cebrian M. Rueda C.  Reyes R et a l (1997) \ndichlorodiphenyltrichloroethane serum levels and breast cancer risk: a case -control study from Mexico. Cancer \nRes 57:3728 \u20133732  \n L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez -Carrillo L . 2004. Dichlorodiphenyldichloroethane burden \nand breast cancer risk: A meta -analysis of the epidemiologic evidence. Environ. Health Perspect. 112:207 \u2013214. \n Romieu I . Hernandez-Avila M . Lazcano- Ponce E. . Weber JP . Dewailly E . Breast cancer, lactation history, and \nserum organochlorines . Am J Epidemiol 2000 15Aug;152(4):363- 70. \n \n624) Plasma vitamin B12 concentrations and the risk of colorectal cancer: A nested case-referent study. Dahlin AM. \net al. Int J Cancer 2008 1May;122(9):2057-2061   \n87                 Trabajo (s) citado (s): \n Lajous M. Romieu I.  Sabia S. Boutron-Ruault MC. Clavel-Chapelon F. Folate, vitamin B12 and postmenopausal \nbreast cancer in a prospective study of French women. Cancer Causes Control 17, 1209 \u20131213, 2006. \n \n625) Pobreza y marginalidad como criterio de priorizaci\u00f3n para las enfermedades catastr\u00f3ficas en M\u00e9xico. Santos-\nPadr\u00f3n H. Rev C ub Salud p\u00fablica 2008;34(2) \n                Trabajo (s) citado (s): \n Palacio -Mejia LS . Rangel-G\u00f3mez G . Hern\u00e1ndez-Avila M . Lazcano-Ponce E.  Cervical cancer, a disease of poverty: \nMortality differences between urban and rural areas in Mexico . Salud Publica Mex 2003;45(Suppl 3):S315 -S325.  \n \n626) Policy development for human papillomavirus vaccine introduction in low-resource settings. Tsui J. \nLaMontagne DS. et al.  The Open Vaccine Journal 2009;2:113- 22 \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n627) Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Jonge R. et al. \nBlood 2009 5mar;113(10):2284-9 \n                Trabajo (s) citado (s): \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carrillo L.  et al. Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T \nand A1298C polymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n \n628) POPs in breast milk: women\u2019s breast canc er risk. Sarkar S. Nutr Food Sci 2009;39(4):360-9 \n                Trabajo (s) citado (s): \n L\u00f3pez -Carrillo L.  L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L.  Blair A.  Cebri\u00e1n -Garc\u00eda M. Garc\u00eda RM. (2002). Serum \nlevels of beta -hexachlorocyclohexane, hexachlorobenzene and  polychlorinated biphenyls and breast cancer in \nMexican women. Eur. J. Cancer Prev. 11, 129 -135. \n \n629) Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an \nHPV-vaccination program in Denmark. Kjaer SK, Breugelmans G, Munk C, et al. Int J Cancer  2008 \n15Oct;123(8):1864- 70. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n630) Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in \nAustralia. Newall AT, Brotherton JML, Quinn HE, et al. Clin Infect Dis 2008 1Jun;46(11):1647- 55. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n631) Postmenopausal Breast Cancer Risk and Dietary Patterns in the E3N -EPIC Prospective Cohort Study. Cottet, V. \net al. Am J Epidemiol 2009 15Nov ;170(10):1257 -1267  \n                Trabajo (s) citado (s): \n Lajous M. Romieu I.  Sabia S. Boutron-Ruault MC. Clavel-Chapelon F. Folate, vitamin B12 and postmenopausal \nbreast cancer in a prospective study of French women. Cancer Causes Control 17, 1209 \u20131213, 2006.  \n \n632) Potential Barriers to HPV Vaccine Provision Among Medical Practices in an Area with High Rates of Cervical \nCancer. Keating KM. Brewer NT. et al. J Adolesc Health 2008; 43(4): S61-S67. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n633) Poverty eradication and decreased human papilloma virus related cancer of the penis and vulva in Jamaica. \nFletcher HM, Hanchard B. J Obstet Gynaecol 2008 Apr;28(3):333- 5. \n                Trabajo (s) citado (s): \n \n88 \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n634) Practical relevant advanced education with first \"Paediatrics Update\" .  Ayazpoor U. Monatsschrift \nKinderheilkunde 2008 Aug;156(8):732- 3. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n635) Predicting the Effect of Successful Human Papillomavirus Vaccination on Existing Cervical Cancer Prevention \nPrograms in the United States.  Castle PE, Solomon D, Saslow D, et al. Cancer 2008 15Nov;113(10):3031-5. \nSuppl.   \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n636) Pregnancy and Infant Outcomes in the Clinical Trials of a Human Papillomavirus Type 6/11/16/18 Vaccine A \nCombined Analysis of Five Randomized Controlled Trials. Garland SM, Ault KA, Gall SA, et al. Obstet \nGynecol 2009 Dec;114(6): 1179- 88. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n637) Pregnancy Outcomes Using Assisted Reproductive Technology After Fertility-Preserving Therapy in Patients \nWith Endometrial Adenocarcinoma or Atypical Complex Hyperplasia . Han AR, Kwon YS, Kim DY, et al. Int J \nCancer 2009 Jan;19(1):147- 51. \n                Trabajo (s) citado (s): \n Salazar -Martinez E . Lazcano-Ponce EC.  Lira-Lira GG . Escudero-De los Rios P . Salmeron-Castro J . Hern\u00e1ndez-\nAvila M . Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico . \nCancer Res 1999 1Aug;59(15):3658- 62. \n \n638) Preoperative levels of plasma micronutrien ts are related to endometrial cancer risk .  Jeong NH, Song ES, Lee \nJM, et al. Acta Obstet Gynecol Scand 2009;88(4):434 -9. \n                Trabajo (s) citado (s): \n Salazar -Martinez E .Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Gonz\u00e1lez-Lira G . Escudero-De Los Rios P . \nHern\u00e1ndez-Avila M . Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico . Int J \nGynecol Cancer 2005 Sep-Oct;15(5):938-45.  \n \n639) Preparing for HPV vaccination in South Africa: Key challenges and opinions . Harries J, Moodley J, Barone MA, \net al. Vaccine 2009 1Jan;27(1):38- 44. \n                Trabajo (s) citado (s): \n Lazcano-Ponce EC.  Moss S . de Ruiz PA . Castro JS . Avila MH .Cervical cancer screening in developing countries: \nWhy is it ineffective? The case of  Mexico . Arch Med Res 1999 May-Jun;30(3):240-50.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n640) Prevaccination Distribution of Human Papillomavirus Types in Women Attending at Cervical Cancer \nScreening in Belgium. Arbyn M, Benoy I, Simoens C, et al. Cancer Epidemiol Biomarkers Prev 2009 \nJan;18(1):321- 30. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent hi gh-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A . Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n641) Prevalence and Age Distribution of Human Papillomavirus Infection in a Population of Inuit Women in \nNunavik, Quebec. Hamlin-Douglas LK, Coutlee F, Roger M, et al. Cancer Epidemiol Biomarkers Prev 2008 \nNov;17(11):3141- 9. \n                Trabajo (s) citado (s): \n \n89 \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n642) Prevalence and predictors of high-risk human papillomavirus infection in a population-based sample of \nwomen in rural Uganda. Asiimwe S, Whalen CC, Tisch DJ, et al. Int J STD AIDS 2008 Sep;19(9):605- 10. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n643) Prevalence and Risk Factors of High-Risk Human Papillomavirus in Female Sex Workers in Spain: Differences \nby Geographical Origin. del Amo J, Gonzalez C, Belda J, et al. J Womens Health 2009 Dec;18(12):2057-64. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n644) Prevalence, Acquisition, and Clearance of Cervical Human Papillomavirus Infection among Women with \nNormal Cytology: Hawaii Human Papillomavirus Cohort Study. Goodman MT, Shvetsov YB, McDuffie K, et \nal. Cancer Res 2008 1Nov;68(21):8813- 24. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 20 01 \n1Feb;91(3):412-20.  \n \n645) Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant \nwomen in Kampala, Uganda . Banura C, Franceschi S, van Doorn LJ, et al. Int J Cancer 2008 1Nov;123(9):2180- 7. \n                Trabajo (s) citado (s): \n Hern\u00e1ndez -Gir\u00f3n C . Smith JS . Lorincz A . Lazcano E.. Hern\u00e1ndez-Avila M . Salmeron J . High-risk human \npapillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico . Sex \nTransm Dis 2005 Oct;32(10):613-8.  \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n646) Prevalence of and risk factors for anal human papillomavirus infection in heterosexual men. Nyitray A, \nNielson CM, Harris RB, et al. J Infect Dis 2008 15Jun;197(12):1676- 84. \n                Trabajo (s) citado (s): \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n647) Prevalence of Different HPV Types  and Estimation of Prognostic Risk Factors Based on the Linear Array HPV \nGenotyping Test . Papachristou E, Sypsa V, Paraskevis D, et al. J Med Virol 2009 Dec;81(12):2059 -65.   \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Snijders PJF . Dai M . Thomas JO . Hieu NT . Ferreccio C . Matos E.  Posso H . de Sanjose S . \nShin HR . Sukvirach S . Lazcano-Ponce E.  Mun\u00f3z N . Meijer CJLM . Franceschi S . Smoking and human \npapillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence \nSurveys. Int J Epidemiol 2008 Jun;37(3):536- 46.  \n \n648) Prevalence of epithelial squamous cell abnormalities and associated factors in women of a rural town of \nColombi a. Grisales H, Vanegas AP, Gaviria AM, et al. Biomedica 2008 Jun;28(2):271 -83. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P.  Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n Flores Y . Bishai D . Lazcano E.  Shah K . Lorincz A . Hernandez M . Salmeron J. Improving cervical cancer screening \nin Mexico: Results from the Morelos HPV Study . Salud Publica Mex 2003;54(Suppl 3):S388-S398.  \n \n90  \n649) Prevalence of genital HPV infection among women screened for cervical cancer. Rama CH, Roteli-Martins CM, \nDerchain SFM, et al. Rev Saude Publica 2008 Feb;42(1):123- 30. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n650) Prevalence of genital human papilloma virus infection and genotypes among young women in Sicily, south \nItaly . Ammatuna P, Giovannelli L, Matranga D, et al. Cancer Epidemiol Biomarkers Prev 2008 Aug;17(8):2002- 6. \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n651) Prevalence of High-Risk Human Papillomavirus Among Older Women.  Lindau ST, Drum ML, Gaumer E, et \nal. Obstet Gynecol 2008 Nov;112(5):979- 89. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Vaccarella S . Herrero R . Snijders PJF . Dai M . Thomas JO . Hieu NT . Ferreccio C . Matos E.  Posso H . de Sanjose S . \nShin HR . Sukvirach S . Lazcano-Ponce E. Mun\u00f3z N . Meijer CJLM . Franceschi S . Smoking and human \npapillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence \nSurveys. Int J Epidemiol 2008 Jun;37(3):536- 46.  \n652) Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk \nfactor analysis and implications for screening and prophylaxis.Gupta S, Sodhani P, Sharma A, et al. \nCytopathology 2009 Aug;20(4):249- 55. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Lazcano- Ponce E. Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytolo gy.  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n653) Prevalence of human papillomavirus genital infection among male university students . Guzman P, Ili C, Rifo P, \net al. Rev Med Chile 2008 Nov;136(11):1381- 9. \n                Trabajo (s) citado (s): \n Aguilar LV . Lazcano-Ponce E.  Vaccarella S . Cruz A . Hern\u00e1ndez P . Smith JS . Munoz N . Kornegay JR. Hern\u00e1ndez-\nAvila M . Franceschi S . Human papillomavirus in men: comparison of different genital sites. Sex Transm Infect \n2006 1Feb;82(1):31- 3. \n Lazcano- Ponce E. Herrero R . Munoz N . Hernandez-Avila M . Salmeron J. Leyva A . Meijer CJLM . Walboomers \nJMM . High prevalence of human papillomavirus infection in Mexican males - Comparative study of penile-\nurethral swabs and urine samples . Sex Transm Dis 2001 May;28(5):277-80.  \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n654) Prevalence of human papillomavirus genotypes in women fro m a rural region of Puebla, Mexico. Velazquez -\nMarquez N, Paredes -Tello MA, Perez -Terron H, et al. Int J Infect Dis 2009 Nov;13(6):690 -5. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n Hern\u00e1ndez Avila M . Lazcano-Ponce EC . Berumen Campos J . Cruz Vald\u00e9z A . De Ruiz PPA . Gonzalez Lira \nG.Human papilloma virus 16-18 infection and cervical cancer in Mexico: A case-control study . Arch Med Res 199 7 \nSummer;28(2):265- 71. \n \n655) Prevalence of human papillomavirus in Indonesia: a population -based study in three regions. Vet JNI, de Boer \nMA, van den Akker BEWM, et al. Br J Cancer 2008 8Jul;99(1):214 -8. \n                Trabajo (s) citado (s): \n \n91 \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A . Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Vaccarella S . Franceschi S . Herrero R. Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n656) Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase \nIII vaccine trial. Six L, Leodolter S, Sings HL, et al. Wiener Klinische Wochenschrift 2008 Nov;120(21-22):666- 71. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n657) Prevalence of human papillomavirus type 16 and its variants in abnormal squamous cervical cells in Northeast \nThailand. Chopjitt P, Ekalaksananan T, Pientong C, et al. Int J Infect Dis 2009 Mar;13(2):212- 9. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n658) Prevalence of mucosal and cutaneous human papillomaviruses in different histologic subtypes of vulvar \ncarcinoma. de Koning MNC, Quint WGV, Pirog EC. Modern Pathol 2008 Mar;21(3):334- 44. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n659) Prevalence of oncoge nic human papillomavirus infection in an organised screening population in Finland. \nLeinonen M, Kotaniemi -Talonen L, Anttila A, et al. Int J Cancer 2008 15Sep;123(6):1344 -9. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n660) Prevalence of Single and Multiple Human Papillomavirus Types in Cervical Cancer and Precursor Lesions in \nHubei, China . Cai HB, Ding XH, Chen CC. Oncology 2009;76(3):157- 61. \n                Trabajo (s) citado (s): \n Lazcano-Ponce EC.  Moss S . de Ruiz PA . Castro JS . Avila MH .Cervical cancer screening in developing countries: \nWhy is it ineffective? The case of  Mexico . Arch Med Res 1999 May-Jun;30(3):240-50.  \n \n661) Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. \nSargent A, Bailey A, Almonte M, et al. Br J Cancer 2008 13May;98(10):1704- 9. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n662) Preventing Cancer. Molokhia EA, Perkins A. Primary Care 2008 Dec;35(4):609. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n663) Preventing cervical cancer: The pap test and the HPV vaccine. Waxman AG, Zsemlye MM. Med Clin North Am \n2008 Sep;92(5):1059. \n \n92                 Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n664) Preventing Vaccine-Preventable Diseases in Low-Resource Communities. Rodewald LE, Markowitz LE.  Arch \nPediatr Adolesc Med 2009 May;163(5):487- 8. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n665) Prevention of cervical cancer: Where immunology meets diagnostics. Meijer CJLM, Heideman DAM, Berkhof \nH, et al. Immunol Lett 2009 21Feb;122(2):126- 7. \n                Trabajo (s) citado (s): \n Villa LL, et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n666) Prevention of Human Papillomavirus Infections and Associated Diseases by Vaccination: A New Hope for \nGlobal Public Health.  Harper DM. Public Health Genom 2009;12(5-6):319- 30. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n667) Primary and Secondary Prevention of Cervical Cancer - Opportunities and Challenges. Markowitz LE, Unger \nER, Saraiya M. J Natl Cancer Inst 2009 1Apr;101(7):439 -40. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n668) Primary and secondary prevention of cervical cancer. Grce M. Expert Rev Mol Diagn 2009 Nov;9(8):851- 7. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n669) Projecting future drug expenditures-2009. Hoffman JM, Shah ND, Vermeulen LC, et al. Am J Health Syst \nPharm 2009 1Feb;66(3):237- 57. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n670) Probiotics for Preventive Health. Minocha A. Nutr Clin Pract 2009;24(2):227- 41 \n                Trabajo (s) citado (s): \n Ornelas IJ. Galvan-Potrillo M. L\u00f3pez-Carrillo L . Protective effect of yoghurt consumption on Helicobacter pylori \nseropositivity in a Mexican population. Public Health Nutr 2007;10:1283 \u20137. \n \n671) Progestogen use in women approaching th e menopause and breast cancer risk . Campagnoli C. et al. Maturitas \n2009 20Apr; 62(4):338 -342 \n                Trabajo (s) citado (s): \n Fabre A. Fournier A. Mesrine S.Gompel A. Desreux J. Berrino F. Boutron MC. Romieu I.  Clavel F. et al. \nProgestagens use before  menopause and breast cancer risk according to histology and hormone -receptors. Cancer \nEpidemiol Biomarkers Prev 2008;17:2723 \u20138. \n \n672) Prognostic Factors for Gallbladder Cancer in Japan. Kayahara M, Nagakawa T, Nakagawara H, et al. Ann Surg \n2008 Nov;248(5):807 -14. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II. de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n673) Promoter Methylation Profile in Preneoplastic and Neoplastic Gallbladder Lesions. Garcia P, Manterola C, \nAraya JC, et al. Mol Carcinogen 2009 Jan;48 (1):79- 89. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF. Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n  \n93 674) Promoting the effective traslation of the framework convention on tobacco control: A case study of challenges \nand opportunities for strategic communications in Mexico. Thrasher JF. et al.  Evaluat Health Prof 2008 \nJun;31(2):145- 66 \n                Trabajo (s) citado (s): \n Tovar-Guzm\u00e1n V . L\u00f3pez-Antu\u00f1ano FJ . Rodr\u00edguez -Salgado N. (2005). Trends in mortality from lung cancer in \nMexico, 1980 -2000. Revista Panamericana de Salud P\u00fablica , 17(4),254 -262. \n \n675) Prophylactic HPV vaccination for women over 18 years of age. Adams M, Jasani B, Fiander A. Vaccine 2009 \n26May;27(25-26):3391-4.Sp. Iss. SI. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n676) Prophylactic HPV vaccination : a major breakthrough in the fight against cervical cancer? Saleem A, Tristram A, \nFiander A, et al. Minerva Medica 2009 Dec;100(6):503 -23. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n677) Prophylactic HPV vaccines. Cid-Arregui A. The Open Access Vaccine Journal 2009;2:123- 33 \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions. NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n678) Prophylactic HPV vaccines: New interventions for cancer control. Barr E, Sings HL. Vaccine 2008 \n18Nov;26(49):6244 -57. Sp. Iss. SI.  \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders P JF. Arslan A . Anh PTH . Bosch FX . Ferreccio C. Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Giuliano AR . Lazcano -Ponce E.  Villa L . Nolan T . Marchant C . Radley D . Golm G .  McCarroll K . Yu J. Esser MT . \nVuocolo SC . Barr E Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) \nhuman papillomavirus virus-like-particle vaccine .. J Infect Dis 2007 15Oct;196(8):1153- 62. \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n679) Prospects and prejudices of human papillomavirus vaccines in India. Das BC, Hussain S, Nasare V, et al. \nVaccine 2008 23May;26(22):2669- 79. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n680) Pruebas moleculares para la detecci\u00f3n del virus papiloma humano. Desaf\u00edos y posibilidades. Cavazza ME. \nCorrenti M. Dermatolog\u00eda Venezolana 2004;42(3):6- 10. \n                Trabajo (s) citado (s): \n Dzuba IG. Yunes -D\u00edaz E. Allen B.  Leonard YF. Lazcano- Ponce EC.  et al. The Acceptability of Self -collected \nSamples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women\u2019s \nHealth & Gende r-Based Medicine, 2002;11(3):265 -275. \n \n681) Public Health Issues Related to HPV Vaccination.  Hershey JH, Velez LF. J Public Health Manag Pract 2009 \nSep-Oct;15(5):384- 92. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n682) Public knowledge and attitudes towards Human Papilloma Virus (HPV) vaccination. Walsh CD. Gera A. et al. \nBMC Public Health 2008;8. \n                Trabajo (s) citado (s): \n \n94 \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);2 01-9. \n \n683) Public policies for the detection of breast cancer in Mexico .  Mart\u00ednez -Monta nez OG, Uribe -Zuniga P, \nHernandez -Avila M. Salud Publica Mex 2009;51(Suppl 2):S350 -S360.  \n                Trabajo (s) citado (s): \n Lazcano- Ponce E. Palacio-Mejia LS . Allen-Leigh B . Yunes-Diaz E . Alonso P . Schiavon R . Hern\u00e1ndez-Avila M . \nDecreasing cervical cancer mortality in Mexico: Effect of Papanicolaou coverage, birthrate and the importance of \ndiagnostic validity of cytology . Cancer Epidemiol Biomarkers Prev 2008 Oct;17(10):2808-17.  \n Romieu I . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Willett W . Hern\u00e1ndez-Avila M . Carbohydrates and the risk \nof breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2004 Aug;13(8):1283-9.  \n Lazcano-Ponce EC . Najera Aguilar P . Buiatti E. Alonso De Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The \ncervical cancer screening program in Mexico: problems with access and coverage .  Cancer Causes Control 1997 \nSep;8(5):698 -704. \n Ortiz-Rodriguez SP . Torres-Mejia G . Mainero-Ratchelous F . Angeles-Llerenas A . Lopez-Caudana AE . Lazcano-\nPonce E.  Romieu I .  Physical activity and breast cancer risk in Mexican women . Salud Publica Mex 2008 Mar-\nApr;50(2):126- 35. \n L\u00f3pez -Rios O . Lazcano-Ponce EC . Tovar Guzman V . Hernandez Avila M . Breast cancer epidemiology in Mexico. \nDemographic transition consequence . Salud Publica Mex 2997 Jul -Aug;39(4):259 -65.  \n Romieu I . Hern\u00e1ndez-Avila M . Lazcano E.  L\u00f3pez L . Romero-Jaime R . Breast cancer and lactation history in \nMexican women . Am J Epidemiol 1996 15Mar;143(6):543-52.  \n \n684) p53 and p27 gene expression in subserosal gallbladder carcinoma. Roa I, Lantadilla S, Ibacache G, et al. Rev \nMed Chile 2009 Aug;137(8):1017- 22. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \nP16(INK4a) immunohistochemistry improves the reproducibility of the histological diagnosis of cervical intraepithelial \nneoplasia in cone biopsies . Gurrola -Diaz CM, S uarez -Rincon AE, Vazquez -Camacho G, et al. Gynecol Oncol 2008 \nOct;111(1):120 -4.  \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  de Ruiz PA . L\u00f3pez-Carrillo L . Najera-Aguilar P . Avila-Ceniceros R . Escandon-Romero C.  \nCisneros MT . Hern\u00e1ndez-Avila M . Validity and reproducibility of cytologic diagnosis in a sample of cervical \ncancer screening centers in Mexico .  Acta Cytol 1997 Mar-Apr;41(2):277- 84. \n Lazcano- Ponce EC.  de Ruiz P A. Mart\u00ednez Arias C . Murguia Riechers L . Reproducibility study of cervical \ncytopathology in Mexico: A need for regulation and professional accreditation . Diagn Cytopathol 1997 \nJul;17(1):20- 4. \n \n685) Quadrivalent HPV vaccine reduced risk for HPV infection and related disease in women 24 to 45 years of age. \nMunoz N, Manalastas R, Pitisuttithum P, et al.. Ann Intern Med 2009 20Oct;151(8):JC4- 12.    \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n686) Racial Differences in HPV Knowledge, HPV Vaccine Acceptability, and Related Beliefs Among Rural, \nSouthern Women.  Cates J. Brewer NT. et al.  J Rural Health 2009; 25(1): 93- 97. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n687) Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus \nInfection in Black Oropharyngeal Cancer Patients. Settle K, Posner MR, Schumaker LM, et al. Cancer Prev Res \n2009 Sep;2(9):776- 81. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n688) Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human \npapillomavirus vaccination programme for young women. Fairley CK, Hocking JS, Gurrin LC, et al. Sex \nTransm Infect 2009 Dec;85(7):499- 502. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.   \n95  \n689) Rationale and design of a community -based double -blind randomized cli nical trial of an HPV 16 and 18 \nvaccine in Guanacaste, Costa Rica. Herrero R, Hildesheim A, Rodriguez AC, et al. Vaccine 2008 \n2Sep;26(37):4795 -808. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n690) Reassessing the epidemiology of huma n papillomavirus infection: Back to basics. Franco EL, Trottier H. Sex \nTransm Dis 2008 Mar;35(3):283 -5. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n691) Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Kanodia S, Da \nSilva DM, Kast WM. Int J Cancer 2008 15Jan;122(2):247- 59. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n692) Recent patterns in gastric cancer: A global overview . Bertuccio P, Chatenoud L, Levi F, et al. Int J Cancer 2009 \n1Aug;125(3):666- 673. \n                Trabajo (s) citado (s): \n Torres J . L\u00f3pez-Carrillo L.Lazcano E.  Camorlinga M . Flores-Luna L . Munoz O . Trends in Helicobacter pylori \ninfection and gastric cancer in Mexico . Cancer Epidemiol Biomarkers Prev 2005 Aug;14(8():1874-7.  \n Ward MH. L\u00f3pez-Carrillo L.  Dietary Factors and the Risk of Gastric Cancer in Mexico City.  Am J Epidemiol \n1999;149(10):925- 32. \n \n693) Recommendations for Cervical Cancer Prevention in Asia Pacific. Garland SM, Cuzick J, Domingo EJ, et al. \nVaccine 2008 19Aug;26(Suppl 12):M89-M98. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n694) Recommendations for Cervical Cancer Prevention in Latin Ame rica and the Caribbean . Munoz N, Franco EL, \nHerrero R, et al.  Vaccine 2008 19Aug;26(Suppl 11):L96 -L107.  \n                Trabajo (s) citado (s): \n Murillo R . Almonte M  Pereira A . Ferrer E . Gamboa OA . Jeronimo J . Lazcano-Ponce E.  Cervical Cancer Screening \nPrograms in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48.  \n Herrero R . Ferreccio C . Salmeron J . Almonte M . S\u00e1nchez GI . Lazcano-Ponce E. Jeronimo J . New Approaches to \nCervical Cancer Screening in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L49-L58.  \n Winkler JL . Wittet S . Bartolini RM . Creed-Kanashiro HM . Lazcano-Ponce E. Lewis-Bell K . Lewis MJ . Penny ME . \nDeterminants of Human Papillomavirus Vaccine Acceptability in Latin America and the Caribbean . Vaccine 2008 \n19Aug;26(Suppl 11):L73-L79.  \n Franco EL . Tsu V . Herrero R . Lazcano- Ponce E.  Hildesheim A.  Mun\u00f3z N . Murillo R . S\u00e1nchez GI . Andrus JK . \nIntegration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the \nCaribbean . Vaccine 2008 19 Aug;26(Suppl 11):L88-L95.   \n \n695) Recurrent Respiratory Papillomatosis: A Review. Derkay C, Wiatrak B. Laryngoscope 2008 Jul;118(7):1236- 47. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n696) Recurrent respiratory papillomatosis: update 2008. Gallagher TQ, Derkay CS. Curr Opin Otolatyngol Head \nNeck Surg 2008 Dec;16(6):536- 42. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n96  \n697) Recurrencia de c\u00e1ncer de mama en mujeres del Noroeste de M\u00e9xico. P\u00e9rez-Michel LM. Et al. Cir Cir 2009 May-\nJun;77(3):179- 85 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L . Torres-S\u00e1nchez L . L\u00f3pez-Cervantes M. et al. Identificaci\u00f3n de lesiones mamarias en M\u00e9xico. \nSalud P\u00fablica de M\u00e9xico 2001;43(3):199 \u2013202. \n \n698) Recursos disponibles para el tratamiento del c\u00e1ncer de mama en M\u00e9xico. Mohar A. et al. Salud Publica Mex \n2009;51(supl  2):S263-S269.  \n                Trabajo (s) citado (s): \n Poblano-Verastegui O. Figueroa-Perea JG. L\u00f3pez -Carrillo L.  Institutional factors contributing to the utilization of \nbreast clinical examination. Salud P\u00fablica de M\u00e9xico, 2004;46(4):294 \u2013305. \n \n699) Redox-sensitive regulation of gene expression in human primary macrophages exposed to inorganic arsenic. \nBourdonnay E. et al. J Cell Biochem 2009;107(3):537- 47 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo  P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessment \nof lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n700) Reductions in Human Papillomavirus-Disease Resource Use and Costs with Quadrivalent Human \nPapillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccination: The FUTURE Study Economic Evaluation.  \nInsinga RP, Dasbach EJ, Allen SE, et al. Value in  Health 2008 Dec;11(7)L:1022- 32. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n701) Regional Differences in Time to Pregnancy Among Fertile Women from Five Colombian Regions with \nDifferent use of Glyphosate . Sanin LH, Carrasquilla G, Solomon KR, et al. J Toxicol Environ Health Part- A \n2009;72(!5-16):949- 60. \n                Trabajo (s) citado (s): \n Romieu I . Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Willett W . Hern\u00e1ndez-Avila M . Carbohydrates and the risk \nof breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2004 Aug;13(8):1283-9.  \n \n702) Relationship Between Cigarette Smoking and Human Papilloma Virus Types 16 and 18 DNA Load . Xi LF, \nKoutsky LA, Castle PE, et al. Cancer Epidemiol Biomarkers Prev 2009 Dec;18(12):3490-6 Special Issue I. \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Snijders PJF . Dai M . Thomas JO . Hieu NT . Ferreccio C . Matos E.  Posso H . de Sanjose S . \nShin HR . Sukvirach S . Lazcano-Ponce E.  Mun\u00f3z N . Meijer CJLM . Franceschi S . Smoking and human \npapillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence \nSurveys. Int J Epidemiol 2008 Jun;37(3):536- 46.  \n \n703) Relationships, love and sexuality: what the Filipino teens think and feel . de Irala J, Osorio A, del Burgo CL, et \nal.  BMC Public Health 2009 5Aug;9: Artic 282. \n                Trabajo (s) citado (s): \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemi ol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n704) Reproductive factors and breast cancer: principal findings in Latin Ametica and the World. Torres -Mej\u00eda J. \n\u00c1ngeles -Llerenas A. Salud Publica Mex 2009;51(Supl 2):S165 -S171  \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L.  Bravo-Alvarado J. Poblano-Verastegui O. Ortega Altamirano D., Reproductive determinants of \nbreast cancer in Mexican women. Ann N Y Acad Sci 1997; 837:537-50. \n Tovar -Guzman V . Hern\u00e1ndez-Gir\u00f3n C . Lazcano -Ponce E.  Romieu I . Avila MH . Breast cancer in Mexican women: \nan epidemiological study with cervical cancer control . Rev Saude Publica 2000 Apr;34(2):113-9 .  \n Olaya -Contreras P . Pierre B . Lazcano- Ponce EC.  Villamil-Rodriguez J . Posso-Valencia HJ . Reproductive risk \nfactors associated with breast cancer in Columbian women . Rev Saude Publica 1999 Jun;33(3):237- 45. \n Romieu I . Hern\u00e1ndez-Avila M . Lazcano E.  L\u00f3pez L . Romero-Jaime R . Breast cancer and lactation history in \nMexican women . Am J Epidemiol 1996 15Mar;143(6):543-52.  \n \n705) Reprodutibilidade do teste de captura h\u00edbrida de segunda gera\u00e7\u00e3o na detec\u00e7\u00e3o de HPV de alto risco em \nmaterial cervicovaginal de autocoleta. Cremonesi A. Taromaru E. et al.  J Bras Doen\u00e7as Sex Transm 2004;16(4):5-\n10, 2004. \n                Trabajo (s) citado (s): \n \n97 \n Dzuba IG. Yunes -D\u00edaz E. Allen B.  Leonard YF. Lazcano- Ponce EC.  et al. The Accep tability of Self -collected \nSamples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women\u2019s \nHealth & Gender -Based Medicine, 2002;11(3):265 -275. \n \n706) Requiring Human Papillomavirus Vaccine for Immigrant Women. Hachey KJ, Allen RH, Nothnagle M, et al. \nObstet Gynecol 2009 Nov;114(5):1135- 9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n707) Residuos de plaguicidas organofosforados en cabezuela de br\u00f3coli (Brassica Oleracea) determinados por \ncromatograf\u00eda de gases. P\u00e9rez MA. Et al. Rev Int Contam Ambient 2009;25(2):103- 10 \n                Trabajo (s) citado (s): \n L\u00f3pez -Carrillo L.  L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L.  Blair A.  Cebri\u00e1n -Garc\u00eda M. Garc\u00eda RM. (2002). Serum \nlevels of beta -hexachlorocyclohexane, hexachlorobenzene and polychlorinat ed biphenyls and breast cancer in \nMexican women. Eur. J. Cancer Prev. 11, 129 -135. \n \n708) Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with \nconventional cytology as the primary cervical cancer screening test . Ronco G, Giorgi-Rossi P, Carozzi F, et al. J \nNatl Cancer Inst 2008 2Apr;100(7):492- 501. \n                Trabajo (s) citado (s): \n Salmeron J . Lazcano-Ponce E.  Lorincz A . Hernandez M . Hern\u00e1ndez P . Leyva A . Uribe M . Manzanares H . Antunez \nA. Carmona E . Ronnett BM . Sherman ME . Bishai D . Ferris D . Flores Y . Yunes E . Shah KV . Comparison of HPV-\nbased assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico . Cancer Causes \nControl 2003 Aug;14(6):505-12.  \n \n709) Rethinking global access to vaccines. Chokshi DA, Kesselheim AS. BMJ 2008 5Apr;336(7647):750- 3. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n710) Reversal of Human Papillomavirus-Specific T Cell Immune Suppression through TLR Agonist Treatment of \nLangerhans Cells Exposed to Human Papillomavirus Type 16. Fahey LM, Raff AB, Da Silva DM, et al. J \nImmunol 2009 1Mar;182(5):2919- 28. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n711) Review and pooled analysis of studies on MTHFR C677T polymorphism and esophageal cancer. Langevin SM. \net al. Toxicol Lett 2009;184:73- 80 \n                Trabajo (s) citado (s): \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carrillo L.  et al. Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T \nand A1298C polymorphisms  and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n \n712) Review of salt consumption and stomach cancer risk: Epidemiological and biological evidence. Wang XQ. Et al. \nWorld J Gastroenterol 2009 May;15(18):2204-2213 \n                Trabajo (s) citado (s): \n Ward MH. L\u00f3pez-Carrillo L.  Dietary Factors and the Risk of Gastric Cancer in Mexico City.  Am J Epidemiol \n1999;149(10):925- 32. \n L\u00f3pez-Carrillo L . L\u00f3pez-Cervantes M. Ward MH. Bravo-Alvarado J. Ram\u00edrez-Espitia A. Nutrient intake and \ngastric cancer in Mexico. Int J Cancer 1999; 83: 601- 605 \n \n713) Review of the etiology of breast cancer with special attention to organochlorines as potential endocrine \ndisruptors. Salehi F. et al. J Toxicol Environ Health B Crit Rev 2008 Mar;11(3 -4):276 -300 \n                Trabajo (s) citado (s): \n L\u00f3pez -Carrillo L.  L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L.  Blair A.  Cebri\u00e1n -Garc\u00eda M. Garc\u00eda RM. (2002). Serum \nlevels of beta -hexachlorocyclohexane, hexachlorobenzene and polychlorinated biphenyls and breast cancer in \nMexican women. Eur. J. Cancer Prev. 11, 129 -135. \n L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez -Carrillo L . 2004. Dichlorodiphenyldichloroethane burden \nand breast cancer risk: A meta -analysis of the epidemiologic evidence. Environ. Health Perspect. 112:207 \u2013214. \n \n714) Risk Assessment to Guide the Prevention of Cervical Cancer. Castle PE.  Sideri M. et al. Journal of Lower \nGenital Tract Disease 2008; 12(1): 1- 7. \n                Trabajo (s) citado (s):  \n98 \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n715) Risk estimation for the next generation of prevention programmes for cervical cancer. Katki HA, Wacholder S, \nSolomon D, et al. Lancet Oncol 2009 Nov;10(11):1022- 3. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n716) Risk factors and frequency of occurrence of HPV DNA of high oncogenic types in paraepidermal epithelium \ncells of the uterine cervix, in the trophoblast, and in the peripheral blood of pregnant patients . Agata T, \nMalgorzata S, Daria R, et al. Ginekol Pol 2008 Dec;79(12):871 -6. \n                Trabajo (s) citado (s): \n Hernandez -Gir\u00f3n C . Smith JS . Lorincz A . Chaidez EA . Lazcano E.  Hern\u00e1ndez-Avila M . Salmeron J . The \nprevalence of high-risk HPV infection in pregnant women from Morelos, Mexico . Salud Publica Mex 2005 Nov-\nDec;47(6):423-9.  \n  \n717) Risk factors associated with histological alterations of the female genital tract in patients attending a first -level \nmedical care facility . Hernandez -Valencia M, Rodriguez -Lundes  O, de Oca MELM, et al. Cir Cir 2009 Nov -\nDec;77(6):419 -21. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Hern\u00e1ndez -Avila M. L\u00f3pez -Carrillo L.  De Ru\u00edz PA. Torres -Lobat\u00f3n A. Gonz\u00e1lez -Lira A. \nRomieu I.  Reproductive factors and sex life -history and c ervical -cancer in Mexico City. Rev Invest Clin 1995 Sep -\nOct;47(5):377 -85. \n \n718) Risk factors for cervical cancer among HPV positive women in Mexico . Flores YN, Bishai DM, Shah KV, et al. \nSalud Publica Mex 2008 Jan-Feb;50(1):49- 58. \n                Trabajo (s) citado (s): \n Salmeron J . Lazcano-Ponce E.  Lorincz A . Hernandez M . Hern\u00e1ndez P . Leyva A . Uribe M . Manzanares H . Antunez \nA. Carmona E . Ronnett BM . Sherman ME . Bishai D . Ferris D . Flores Y . Yunes E . Shah KV . Comparison of HPV-\nbased assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico . Cancer Causes \nControl 2003 Aug;14(6):505-12.  \n \n719) Risk factors for endometrial cancer in Turkish women: Results from a hospital-based case-control study . Reis \nN, Beji NK. Br J Oncol Nurs 2009 Apr;13(2):122- 7. \n                Trabajo (s) citado (s): \n Salazar -Martinez E . Lazcano-Ponce EC.  Lira-Lira GG . Escudero-De los Rios P . Salmeron-Castro J . Hern\u00e1ndez-\nAvila M . Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico . \nCancer Res 1999 1Aug;59(15):3658- 62. \n \n720) Risk facto rs for Human Papillomavirus Exposure and Co -factors for Cervical Cancer in Latin America and the \nCaribbean. Almonte M, Albero G, Molano M, et al. Vaccine 2008 19Aug;26(Suppl 11):L16 -L36. \n                Trabajo (s) citado (s): \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexico . Int J Cancer 2006 15Oct;119(8):1934-9.  \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n P\u00e9rez G . Lazcano -Ponce E.  Hern\u00e1ndez-Avila M . Garcia PJ. Mun\u00f3z N . Villa LL . Bryan J . Taddeo FJ . Lu S . Esser MT . \nVuoco S . Sattler C . Barr E . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, \n11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8.  \n Herrero R . Ferreccio C . Salmeron J . Almonte M . S\u00e1nchez GI . Lazcano-Ponce E.  Jeronimo J. New Approaches to \nCervical Cancer Screening in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L49-L58.  \n Murillo R . Almonte M  Pereira A . Ferrer E . Gamboa OA . Jeronimo J. Lazcano-Ponce E. Cervical Cancer Screening \nPrograms in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48.  \n Vaccarella S . Franceschi S . Herrero R. Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 F eb;15(2):326 -33.  \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC . Estrada RA . Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n99 \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n721) Role of genetic variant A-204C of cholesterol 7 alpha-hydroxylase (CYP7A1) in susceptibility to gallbladder \ncancer. Srivastava A, Pandey SN, Choudhuri G, et al. Mol Genet Metab 2008 May;94(1):83- 9. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n722) Role of molecular markers and gene profiling in head and neck cancers. Gold KA, Kim ES. Curr Opin Oncol \n2009 May;21(3):206- 11. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n723) Safety and efficacy of vaccines. Bartlett BL, Tyring SK. Dermatol Ther 2009 Mar-Apr;22(2):97- 103. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n724) Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, \nplacebo-controlled trial in 176 Korean subjects. Kang S, Kim KH, Kim YT, et al. Int J Gynecol Cancer 2008 Sep-\nOct;18(5):1013- 9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n725) Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-\nlike particle (VLP) and hepatitis B (HBV) vaccines. Wheeler CM, Bautista OM, Tomassini JE, et al. Vaccine 2008 \n30Jan;26(5):686-96. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n726) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-\nparticle vaccine in Latin American women. Perez G, Lazcano -Ponce E, Hernandez -Avila M, et al. Int J Cancer \n2008 15Mar;122(6):1311 -8. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n727) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) r ecombinant \nvaccine in women aged 24 -45 years: a randomised, double -blind trial. Munoz N, Manalastas R, Pitisuttithum P, \net al. Lancet 2009 6Jun;373(9679):1949 -57. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n728) Safety of human papillomavirus (HPV) vaccines: A review  of the international ex perience so far. Agorastos T. \nChatzigeorgiou K. et al. Vaccine 2009; 27(52): 7270 -7281.  \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n729) Screening and Prevention: Cervical Cancer. Weinstein LC, Buchanan EM, Hillson C, et al. Primary Care 2009 \nSep;36(3).559 \n \n100                 Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions. NEJM 2007 10May;356(19):1915-27.  \n \n730) Second primary head and neck tumor risk in patients with cervical cancer-seer data analysis . Ragin CCR, Taioli \nE. Head Neck J Sci Spec Head Neck 2008 Jan;30(1):58- 66. \n                Trabajo (s) citado (s): \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n731) Selected Aspects of Mediterranean Diet and Cancer Risk. Pelu cchi C. et al. Nutr Cancer  2009;61(6):756 -766 \n                Trabajo (s) citado (s): \n Lajous M. Romieu I.  Sabia S. Boutron-Ruault MC. Clavel-Chapelon F. Folate, vitamin B12 and postmenopausal \nbreast cancer in a prospective study of French women. Cancer Causes Control 17, 1209 \u20131213, 2006. \n \n732) Self-report is a valid measure of circumcision status in homosexual men . Templeton DJ, Mao L, Prestage GP, et \nal. Sex Transm Infec 2008 1Jun;84(3):187- 8. \n                Trabajo (s) citado (s): \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n733) Self-reported sexual debut and behavior in young adults aged 48-24 years in seven European countries: \nImplications for HPV vaccination programs . Crochard A, Luyts D, di Nicola S, et al. Gynecol Oncol 2009 \nDec;115(3):S7-S14. Suppl. 1. \n                Trabajo (s) citado (s): \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n734) Self-sampling for human papillomavirus in a community setting: Feasibility in Hispanic women. De Alba I. \nAnton -Culver  H. et al. Cancer Epidemiol Biomark ers Prev 2008; 17(8): 2163 -2168.  \n                Trabajo (s) citado (s): \n Dzuba IG. Yunes -D\u00edaz E. Allen B.  Leonard YF. Lazcano- Ponce EC.  et al. The Acceptability of Self -collected \nSamples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women\u2019s \nHealth &  Gender -Based Medicine, 2002;11(3):265 -275. \n \n735) Seroprevalence of Human Papillomavirus Types 6, 11, 16, and 18 in the United States: National Health and \nNutrition Examination Survey 2003-2004. Markowitz LE, Sternberg M, Dunne EF, et al. J Infect Dis 2009 \n1Oct;200(7):1059- 67. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Giuliano AR . Lazcano -Ponce E. Villa LL . Flores R . Salmeron J . Lee JH . Papenfuss MR . Abrahamsen M . Jolles E. \nNielson CM . Baggio ML. Silva R . Quiterio M . The human papillomavirus infection in men study: Human \npapillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States . \nCancer Epidemiol Biomarkers Prev 2008 Aug;17(8):2036-43.  \n \n736) Seroprevalence of 34 human papillomavirus ty pes in the German general population. Michael KM, Waterboer \nT, Sehr P, et al. PLoS Pathogens 2008 Jun;4(6):e1000091   \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n \n737) Serum organochlorines and breast cancer risk in Japanese women: a case \u2013control study. Itoh H. et al. Cancer \nCauses Control 2009;20:567- 80 \n                Trabajo (s) citado (s): \n L\u00f3pez -Carrillo L.  L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L.   Blair A.  Cebri\u00e1n -Garc\u00eda M. Garc\u00eda RM. (2002). Serum \nlevels of be ta-hexachlorocyclohexane, hexachlorobenzene and polychlorinated biphenyls and breast cancer in \nMexican women. Eur. J. Cancer Prev. 11, 129 -135.  \n101 \n L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez -Carrillo L . 2004. Dichlorodiphenyldichloroethane burden \nand breast cancer risk: A meta -analysis of the epidemiologic evidence. Environ. Health Perspect. 112:207 \u2013214. \n L\u00f3pez -Carrillo L . Blair A. L\u00f3pez -Cervantes M. Cebrian M. Rueda C.  Reyes R et al (1997) \ndichlorodiphenyltrichloroethane serum levels and breast cance r risk: a case -control study from Mexico. Cancer \nRes 57:3728 \u20133732  \n Romieu I . Hernandez-Avila M . Lazcano- Ponce E. . Weber JP . Dewailly E . Breast cancer, lactation history, and \nserum organochlorines . Am J Epidemiol 2000 15Aug;152(4):363- 70. \n \n738) Sex differences in injection site reactions with human vaccines. Cook IF. Hum Vaccines 2009 Jul;5(7):441- 9. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n739) Sexual Behaviour and HPV Infections in 18 to 29 Year Old Women in the Pre-Vaccine Era in the Netherlands . \nLenselink CH, Melchers WJG, Quint WGV, et al. PLoS One 2008 17Nov;3(11):e3743. \n                Trabajo (s) citado (s): \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol  Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n740) Sexually transmitted infections. Frenkl TL, Potts J. Urol Clin North Am 2008 Feb;35(1):33. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n741) Sexually Transmitted Viral Infections in Women: HIV, HSV, and HPV. Morrison EAB. Infect Med 2009 \nJan;26(1):13- 17. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n742) Short version of the German evidence -based Guidelines for prophylactic vaccination against HPV -associated \nneoplasia. Pathirana D, Hillemanns P, Petry KU, et al. Vaccine 2009 23Jul;27(34):45 51-9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n743) Single nucleotide polymorphism in the ABCG8 transporter gene is associated with gallbladder cancer \nsusceptibility. Srivastava A, Tulsyan S, Pandey SN, et al. Liver Int 2009 Jul;29(6):831- 7. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n744) Single -Nucleotide Polymorphisms of DNA Repair Genes OGG1 and XRCC1: Association with Gallbladder \nCancer in North Indian Population. Srivastava A, Srivastava K, Pandey SN, et al. Ann Surg Oncol 2009 \nJun;16(6):1695 -1703.  \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n745) Smoking and human papillomavirus infection: the pursuit of credibility for an epidemiologic association  \n(Commentary).  Franco EL, Spence AR. Int J Epidemiol 2008 Jun;37(3):547-8.  \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Snijders PJF. Dai M . Thomas JO . Hieu NT . Ferreccio C . Matos E . Posso H . de Sanjose S . \nShin HR . Sukvirach S . Lazcano-Ponce E.  Mun\u00f3z N . Meijer CJLM . Franceschi S . Smoking and human \npapillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence \nSurveys. Int J Epidemiol 2008 Jun;37(3):536- 46.  \n \n746) Smoking worsens the prognosis of mild abnormalities in cervical cytology . Guarisi R, Sarian LO, Hammes LS, \net al. Acta Obstet Gynecol Scand 2009;88(5): 514-20.  \n                Trabajo (s) citado (s): \n \n102 \n Vaccarella S . Herrero R . Snijders PJF . Dai M . Thomas JO . Hieu NT . Ferreccio C . Matos E.  Posso H . de Sanjose S . \nShin HR . Sukvirach S . Lazcano-Ponce E.  Mun\u00f3z N . Meijer CJLM . Franceschi S . Smoking and human \npapillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence \nSurveys. Int J Epidemiol 2008 Jun;37(3):536- 46.  \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n747) Social inequality in Pap smear coverage: identifying under-users of cervical cancer screening in Argentina .  \nArrossi S, Ramos S, Paolino M, et al. Reprod Health Matt 2008 Nov;16(32):50- 8. \n                Trabajo (s) citado (s): \n Lazcano-Ponce EC. Moss S . Cruz-Vald\u00e9z A. de Ruiz PA . Martinez-Le\u00f3n CJ . Casares-Queralt S . Hern\u00e1ndez-Avila \nM. The positive experience of screening quality among users of a cervical cancer detection center : Arch Med Res \n2002 Mar-Apr;33(2):186-92.   \n Herrero R . Ferreccio C . Salmeron J . Almonte M . S\u00e1nchez GI . Lazcano-Ponce E.  Jeronimo J . New Approaches to \nCervical Cancer Screening in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L49-L58.  \n Lazcano-Ponce EC . Najera Aguilar P . Buiatti E. Alonso De Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The \ncervical cancer screening program in Mexico: problems with access and coverage .  Cancer Causes Control 1997 \nSep;8(5):698 -704. \n \n748) Sociocultural Issues in the Introduction of Human Papillomavirus Vaccine in Low-Resource Settings. Bingham \nAJ. Drake K. et al. Arch Pediat Adolesc Med 2009; 163(5): 455- 461. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n749) Socio -demographic, lifestyle, gynecological, and obstetric predictors of serum or plasma  concentrations of \nhomocysteine, folic acid, and vitamins B12 and B6 among low -income  women in S\u00e3o Paulo, Brazil. Carnei ro-\nAlmeida L. Tomita LY. et al.  Cad. Sau de P\u00fablica, Rio de Janeiro 2008 mar;24(3):587 -596,  \n                Trabajo (s) citado (s): \n Lajous M . Lazcano -Ponce E . Hern\u00e1ndez-Avila M . Willett W . Romieu I . Folate, vitamin B-6, and vitamin B- 12 \nintake and the risk of breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2006 \nMar;15(3):443-8.   \n \n750) Sociodemographic predictors of HPV testing and vaccination acceptability: results from a population-\nrepresentative sample of British women. Marlow LAV, Waller J, Wardle J. J Med Screen 2008;15(2):91- 6. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n751) Somatostatin elevates topoisomerase II alpha and enhances the cytotoxic effect of doxorubicin on gallbladder \ncancer cells. Quan ZW, Yue JN, Li JY, et al. Chemotherapy 2008;54(6):431 -7. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder canc er. CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n752) State -of-the-art of infections produced by human papillomavirus. Reina JC, Munoz N, Sanchez GI. Colombia \nMedica 2009 Apr -Jun;39(2):189 -95. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A . Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n753) Stomach cancer in 67 Chinese counties: evidence of interaction between salt consumption and helicobacter \npylori infection. Wang X. et al. Asia Pac J Clin Nutr 2008;17(4):644 -50 \n                Trabajo (s) citado (s): \n Ward MH. L\u00f3pez-Carrillo L.  Dietary Factors and the Risk of Gastric Cancer in Mexico City.  Am J Epidemiol \n1999;149(10):925- 32. \n  \n103 754) Study Comparing Human Papillomavirus (HPV) Real-Time Multiplex PCR and Hybrid Capture II INNO-LiPA \nv2 HPV Genotyping PCR Assays.  Iftner T, Germ L, Swoyer R, et al. J Clin Microbiol 2009 Jul;47(7):2106- 13. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n755) Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human \npapillomavirus. Lembo D, Donalisio M, Rusnati M, et al. Antimicrob Agents Chemother  2008 Apr;52(4):1374-\n81. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n756) Sulfated K5 Escherichia coli polysaccharide derivatives: A novel class of candidate antiviral microbicides. \nRusnati M, Vicenzi E, Donalisio M, et al. Pharmacol Ther 2009 Sep;1 23(3):310 -22. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n757) Sunlight, vitamin D and the prevention of cancer: a systematic review of epidemiological studies . van der Rhee \nH, Coebergh JW, de Vries E. Eur J Cancer Prev 2009 26Aug. \n                Trabajo (s) citado (s): \n Salazar -Martinez E .Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Gonz\u00e1lez-Lira G . Escudero-De Los Rios P . \nHern\u00e1ndez-Avila M . Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico . Int J \nGynecol Cancer 2005 Sep -Oct;15(5 ):938 -45.  \n \n758) Sunlight, the vitamin D endocrine system, and their relationships with gynaecologic cancer . Perez-Lopez FR. \nMaturitas 2008 Feb;59(2):101- 13. \n                Trabajo (s) citado (s): \n Salazar -Martinez E .Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Gonz\u00e1lez-Lira G . Escudero-De Los Rios P . \nHern\u00e1ndez-Avila M . Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico . Int J \nGynecol Cancer 2005 Sep -Oct;15(5 ):938 -45.  \n \n759) Surgical management for carcinoma of the gallbladder: a single- institution experience in 25 years. Liang JW, \nDong SX, Zhou ZX, et al. Chin Med J 2008 5Oct;121(19):1900- 5. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n760) Surgical Management of Gallbladder Cancer. Reddy SK, Clary BM, Surg Oncol Clin North Am 2009 \nApr;18(2):307+. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n761) Synergistic effect of HLA class II loci and cytokine gene polymorphisms on the risk of gastric cancer in \nJapanese patients with Helicobacter pylori  infection. Ando T. et al. Int J Cancer 2009;125:2595-602 \n                Trabajo (s) citado (s): \n Sicinschi LA. L\u00f3pez-Carrillo L. Constanza-Camargo M. et al. 2006. Gastric cancer risk in a Mexican pop ulation: \nrole of Helicobacter pylori CagA positive infection and polymorphisms in interleukin -1 and -10 genes. Int. J. \nCancer. 118:649 \u2013657. \n \n762) Systematic Review of Meta -Analyses on Gene Polymorphisms and Gastric Cancer Risk. Gianfagna F. et al. \nCurr Genomics  2008 Sep;9(6):361 -74 \n                Trabajo (s) citado (s): \n Boccia S. Hung R. Ricciardi G. Gianfagna F. Ebert MPA. Fang JY. Gao CM. Gotze T. Graziano F. Lacasa\u00f1a -Navarro \nM. Ling D . L\u00f3pez -Carrillo L.  et al. Meta - and pooled analyses of the methylenetetrahyd rofolate reductase C677T \nand A1298C polymorphisms and gastric cancer risk: a huge -GSEC review. Am J Epidemiol . 2008; 167(5):505 -516. \n \n763) Targeted therapies for cancer of the gallbladder. Thomas MB. Curr Opin Gastroenterol 2008 May;24(3):372- 6. \n                Trabajo (s) citado (s):  \n104 \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n764) Targeting Proteins for Destruction by the Ubiquitin System: Implications for Human Pathobiology. Schwartz \nAL, Ciechanover A. Annu Rev Pharmacol Toxicol 2009;49:73- 96. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n765) Temporal trends over 3 decades and intrafamilial clustering of HPV types in Swedish patients with cervical \ncancer in situ. Ivansson EL, Gustavsson IM, Wilander E, et al. Int J Cancer 2009 15Dec;125(12):2930 -5. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n766) The accuracy of the HPV-DNA test for detecting highgrade disease (CIN 2+) in women with minor cytological \nabnormalities (ASC-US and LSIL) in patients affiliated to the social security system in Bogota, Colombia. \nIsaza -Ruget MA.   Perez G.  Morales -Reyes OL. et al. Rev Colomb  Obstet Ginecol 2009; 60( 3):213 -222. \n                Trabajo (s) citado (s): \n Murillo R . Almonte M  Pereira A . Ferrer E . Gamboa OA . Jeronimo J . Lazcano-Ponce E. Cervical Cancer Screening \nPrograms in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48.  \n \n767) The Bifidobacterium dentium Bd1 Genome Sequence Reflects Its Ge netic Adaptation to the Human Oral \nCavity . Ventura M, Turroni F, Zomer A, et al. PLoS Genet 2009 Dec;5(12):Article e1000785 . \n                Trabajo (s) citado (s): \n Romo -Gonzalez C . Salama NR . Burgeno-Ferreira J. Ponce-Castaneda V . Lazcano-Ponce EC.  Camorlinga-Ponce M . \nTorres J . Differences in Genome Content among Helicobacter pylori Isolates from Patients with Gastritis, \nDuodenal Ulcer, or Gastric Cancer Reveal Novel Disease-Associated Genes . Infect Immun 2009 May;77(5):2201- 11. \n \n768) The case for a gender-neutral (Universal) human papillomavirus vaccination policy in the United States: Point. \nGiuliano AR, Salmon D. Cancer Epidemiol Biomarkers Prev 2008 Apr;17(4):805- 8. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n Lazcano- Ponce E. Herrero R . Munoz N . Hernandez-Avila M . Salmeron J. Leyva A . Meijer CJLM . Walboomers \nJMM . High prevalence of human papillomavirus infection in Mexican males - Comparative study of penile-\nurethral swabs and urine samples . Sex Transm Dis 2001 May;28(5):277-80.  \n \n769) The Challenge of Eliminating Cervical Cancer in the United States: A Story of Politics, Prudishness, and \nPrevention. Fisher JW, Brundage SI. Women Health 2009;49(2-3):246- 61. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n770) The current and future role of screening in the era of HPV vaccination. Myers E, Huh WK, Wright JD, et al. \nGynecol Oncol 2008 May;109(2):S31 -S39. Suppl. 1.  \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n771) The Development of a Cervical Cancer Prevention Program for Underser ved Women in the Dominican \nRepublic . Montgomery K, Montgomery OC. Oncol Nurs Forum 2009 Sep; 36(5):495 -497.  \n                Trabajo (s) citado (s): \n Murillo R . Almonte M  Pereira A . Ferrer E . Gamboa OA . Jeronimo J. Lazcano-Ponce E. Cervical Cancer Screening \nPrograms in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48.  \n \n772) The disparity of cervical cancer in diverse populations. Downs LS, Smith JS, Scarinci I, et al. Gynecol Oncol \n2008 May;109(2):S22-S30. Suppl 1. \n                Trabajo (s) citado (s): \n \n105 \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n773) The economic impact of HPV vaccines: not just cervical cancer. Myers ER. Am J Obstet Gynecol 2008 \nMay;198(5):487- 8. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n774) The effect of training on the knowledge levels and beliefs regarding breast self -examination on women \nattending a public education centre. Hacihasanoglu R. Gozum S. Eur J Oncol Nurs 2008 Feb;12(1):58 -64 \n                Trabajo (s) citado (s): \n Ortega-Altamirano D. L\u00f3pez-Carrillo L.  L\u00f3pez-Cervantes M.  Estrategias para la ense\u00f1anza del autoexamen del \nseno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 \u201325. \n \n775) The efficacy of HPV 16/18 vaccines on sexually active 18 -23 year old women and the impact of HPV vaccination \non organized cervical cancer screening. Sigurdsson K, Sigvaldason H, Gudmundsdottir T, et  al. Acta Obster \nGynecol Scand 2009;88(1):27 -35. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n776) The Epidemiology behind the HPV Vaccine Discovery. Koutsky L. Ann Epidemiol 2009 Apr;19(4):239- 44. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n777) The future of vaccines for cervical cancer. Huh WK, Roden RBS. Gynecol Oncol 2008 May;109(2):S48-56. Suppl \n1. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n778) The Health and Economic Impact of Cervical Cancer Screening and Human Papillomavirus Vaccination in \nKidney Transplant Recipients. Wong G, Howard K, Webster A, et al. Transplantation 2009 15Apr;87(7):1078- 91. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n779) The HPV Vaccine: A Content Analysis of Online News Stories. Habel MA.  Liddon N. et al. J Womens Health \n2009; 18(3): 401 -407. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n780) The HPV Vaccines-Which to Prefer?  Bornstein J. Obstet Gynecol Surv 2009 May;64(5):345- 50. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n781) The human papillomavirus vaccine: A powerful tool for the primary prevention of cervical cancer . Munoz N, \nReina JC, Sanchez GI. Colombia Medica 2008 Apr -Jun;39(2):196 -204 \n                Trabajo (s) citado (s): \n P\u00e9rez G . Lazcano- Ponce E. Hern\u00e1ndez-Avila M . Garcia PJ . Mun\u00f3z N . Villa LL. Bryan J . Taddeo FJ . Lu S . Esser MT . \nVuoco S. Sattler C . Barr E . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, \n11, 16, 18) L1 virus-like-particle vaccine in Latin American women . Int J Cancer 2008 15Mar;122(6):1311- 8.  \n \n782) The human papillomavirus vaccine in Canada. Morris SK, Nguyen CK. Can J Public Health 2008 Mar-\nApr;99(2):114- 6. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n106 \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n783) The human papillomavirus vaccine. Heymann WR. J Am Acad Dermatol 2008 Jun; 58(6):1047- 8. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n784) The impact of Mexico's conditional cash transfer programme, Oportunidades, on birthweight . Barber SL, \nGertler PJ. Trop Med Int Health 2008 Nov;13(11):1405-14. \n                Trabajo (s) citado (s): \n Palacio -Mejia LS . Rangel-G\u00f3mez G . Hern\u00e1ndez-Avila M . Lazcano-Ponce E.  Cervical cancer, a disease of poverty: \nMortality differences between urban and rural areas in Mexico . Salud Publica Mex 2003;45(Suppl 3):S315 -S325.  \n \n785) The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European \nwomen aged 16 to 24 .  Majewski S, Bosch FX, Dillner J, et al.  J Eur Acad Dermatol Venereol 2009 \nOct;23(10): 1147-55.   \n                Trabajo (s) citado (s): \n Giuliano AR . Lazcano -Ponce E.  Villa L . Nolan T . Marchant C . Radley D . Golm G .  McCarroll K . Yu J . Esser MT . \nVuocolo SC . Barr E Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) \nhuman papillomavirus virus-like-particle vaccine .. J Infect Dis 2007 15Oct;196(8):1153- 62. \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n786) The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle \nVaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Na\u00efve Women \nAged 16-26 Years. Brown DR, Kjaer SK, Sigurdsson K, et al. J Infect Dis 2009 1Apr;199(7):926- 35. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n787) The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle \nVaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged \n16-26 Years. Wheeler CM, Kjaer SK, Sigurdsson K, et al. J Infect Dis 2009 1Apr;199(7):936- 44. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n788) The Impact of Pesticide Exposure on Breast Cancer Incidence. Evidence from Cos ta Rica. Santamar\u00eda Ulloa C. \nPobl Salud Mesoam 2009 Jul -Dic;7(1):  \n                Trabajo (s) citado (s): \n L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez -Carrillo L . 2004. Dichlorodiphenyldichloroethane burden \nand breast cancer risk: A meta -analysis of the epidemiologic evidence. Environ. Health Perspect. 112:207 \u2013214. \n \n789) The Mexican Cervical Cancer Screening Trial Self-Sampling for Human Papillomavirus With Unaided Visual \nInspection as a Secondary Screen . Belinson JL, Pretorius RG, Enerson C, et al. Int J Gynecol Cancer 2009 \nJan;19(1):27- 32. \n                Trabajo (s) citado (s): \n Flores Y . Bishai D . Lazcano E.  Shah K . Lorincz A . Hernandez M . Salmeron J. Improving cervical cancer screening \nin Mexico: Results from the Morelos HPV Study . Salud Publica Mex 2003;54(Suppl 3):S388-S398.  \n \n790) The new challenges in the prevention of cervical cancer - Introduction. Monsonego J. Vaccine 2008 \n14Mar;26(Suppl 1):A4-A6. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n791) The Nurse's Role in the Prevention of Cervical Cancer Among Underserved and Minority Populations. Rogers \nNM, Cantu AG. J Commun Health 2009 Apr;34(2):135- 43. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n792) The pediatrician's role in preventing cervical cancer.  Blatter MM, Monk BJ. Clin Pediatr 2008 Sep;47(7):627- 38. \n                Trabajo (s) citado (s):  \n107 \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n793) The Pine River Statement: Human Health Consequences of DDT Use. Eskenazi B. et al. Environ Health \nPerspect 2009 Sep:117(9);1359- 67 \n                Trabajo (s) citado (s): \n L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez -Carrillo L . 2004. Dichlorodiphenyldichloroethane burden \nand breast cancer risk: A meta -analysis of the epidemiologic ev idence. Environ. Health Perspect. 112:207 \u2013214. \n \n794) The predicted impact of vaccination on human papillomavirus infections in Australia. Smith MA, Canfell K, \nBrotherton JML, et al. Int J Cancer 2008 15Oct;123(8):1854- 63. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n795) The prevalence and significance of high-risk human papillomavirus DNA test in southern Malaysia and \nSingapore. Tay SK, Tay YK. Aust New Z J Obstet Gynaecol 2009 Jun;49(3):323- 7. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n796) The psychosocial burden of human papillomavirus related disease and screening interventions. Pirotta M, Ung \nL, Stein A, et al. Sex Transm Infect 2009 Dec;85(7):508- 13. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n797) The Risks and Benefits of HPV Vaccination.  Haug C. JAMA 2009 19Aug;302(7):795 -6. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazca no-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n798) The relationship between smoking and age at the menopause: A systematic review . Parente RC, Faerstein E, \nCeleste RK, et al. Maturitas 2008 20Dec;61(4):287 -98.  \n                Trabajo (s) citado (s): \n Garrido -Latorre F . Lazcano-Ponce EC . L\u00f3pez-Carrillo L . Hern\u00e1ndez-Avila M . Age of natural menopause among \nwomen in Mexico City . Int J Gynecol Obstet 1996 May;53(2):159-66.  \n \n799) The role of body weight in the relationship between physical activity and endometrial cancer: Results from a \nlarge cohort of US women . Patel AV, Feigelson HS, Talbot JT, et al. Int J Cancer 2008 15Oct;123(8):1877- 82. \n                Trabajo (s) citado (s): \n Salazar -Martinez E . Lazcano-Ponce E . Lira-Lira GG . Escudero-De los Rios P . Salmeron-Castro J . Larrea F . \nHernandez-Avila M .Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer \namong Mexican women . Cancer Causes Control 2000 Sep;11(8):707- 11. \n \n800) The role of diet and other environmental factors in the causation of gastric cancer in Iran - A population based \nstudy. Pourfarzi F. et al. Int J Cancer 2009;125:1953- 60 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L . L\u00f3pez-Cervantes M. Ward MH. Bravo-Alvarado J. Ram\u00edrez-Espitia A. Nutrient intake and \ngastric cancer in Mexico. Int J Cancer 1999; 83: 601- 605 \n \n801) The role of high -risk HPV -DNA testing in the male sexual partners of women with HPV -induced lesions . \nGiraldo PC, Eleuterio J, Cavalcante DIM, et al. Eur J Obstet Gynecol Reprod Biol 2008 Mar;137(1):88 -91. \n                Trabajo (s) citado (s): \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n \n108 802) The Role of Male Circumcision in the Prevention of Human Papillomavirus and HIV Infection. Gray RH, \nWawer MJ, Serwadda D, et al. J Infect Dis 2009 1Jan;199(1):1- 3. \n                Trabajo (s) citado (s): \n Vaccarella S . Lazcano-Ponce E.  Castro JA.  Cruz-Valdez A . Diaz V . Schiavon R . Hern\u00e1ndez P . Kornegay JR. \nHern\u00e1ndez M . Franceschi S . Prevalence and determinants of human papillomavirus infection in men attending \nvasectomy clinics in Mexi co. Int J Cancer 2006 15Oct;119(8):1934-9.  \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n803) The role of obesity, physical activity and dietary fa ctors on the risk for breast cancer: Mexican experience . \nRomieu I, Lajous M. Salud Publica Mex 2009;51(Supl 2): S172 -S180.   \n                Trabajo (s) citado (s): \n Ortiz -Rodriguez SP. Torres-Mejia G . Mainero-Ratchelous F . Angeles-Llerenas A . Lopez-Caudana AE . Lazcano-\nPonce E.  Romieu I .  Physical activity and breast cancer risk in Mexican women . Salud Publica Mex 2008 Mar-\nApr;50(2):126-35.  \n Torres-Sanchez L. L\u00f3pez-Carrillo L.  Lopez-Cervantes M. Rueda-Neria C, Wolff MS (2000) Food sources of \nphytoestrogens and breast cancer risk in Mexican women. Nutr Cancer 37:134 \u2013139 \n Bonilla-Fernandez P. L\u00f3pez-Cervantes M. Torres-S\u00e1nchez LE.  Tortolero-Luna G. L\u00f3pez-Carrillo L.  Nutritional \nfactors and breast cancer in Mexico. Nutr Cancer 2003;45(2):148 \u2013155. \n Lacasa\u00f1a -Navarro M. Galv\u00e1n -Portillo M . Chen J. L\u00f3pez -Cervantes M. L\u00f3pez -Carrillo L.  \nMethylenetetrahydrofolate reductase 677C>T polymorphism and gastric cancer susceptibility in Mexico. Eur J \nCancer 2006;42:528 -533. \n Torres -S\u00e1nchez L. Galv\u00e1n -Portillo M.  Wolff MS. L\u00f3pez -Carrillo L.  (2008) Dietary consumption of phytochemicals \nand breast cancer risk in Mexican women. Public Health Nutr 23:1-7 \n L\u00f3pez -Rios O . Lazcano-Ponce EC . Tovar Guzman V . Hernandez Avila M . Breast cancer epidemiology in Mexico. \nDemographic transition consequen ce. Salud Publica Mex 2997 Jul -Aug;39(4):259 -65.  \n \n804) The role of the National Office for Tobacco Control in Mexico. Regalado -Pineda J. Rodr\u00edguez -Ajenjo CJ. Salud \nPublica Mex 2008;50(Supl 3):S355 -S365  \n                Trabajo (s) citado (s): \n Reynales-Shigematsu L . Ju\u00e1rez-M\u00e1rquez S. Valdez-Salgado R . Costo de atenci\u00f3n m\u00e9dica atribuible al tabaquismo \nen el IMSS, Morelos. Salud P\u00fablica Mex 2005; 47: 451- 7. \n Reynales-Shigematsu LM.  Costos de atenci\u00f3n m\u00e9dica de las enfermedades atribuibles al consumo de tabaco en \nlas Am\u00e9ricas: revisi\u00f3n de la literatura. Salud Publica Mex 2006;48(supl 1):S190-S200.  \n \n805) The vaccine against HPV: the conflict of interest. Laurell AC. Salud Colectiva 2009 Jan-Apr;5(1):127- 8. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n806) The war against cervical cancer in Latin America and the Caribbean. Triumph of the scientists. Challenge for \nthe comm unity Foreword . Correa P. Vaccine 2008 19Aug;26(Suppl 11):III -IV  \n                Trabajo (s) citado (s): \n Murillo R . Almonte M  Pereira A . Ferrer E . Gamboa OA . Jeronimo J . Lazcano-Ponce E. . Cervical Cancer Screening \nPrograms in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48.  \n Herrero R . Ferreccio C . Salmeron J . Almonte M . S\u00e1nchez GI . Lazcano-Ponce E. Jeronimo J . New Approaches to \nCervical Cancer Screening in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L49-L58.  \n Franco EL . Tsu V . Herrero R . Lazcano- Ponce E. . Hildesheim A . Mun\u00f3z N . Murillo R . S\u00e1nchez GI . Andrus JK . \nIntegration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the \nCaribbean . Vaccine 2008 19 Aug;26(Suppl 11):L88-L95.   Supplement: Suppl. 11 Published: AUG 19 2008.  \n \n807) Therapeutic HPV DNA vaccines.  Monie A, Tsen SWD, Hung CF, et al. Expert Rev Vaccines 2009 Sep;8(9):1221-\n35. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesio ns. NEJM 2007 10May;356(19):1915-27.  \n \n808) Therapeutic Human Papillomavirus Vaccination. Albers AE, Kaufmann AM. Public Health Genom 2009;12(5 -\n6):331 -42. \n                Trabajo (s) citado (s): \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.   \n109 \n Villa LL, et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n809) Tipos histol\u00f3gicos y m\u00e9todos diagn\u00f3sticos en cancer pulmonary en un centro hospitalario de tercer nivel. \nMexico. Gurrola-D\u00edaz CM. et al. Gac Med Mex 2009;145(2):97-101 \n                Trabajo (s) citado (s): \n Tovar-Guzm\u00e1n V . L\u00f3pez-Antu\u00f1ano FJ . Rodr\u00edguez -Salgado N. (2005). Trends in mortality from lung cancer in \nMexico, 1980 -2000. Revista Panamericana de Salud P\u00fablica , 17(4),254 -262. \n \n810) Total Particulate Matter and Wound Healing: An in vivo Study with Histological Insights . Ejaz S, Ashraf M, \nNawaz M, et al. Biomed Environ Sci 2009 Aug;22(4): 278-87. \n                Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Snijders PJF . Dai M . Thomas JO . Hieu NT . Ferreccio C . Matos E.  Posso H . de Sanjose S . \nShin HR . Sukvirach S . Lazcano-Ponce E.  Mun\u00f3z N . Meijer CJLM . Franceschi S . Smoking and human \npapillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence \nSurveys. Int J Epidemiol 2008 Jun;37(3):536- 46.  \n \n811) Toxicity of inorganic arsenic and its metabolites on haematopoietic progenitors \"in vitro\": Comparison \nbetween species and sexes. Ferrario D. Toxicology 2008 Jul;249(2-3):102-8 \n                Trabajo (s) citado (s): \n Soto -Pena GA. Luna AL. Acosta -Saavedra L. Conde -Moo P. L\u00f3pez -Carrillo L . Cebrian ME. et al. 2006. Assessment \nof lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J 20(6):779 \u2013781. \n \n812) Trade-offs in cervical cancer prevention - Balancing benefits and risks. Stout NK, Goldhaber-Fiebert JD, \nOrtendahl JD, et al. Arch Intern Med 2008 22Sep;68(17):1881- 9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n813) Transpl acental transmission of Human Papillomavirus . Rombaldi RL, Serafini EP, Mandelli J, et al. Virol J 2008 \n25Sep;5: Artic 106.  \n                Trabajo (s) citado (s): \n Hern\u00e1ndez -Gir\u00f3n C . Smith JS . Lorincz A . Lazcano E. . Hern\u00e1ndez-Avila M . Salmeron J . High-risk human \npapillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico . Sex \nTransm Dis 2005 Oct;32(10):613-8.  \n \n814) Treatment of cervical cancer in Italy: Strategies and their impact on the women. De Vincenzo R, Amadio G, \nRicci C, et al. Vaccine 2009 29May;27(Suppl 1):A39 -A45. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n \n815) Treatment patterns and associated costs for genital warts in Italy. Merito M, Largeron N, Cohet C, et al. Curr \nMed Res Opin 2008;24(11):3175-83. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n816) Trends in cervical cancer mortality in Korea 1993-2002: Corrected mortality using national death certification \ndata and national cancer incidence data. Shin HR, Park S, Hwang SY, et al. Int J Cancer 2008 15Jan;122(2):393-\n97.  \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Vaccarella S . Franceschi S . Herrero R . Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n \n817) Trends in Presentation and Survival for Gallbladder Cancer During a Period of More Than 4 Decades A \nSingle-Institution Experience. Konstantinidis IT, Deshpande V, Genevay M, et al. Arch Surg 2009 \nMay;144(5):441- 7. \n                Trabajo (s) citado (s):  \n110 \n Lazcano- Ponce EC.  Miquel JF . Mun\u00f3z N . Herrero R . Ferrecio C . Wistuba II . de Ruiz PA . Urista GA . Nervi F . \nEpidemiology and molecular pathology of gallbladder cancer . CA Cancer Journal forClinicians 2001 Nov-\nDec;51(6):349-64.  \n \n818) Type-specific HPV infection and multiple HPV types: Prevalence and risk factor profile in nearly 12,000 \nyounger and older Danish women. Nielsen A, Kjaer SK, Munk C, et al. Sex Transm Dis 2008 Mar;35(3):276- 82. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Lazcano- Ponce E.  Herrero R . Munoz N . Cruz A . Shah KV . Alonso P . Hern\u00e1ndez P . Salmeron J . Hernandez M . \nEpidemiology of HPV infection among Mexican women with normal cervical cytology .  Int J Cancer 2001 \n1Feb;91(3):412-20.  \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n819) Twenty-Year Trends in the Incidence and Prevalence of Diagnosed Anogenital Warts in Canada . Kliewer EV, \nDemers AA, Elliott L, et al. Sex Transm Dis 2009 Jun;36(6): 380-6.  \n                Trabajo (s) citado (s): \n Giuliano AR . Lazcano- Ponce E.  Villa LL. Flores R . Salmeron J. Lee JH . Papenfuss MR . Abrahamsen M . Jolles E. \nNielson CM . Baggio ML . Silva R . Quiterio M . The human papillomavirus infection in men study: Human \npapillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States . \nCancer Epidemiol Biomarkers Prev 2008 Aug;17(8):2036-43.  \n \n820) Understanding HPV Disease and Prevention: A Guide for School Nurses. Lockwood-Rayermann S, McIntyre \nSJ. J School Nurs 2009 Aug;25(4):261- 9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n821) Understanding the Reasons Why Mothers Do or Do Not Have Their Adolescent Daughters Vaccinated Against \nHuman Papillomavirus. Dempsey AF, Abraham LM, Dalton V, et al. Ann Epidemiol 2009 Aug;19(8):531- 8. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Rivera L. Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n822) Update on infectious disease prevention: Human papillomavirus, hepatitis A. Longworth DL. Clevel Clin J \nMed 2008 Jun;75(6):402. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n823) Update on Quadrivalent Human Papillomavirus Vaccination and Pregnancy Outcomes Is Contraception \nAdvisable? Smith-McCune K, Sawaya GF. Obstet Gynecol 2009 Dec;114(6):1168- 9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n824) Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: \nprospective cohort study . Brabin L, Roberts SA, Stretch R, et al. BMJ 2008 10May;336(7652):1056- 8. \n                Trabajo (s) citado (s): \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n825) Upstream Regulatory Region Alterations Found in Human Papillomavirus Type 16 (HPV-16) Isolates from \nCervical Carcinomas Increase Transcription, ori Function, and HPV Immortalization Capacity in Culture. Lace \nMJ, Isacson C, Anson JR, et al. J Virol  2009 1Aug;85(15):7457- 66. \n                Trabajo (s) citado (s): \n \n111 \n Berumen J . Ordonez RM . Lazcano E . Salmeron J . Galvan SC.  Estrada RA.  Yunes E . Garcia-Carranca A . Madrigal-\nde la Campa A . Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control \nstudy.  J Natl Cancer Inst 2001 1Sep;93(17):1325-30.  \n \n826) Urinary polyphenols and breast cancer risk: results from the Shanghai Women\u2019s Health Study. Luo J. et al. \nBreast Cancer Res Treat 2009 4Aug. \n                Trabajo (s) citado (s): \n Torres-Sanchez L. L\u00f3p ez-Carrillo L.  Lopez-Cervantes M. Rueda-Neria C, Wolff MS (2000) Food sources of \nphytoestrogens and breast cancer risk in Mexican women. Nutr Cancer 37:134 \u2013139 \n \n827) Urine HPV-DNA detection for cervical cancer screening: Prospects and prejudices .Sehgal A, Gupta S, Parashari \nA, et al. J Obstet Gynaecol 2009;29(7):583- 9. \n                Trabajo (s) citado (s): \n Lazca no-Ponce E. Herrero R . Munoz N . Hernandez-Avila M . Salmeron J. Leyva A . Meijer CJLM . Walboomers \nJMM . High prevalence of human papillomavirus infection in Mexican males - Comparative study of penile-\nurethral swabs and urine samples . Sex Transm Dis 2001 May;28(5):277-80.  \n \n828) Vaccinating against HPV: Physicians' and medical students' point of view. de Carvalho NS, Teixeira LM, \nPradel EM, et al. Vaccine 2009 5May;27(20):2637- 40. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Rivera L. Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n829) Vaccination and screening programs: harmonizing prevention strategies for HPV -related diseases. Mariani L, \nPagliusi S. J Exp Clin Cancer Res 2008 16Dec;27:Artic 84  \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n830) Vaccination after stem cell transplant: a review of recent developments and implications for current practice. \nWilck MB, Baden LR. Curr Opin Infect Dis 2008 Aug;21(4):399-408. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n831) Vaccination against HPV: indications for women and the impact on the cervical screening programme. \nHeideman DAM, Snijders PJF, Berkhof J, et al. BJOG An International Journal of Obstetrics and Gynaecology \n2008 Jul;115(8):938- 46. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n832) Vaccination strategies against HPV. Recommendations from a European perspective. Delere Y. \nBundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 2009 Nov;52(11):1065- 8. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n833) Vaccination against human papillomavirus - an impact on preterm delivery? Estimations based on literature \nreview. Sjoborg KD, Eskild A. Acta Obstet Gynecol Scand 2009;88(3):255- 60. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n  \n112 834) Vaccination against human papillomavirus in Switzerland: simulation of the impact on infection rates. \nBerchtold A. et al. Int J Public Health OnLine October 2009 \n                Trabajo (s) citado (s): \n Insinga RP. Dasbach EJ. Elbasha EH. Puig A. Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human \npapillomavirus (HPV) vaccination in Mexico: a transmission dynamic model based evaluation. Vaccine 2007, \n26:128-139. \n \n835) Vaccination against the human papilloma virus. All that glitters is not gold. Montes JM, Gomez HN. Atencion \nPrimaria 2008 Jun;40(6):311.  \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n836) Vaccinations against the Human Papiloma Virus: questionable aspects. Delgado RC. Ginecol Obstet Clin 2008 \nJul-Sep;9(3):142- 50. \n                Trabajo (s) citado (s): \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n837) Vaccine Adherence in Adolescents. Lehmann C, Benson PAS. Clin Pediatr 2009 Oct;48(8):801- 11. \n                Trabajo (s) citado (s): \n Villa LL, et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Reisinger KS . Block SL . Lazcano-Ponce E . et al.  Safety and persistent immunogenicity of a quadrivalent human \npapillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents . Pediatr Infect \nDis J 2007 Mar;26(3):201-9.  \n \n838) Vaccines against cervical cancer. Rogers LJ, Eva LJ, Luesley DM. Curr Opin Oncol 2008 Sep;20(5):570- 4. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n839) Vacuna contra el virus del papiloma humano. Hern\u00e1ndez WF. Gonz\u00e1lez JH. Universitas Medica 2009 Abr-\nJun;50(2):209- 222. \n                Trabajo (s) citado (s): \n Murillo R . Almonte M  Pereira A . Ferrer E . Gamboa OA . Jeronimo J . Lazcano-Ponce E. Cervical Cancer Screening \nPrograms in Latin America and the Caribbean . Vaccine 2008 19Aug;26(Suppl 11):L37-L48.  \n \n840) Vaginal maturation index self-sample collection in mid-life women: acceptability and correlation with \nphysician-collected samples. Hess R. Austin RM. et al. Menopause-the Journal of the North American \nMenopause Society 2008; 15(4): 726- 729. \n                Trabajo (s) citado (s): \n Dzuba IG. Yunes -D\u00edaz E. Allen B.  Leonard YF. Lazcano- Ponce EC.  et al. The Acceptability of Self -collected \nSamples for HPV Testing vs. the Pap Test as Alternatives in Cervical Cancer Screening. Journal of Women\u2019s  \nHealth & Gender -Based Medicine, 2002;11(3):265 -275. \n \n841) Validity of self-reported Pap smear history in Norwegian women . Klungsoyr O, Nygard M, Skare G, et al. J \nMed Screen 2009;16(2):91- 7. \n                Trabajo (s) citado (s): \n Lazcano- Ponce EC.  Buiatti E . Najera-Aguilar I . Alonso- de-Ruiz P . Hernandez-Avila M . Evaluation model of the \nMexican national program for early cervical cancer detection and proposals for a new approach . Cancer Causes \nControl 1998 May;9(3):241- 51. \n \n842) Value of Conventional Pap Smear, Liquid-Based Cytology, Visual Inspection and Human Papillomavirus \nTesting as Optional Screening Tools Among Latin American Women < 35 and >= 35 Years of Age: Experience \nfrom the Latin American Screening Study . Syrjanen K, Derchain S, Roteli-Martins C, et al. Acta Cytologica \n2008 Nov-Dec;52(6):641- 53. \n                Trabajo (s) citado (s): \n Salmeron J. Lazcano-Ponce E.  Lorincz A . Hernandez M . Hern\u00e1ndez P . Leyva A . Uribe M . Manzanares H . Antunez \nA. Carmona E . Ronnett BM . Sherman ME . Bishai D . Ferris D . Flores Y . Yunes E . Shah KV . Comparison of HPV-\nbased assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico . Cancer Causes \nControl 2003 Aug;14(6):505-12.  \n \n \n113 843) Value of general human papillomavirus vaccination in sexually active women. Hampl M. Deutsche \nMedizinische Wochenschrift 2009 17Apr;134(Suppl 2):S95-S99. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n844) Variables Associated With Human Papillomavirus (HPV) Vaccine Acceptance by Men. Ferris DG, Waller JL, \nMiller J, et al. J Am Board Fam Med 2009 Jan-Feb;22(1):34- 42. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n845) Variation in the age at natural menopause among Polish women in relation to their reproductive histories . \nKaczmarek M. Przeglad Menopauzalny 2008 Apr;7(2):69-76.  \n                Trabajo (s) citado (s): \n Garrido -Latorre F . Lazcano-Ponce EC . L\u00f3pez-Carrillo L . Hern\u00e1ndez-Avila M . Age of natural menopause among \nwomen in Mexico City . Int J Gynecol Obstet 1996 May;53(2):159-66.  \n   \n846) Virus-like particle vaccines and adjuvants: the HPV paradigm. Buonaguro FM, Tornesello ML, Buonaguro L. \nExpert Rev Vaccines 2009 Oct;8(10):1379- 98. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n847) Vitamin D and calcium intake in relation to risk of endometrial cancer: A systematic review of the literature . \nMcCullough ML, Bandera EV, Moore DF, et al. Prev Med 2008 Apr;46(4):298- 302. \n                Trabajo (s) citado (s): \n Salazar -Martinez E .Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Gonz\u00e1lez-Lira G . Escudero-De Los Rios P . \nHern\u00e1ndez-Avila M . Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico . Int J \nGynecol Cancer 2005 Sep -Oct;15(5 ):938 -45.  \n \n848) Vitamin D for Cancer Prevention: Global Perspective . Garland CF, Gorham ED, Mohr SB, et al. Ann Epidemiol \n2009 Jul;19(7):468- 83. \n                Trabajo (s) citado (s): \n Salazar -Martinez E .Lazcano-Ponce E. S\u00e1nchez-Zamorano LM . Gonz\u00e1lez-Lira G . Escudero-De Los Rios P . \nHern\u00e1ndez-Avila M . Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico . Int J \nGynecol Cancer 2005 Sep -Oct;15(5 ):938 -45.  \n Salazar -Mart\u00ednez E . Lazcano-Ponce E.  Lira-Lira GG . Escudero-De los Rios P . Hern\u00e0ndez-Avila M . Nutritional \ndeterminants of epithelial ovarian cancer risk: A case-control study in Mexico . Oncology 2002;63(2):151-7.  \n \n849) Vitamin E intake and risk of esophageal and gastric cancers in the NIH-AARP Diet and Health Study. Carman \nS. et al. Int J Cancer 2009;125:165- 70 \n                Trabajo (s) citado (s): \n L\u00f3pez-Carrillo L . L\u00f3pez-Cervantes M. Ward MH. Bravo-Alvarado J. Ram\u00edrez-Espitia A. Nutrient intake and \ngastric cancer in Mexico. Int J Cancer 1999; 83: 601- 605 \n \n850) Vitamin supplement use and risk for breast cancer: the Shanghai Breast Cancer Study. Dorjgochoo T. et al. \nBreast Cancer Res Treat 2008 Sep;111:269- 78 \n                Trabajo (s) citado (s): \n Lajous M. Romieu I.  Sabia S. Boutron-Ruault MC. Clavel-Chapelon F. Folate, vitamin B12 and postmenopausal \nbreast cancer in a prospective study of French women. Cancer Causes Control 17, 1209 \u20131213, 2006. \n Lajous M . Lazcano-Ponce E.  Hern\u00e1ndez-Avila M . Willett W . Romieu I . Folate, vitamin B-6, and vitamin B- 12 \nintake and the risk of breast cancer among Mexican women . Cancer Epidemiol Biomarkers Prev 2006 \nMar;15(3):443-8.   \n Bonilla-Fernandez P. L\u00f3pez-Cervantes M. Torres-S\u00e1nchez LE.  Tortolero-Luna G. L\u00f3pez-Carrillo L.  Nutritional \nfactors and breast cancer in Mexico. Nutr Cancer 2003;45(2):148 \u2013155. \n \n851) Wanted, dead or alive: New viral vaccines. Amanna IJ, Slifka MK. Antivir Res 2009 Nov;84(2):119 -30. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n852) What About the Partners of Women With Abnormal Pap or Positive HPV Tests?  Hoover K, Friedman A, \nMontano D, et al. Sex Transm Dis 2009 Mar;36(3):141- 6. \n                Trabajo (s) citado (s): \n \n114 \n Lajous M . Mueller N . Cruz-Valdez A . Aguilar LV . Franceschi S . Hernandez-Avila M . Lazcano-Ponce E . \nDeterminants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military \nmen . Cancer Epidemiol Biomarkers Prev 2005 Jul;14(7):1710-6.  \n \n853) What should be known for the introduction of an HPV vaccine?   Mun\u00f3z N, Jacquard AC. Press Med 2008 \nOct;37(10):1377-90.  \n Trabajo (s) citado (s): \n Vaccarella S . Herrero R . Snijders PJF . Dai M . Thomas JO . Hieu NT . Ferreccio C . Matos E.  Posso H . de Sanjose S . \nShin HR . Sukvirach S . Lazcano-Ponce E.  Mun\u00f3z N . Meijer CJLM . Franceschi S . Smoking and human \npapillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence \nSurveys. Int J Epidemiol 2008 Jun;37(3):536- 46.  \n Vaccarella S . Franceschi S . Herrero R. Munioz N . Snijders PJF . Clifford GM . Smith JS . Lazcano-Ponce E.  Sukvirach \nS. Shin HR . de Sanjose S . Molano M . Matos E . Ferreccio C . Anh PTH . Thomas JO . Meijer CJLM .Sexual behavior, \ncondom use, and human papillomavirus: Pooled analysis of the IARC human papillomavirus prevalence surveys . \nCancer Epidemiol Biomarkers Prev 2006 Feb;15(2):326 -33.  \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A . Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677-2684.  \n Vaccarella S . Herrero R . Dai M . Snijders PJF . Meijer CJLM . Thomas JO . Anh PTH . Ferreccio C . Matos E . Posso H . \nde Sanjose S . Shin HR . Sukvirach S . Lazcano-Ponce E.  Ronco G . Rajkumar R . Qiao YL . Munoz N . Franceschi S . \nReproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC \nHPV prevalence surveys . Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2148- 2153.  \n \n854) What's new in dermatologic therapy. Thiers BH. Dermatol Ther 2008 Mar-Apr;21(2):142- 9. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions. NEJM 2007 10May;356(19):1915-27.  \n \n855) What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and \nvaccination.  Lynge E, Antilla A, Arbyn M, et al. Eur J Cancer 2009 Oct;45(15):2714 -21. Sp. Iss . SI. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n856) Why pesticides could be a common cause of prostate and breast cancers in the French Caribbean Island, \nMartinique. An overview on key mechanisms of pesticide-induced cancer . Landau-Ossondo M, Rabia N, Jos-\nPelage J, et al. Biomed Pharmacother 2009 Jul;63(6):383- 95. \n                Trabajo (s) citado (s): \n Romieu I . Hernandez-Avila M . Lazcano- Ponce E. . Weber JP . Dewailly E . Breast cancer, lactation history, and \nserum organochlorines . Am J Epidemiol 2000 15Aug;152(4):363- 70. \n \n857) Will vaccination against human papillomavirus prevent eye disease? A review of the evidence. Hughes DS, \nPowell N, Fiander AN. Br J Ophthalmol 2008 Apr;92(4):460- 5. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n858) Women as prim ary caregivers in Mexico : challenges to well -being. DiGirolamo AM. Salgado -de Snyder N. \nSalud Publica Mex 2008 Nov -Dic;50(16):516 -22 \n                Trabajo (s) citado (s): \n Ortega-Altamirano D. L\u00f3pez-Carrillo L.  L\u00f3pez-Cervantes M.  Estrategias para la ense\u00f1anza del autoexamen del \nseno a mujeres en edad reproductiva. Salud P\u00fablica de M\u00e9xico 2000;42:17 \u201325. \n L\u00f3pez-Carrillo L . Torres-S\u00e1nchez L . L\u00f3pez-Cervantes M. et al. Identificaci\u00f3n de lesiones mamarias en M\u00e9xico. \nSalud P\u00fablica de M\u00e9xico 2001;43(3):199 \u2013202. \n \n859) Women show mixed intentions regarding the uptake of HPV vaccinations in pre-adolescents: A questionnaire \nstudy. Korfage IJ, Essink-Bot ML, Daamen R, et al. Eur J Cancer 2008 Jun;44(9):1186- 92. \n                Trabajo (s) citado (s): \n Lazcano- Ponce E.  Rivera L. Arillo-Santillan E . Salmeron J . Hernandez-Avila M . Munoz N . Acceptability of a \nhuman papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico . Arch Med Res \n2001 May-Jun;32(3):243-7.  \n Zimet GD. Liddon N. Rosenthal SL. Lazcano-Ponce E. Allen B.  Psychosocial aspects of vaccine acceptability. \nVaccine 2006 31Aug;24(Suppl 3);201- 9. \n \n115  \n860) Women's participation in a cervical cancer screening program in northern Peru . Winkler J, Bingham A, Coffey \nP, et al. Health Educ Res 2008 Feb;23(1):10-24.  \n                Trabajo (s) citado (s): \n Lazcano-Ponce EC . Najera Aguilar P . Buiatti E. Alonso De Ruiz P . Kuri P . Cantoral L . Hern\u00e1ndez Avila M . The \ncervical cancer screening program in Mexico: problems with access and coverage .  Cancer Causes Control 1997 \nSep;8(5):698 -704. \n Lazcano- Ponce EC. Castro R . Allen B . Najera P . De Ruiz PA. Hern\u00e1ndez-Avila M . Barriers to early detection of \ncervical-uterine cancer in Mexico . J Womens Health 1999 Apr;8(3):399- 408. \n \n861) Worldwide Impact of the Human Papillomavirus Vaccine. Hakim AA, Dinh TA. Curr Treat Opt Oncol 2009 \nApr;10(1-2):44- 53. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n862) \"I want the one for older women\" - extending the human papillomavirus vaccine population base. Marshall \nHS, Isaacs D. Med J Austr 2008 3Nov;189(9):527. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions. NEJM 2007 10May;356(19):1915-27.  \n \n863) \"I want the one for older women\" - extending the human papillomavirus vaccine population base. Wain GV. \nMed J Austr 2008 5May;188(9):501- 2. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n864) \"U\" shape of age-specific prevalence of high-risk human papillomavirus infection in women attending \nhospitals in Shanghai, China. Xue YZ, Zhang WY, Chen M, et al. Eur J Obstet Gynecol Reprod Biol 2009 \nAug;145(2):214- 8. \n                Trabajo (s) citado (s): \n Franceschi S . Herrero R . Clifford GM . Snijders PJF . Arslan A. Anh PTH . Bosch FX . Ferreccio C . Hieu NT . Lazcano-\nPonce E.  Variations in the age-specific curves of human papillomavirus prevalence in women worldwide :  et al. \nInt J Cancer 2006 1Dec;119(11):2677- 2684.  \n \n865) 2008 Thomas Parran Award Lecture: Translational Research, STD Control, and Health Disparities A Challenge \nand an Opportunity. Hook EW. Sex Transm Dis 2008 Dec;35(12):969- 72. \n                Trabajo (s) citado (s): \n Villa LL , et al. (The Future II Study Group, Lazcano-Ponce E. ).  Quadrivalent vaccine against human \npapillomavirus to prevent high-grade cervical lesions . NEJM 2007 10May;356(19):1915-27.  \n \n866) 1,1-dichloro -2,2-bis(p-chlorophenyl)eth ylene ( p,p'- DDE) disrupts the estrogen -androgen balance regulating the \ngrowth of hormone -dependent breast cancer cells. Aub\u00e9 M. et al. Breast Cancer Res 2008;10(1):R16  \n                Trabajo (s) citado (s): \n L\u00f3pez -Cervantes M. Torres -S\u00e1nchez L . Tobias A. L\u00f3pez-Carrillo L . 2004. Dichlorodiphenyldichloroethane burden \nand breast cancer risk: A meta -analysis of the epidemiologic evidence. Environ. Health Perspect. 112:207 \u2013214. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \n116  \n \n \n \n \n \n \n \n \nImagen: upload.wikipedia.org  \n \nMAR\u00cdA EVA DUARTE DE PER\u00d3N \n1919 - 1952 \nEva per\u00f3n contaba con 33 a\u00f1os cuando el 26 de julio de 1952 el c\u00e1ncer cervical puso fin a su vida, \n\u201cEvita\u201d como le dec\u00edan de cari\u00f1o sus seguidores en Argentina contrajo esta terrible enfermedad \nen 1950 a la edad de 31 a\u00f1os, en ese tiempo el m\u00e9todo de detecci\u00f3n temprana de c\u00e1ncer cervical \ncreado por el Dr. Papanicolaou no era una pr\u00e1ctica com\u00fan, a\u00fan y cuando esta prueba se \ncomenzara a promover en este pa\u00eds en 1946. El presidente de Argentina, el Coronel Juan \nDomingo Per\u00f3n esposo de Eva le encomend\u00f3 al cirujano neoyorquino George Pack que dirigiera \nla histerectom\u00eda en noviembre de 1951, despu\u00e9s se confirmar\u00eda a trav\u00e9s de unos apuntes del \npropio Pack que Eva Per\u00f3n nunca supo que padec\u00eda c\u00e1ncer cervical tampoco de lo grave del caso \ny ni siquiera conoci\u00f3 al medico que la oper\u00f3, quiz\u00e1 por razones pol\u00edticas o por alguna otra dif\u00edcil \nde explicar, lo cierto es que el c\u00e1ncer cervicouterino cobraba una vida m\u00e1s en esta ocasi\u00f3n la de \nuna de las mujeres m\u00e1s emblem\u00e1ticas de todos los tiempos en Argentina y quiz\u00e1 de todo el \nmundo. \nLerner BH. The illness and death of Eva Per\u00f3n: cancer, politics and secrecy. The Lancet 2000 3Jun;355:1988- 91 \n \n \n117 INSTITUTO NACIONAL DE SALUD P\u00daBLICA \nCENTRO DE INVESTIGACI\u00d3N EN SALUD POBLACIONAL \n \n \n \n \n \nDr. Eduardo C\u00e9sar Lazcano Ponce \nDirector Ejecutivo  \n \nDr. Ruy L\u00f3pez Ridaura \nJefe de la Unidad de Investigaci\u00f3n en Diabetes y Riesgo Cardiovascular \n \nDocumento de An\u00e1lisis Citogr\u00e1fico preparado por:  \nC.D. Daniel Angel Acu\u00f1a Montesinos  \nC.D. Silvia Leonor Rojas Mart\u00ednez \nApoyo a la Investigaci\u00f3n  \nUnidad de Investigaci\u00f3n en Diabetes y Riesgo Cardiovascular \nCISP-INSP. \n \n \n \n \n \n \nInstituto Nacional de Salud P\u00fablica \nCISP-LIM-CANCER-MAY O-2010 ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}